

Promoted by



and by

INMI, Istituto Nazionale per le Malattie Infettive

ISS, Istituto Superiore di Sanità

SIICA, Società Italiana di Immunologia,
Immunologia Clinica e Allergologia

SIMaST, Società Interdisciplinare per lo Studio
delle Malattie Sessualmente Trasmissibili

SIV, Società Italiana di Virologia

SIVIM, Società Italiana di Virologia Medica

ANLAIDS, Associazione Nazionale per la lotta contro l'AIDS

ARCIGAY, Associazione LGBT Italiana

LILA, Lega Italiana per la lotta contro l'AIDS

NADIR, Fondazione Nadir Onlus

NPS Italia Onlus, Network Persone Sieropositive

SCIENTIFIC PROGRAMME

Chairs

Cristina Mussini, Modena

Laura Sighinolfi, Ferrara

Andrea Cossarizza, Modena

Scientific Secretariat

Vanni Borghi, Modena

Anna Maria Cattelan, Padova

Francesca Ceccherini-Silberstein, Roma

Mario Clerici, Milano

Andrea De Maria, Genova

Antonio Di Biagio, Genova

Margherita Errico, Milano

Carlo Ferrari, Parma

Andrea Gori, Monza

Giovanni Guaraldi, Modena

Sergio Lo Caputo, Firenze

Franco Maggiolo, Bergamo

Giulia Marchetti, Milano

Silvia Nozza, Milano

Gabriella Verucchi, Bologna

17-19 maggio 2015
RICCIONE
PALAZZO DEI CONGRESSI

SETTIMO
CONGRESSO
NAZIONALE

**Italian
Conference on
AIDS and
Retroviruses**



CAR

Promoted by

SIMIT Società Italiana di Malattie Infettive e Tropicali

and by

INMI, Istituto Nazionale per le Malattie Infettive

ISS, Istituto Superiore di Sanità

SIICA, Società Italiana di Immunologia,
Immunologia Clinica e Allergologia

SIMaST, Società Interdisciplinare per lo Studio delle Malattie Sessualmente
Trasmisibili

SIV, Società Italiana di Virologia

SIVIM, Società Italiana di Virologia Medica

ANLAIDS, Associazione Nazionale per la lotta contro l'AIDS

ARCIGAY, Associazione LGBT Italiana

LILA, Lega Italiana per la lotta contro l'AIDS

NADIR, Fondazione Nadir Onlus

NPS Italia Onlus, Network Persone Sieropositive

Endorsements

Institutions

Ministero della Salute

AIFA, Agenzia Italiana del Farmaco

CNR, Consiglio Nazionale delle Ricerche

Regione Emilia Romagna

Provincia di Rimini

Comune di Riccione

A.O.U. di Bologna, Policlinico S. Orsola - Malpighi

Alma Mater Studiorum - Università degli Studi di Bologna

Azienda Ospedaliero-Universitaria di Ferrara

Azienda Ospedaliero-Universitaria Policlinico di Modena

Azienda USL della Romagna

Università degli Studi di Ferrara

Università degli Studi di Modena e Reggio Emilia

Scientific Societies and Associations

AIMI, Associazione Infermieri Malattie Infettive

AISF, Associazione Italiana per lo Studio del Fegato

AMCLI, Associazione Microbiologi Clinici Italiani

ASA, Associazione Solidarietà AIDS

ASPE, Associazione Studio Patologie Epatiche

Aviralia, Fondazione Aviralia Onlus

Cittadinanzattiva

EpaC, Educazione, Prevenzione e Ricerca sull'Epatite C

MIT, Movimento Identità Transessuale

PLUS, Persone LGBT Sieropositive Onlus

SIMET, Società Italiana di Medicina Tropicale

SIMPIOS, Società Italiana Multidisciplinare per la Prevenzione
delle Infezioni nelle Organizzazioni Sanitarie

CHAIRS

Cristina Mussini, Modena
Laura Sighinolfi, Ferrara
Andrea Cossarizza, Modena

SCIENTIFIC SECRETARIAT

Vanni Borghi, Modena
Anna Maria Cattelan, Padova
Francesca Ceccherini-Silberstein, Roma
Mario Clerici, Milano
Andrea De Maria, Genova
Antonio Di Biagio, Genova
Margherita Errico, Milano
Carlo Ferrari, Parma
Andrea Gori, Monza
Giovanni Guaraldi, Modena
Sergio Lo Caputo, Firenze
Franco Maggiolo, Bergamo
Giulia Marchetti, Milano
Silvia Nozza, Milano
Gabriella Verucchi, Bologna

Organi di Governo**SPC (SCIENTIFIC PROGRAMME COMMITTEE)**

Nicola Abrescia, Napoli
Massimo Andreoni, Roma
Andrea Antinori, Roma
Guido Antonelli, Roma
Michele Breveglieri, Verona
Giampiero Carosi, Brescia
Roberto Cauda, Roma
Andrea Cossarizza, Modena
Stefania D'Amato, Roma
Antonella d'Arminio Monforte, Milano
Andrea De Luca, Siena
Giovanni Di Perri, Torino
Massimo Galli, Milano
Giuseppe Ippolito, Roma
Adriano Lazzarin, Milano
Sergio Lo Caputo, Firenze
Paolo Maggi, Bari
Franco Maggiolo, Bergamo
Bruno Marchini, Roma
Claudio M. Mastroianni, Latina
Cristina Mussini, Modena
Lucia Palmisano, Roma
Giorgio Palù, Padova
Carlo Federico Perno, Roma
Giuliano Rizzardini, Milano
Evangelista Sagnelli, Napoli
Laura Sighinolfi, Ferrara
Guido Silvestri, Atlanta (USA)
Stefano Vella, Roma
Claudio Viscoli, Genova

**CLsC (COMMUNITY LIASON
SUB-COMMETTEE)**

Michele Breveglieri, Verona (ARCIGAY)
Alessandra Cerioli, Como (LILA)
Margherita Errico, Milano (NPS)
Bruno Marchini, Roma (ANLAIDS)
Filippo von Schloesser, Roma (NADIR)

DIREZIONE DI PROGRAMMA

Adriano Lazzarin (*Coordinatore*), Milano
Andrea Antinori (*Segretario*), Roma
Massimo Andreoni, Roma
Michele Breveglieri, Verona
Giampiero Carosi, Brescia
Antonella d'Arminio Monforte, Milano
Carlo Federico Perno, Roma

FACULTY

Nicola Abrescia, Napoli
Sergio Abrignani, Milano
Alessio Aghemo, Milano
Adriana Ammassari, Roma
Massimo Andreoni, Roma
Gioacchino Angarano, Bari
Andrea Antinori, Roma
Guido Antonelli, Roma
Massimo Arlotti, Rimini
Tarik Asselah, Paris F
Claudio Babiloni, Roma
Franco Baldelli, Perugia
Claudia Balotta, Milano
Alessandra Bandera, Monza
Paolo Bassi, Ravenna
Alessandro Battistella, Milano
Davide Bedognetti, Doha Q
Alberto Bignardi, Modena
Teresa Bini, Milano
Gianfranco Bocchi, Bologna
Paolo Bonfanti, Lecco
Anna Bonini, Milano
Stefano Bonora, Torino
Marco Borderi, Bologna
Vanni Borghi, Modena
Antonio Boschini, Rimini
Michele Breveglieri, Verona
Maurizia Brunetto, Pisa
Raffaele Bruno, Pavia
Peter Buggisch, Hamburg D
Ernesto Caffo, Modena
Andrea Calcagno, Torino
Leonardo Calza, Bologna
Lorenza Camponovo, Monza
Claudio Cancellieri, Forlì
Maria Rosaria Capobianchi, Roma
Giampiero Carosi, Brescia
Antonio Cascio, Messina
Mario Cascio, Palermo
Antonella Castagna, Milano
Francesco Castelli, Brescia
Dario Cattaneo, Milano
Anna Maria Cattelan, Padova
Roberto Cauda, Roma
Francesca Ceccherini-Silberstein, Roma
Benedetto M. Celesia, Catania
Valeria Cento, Roma
Alessandra Cerioli, Como
Massimo Cernuschi, Milano
Antonio Chirianni, Napoli
Antonella Cingolani, Roma

Paola Cinque, Milano
Massimo Clementi, Milano
Mario Clerici, Milano
Cosimo Colletta, Omegna VB
Massimiliano Conforti, Roma
Carlo Contini, Ferrara
Giulio M. Corbelli, Roma
Antonio Cosma, Paris F
Maria Luisa Cosmaro, Milano
Andrea Cossarizza, Modena
Eric Cua, Nice F
Stefania D'Amato, Roma
Antonella d'Arminio Monforte, Milano
Gabriella d'Ettore, Roma
Gianpiero D'Offizi, Roma
Maura Dandri, Hamburg D
Gabriella De Carli, Roma
Andrea De Luca, Siena
Andrea De Maria, Genova
Anita De Rossi, Padova
Antonio Di Biagio, Genova
Simona Di Giambenedetto, Roma
Vito Di Marco, Palermo
Giovanni Di Perri, Torino
Riccardo Dolcetti, Aviano PN
Margherita Errico, Milano
Guido Ferlazzo, Messina
Carlo Ferrari, Parma
Pietro Filippini, Napoli
Alba Carola Finarelli, Bologna
Caroline Foster, London UK
Daniela Francisci, Perugia
Antonina Franco, Siracusa
Giovanni Battista Gaeta, Napoli
Massimo Galli, Milano
Miriam Gargiulo, Napoli
Cristina Gervasoni, Milano
Mauro Giacca, Trieste
Vania Giacomet, Milano
Nicola Gianotti, Milano
Carlo Giaquinto, Padova
Enrico Girardi, Roma
Andrea Gori, Monza
Giovanni Guaraldi, Modena
Roy M. Gulick, New York USA
Beatrice Hahn, Philadelphia USA
Christophe Hézode, Paris F
Maria Rosaria Iardino, Milano
Pietro Lampertico, Milano
Adriano Lazzarin, Milano
Massimo Levrero, Roma
Marco Libanore, Ferrara
Miriam Lichtner, Latina
Giuseppina Liuzzi, Roma
Sergio Lo Caputo, Firenze
Lucia Lopalco, Milano
Daniela Lorenzetti, Roma
Giordano Madeddu, Sassari
Paolo Maggi, Bari
Franco Maggiolo, Bergamo

Giacomo Magnani, Reggio Emilia
Marina Malena, Verona
Porpora Marcasciano, Bologna
Giulia Marchetti, Milano
Bruno Marchini, Roma
Simone Marcotullio, Roma
Esteban Martinez, Barcelona E
Javier Martinez-Picado, Barcelona E
Lorena Martini, Roma
Marco Marzioni, Ancona
Renato Maserati, Pavia
Riccardo Massari, Roma
Claudio M. Mastroianni, Latina
Sandro Mattioli, Bologna
Giovanni Mazzola, Palermo
Francesco Mazzotta, Firenze
Sheena McCormack, London UK
Isabelle Meyer-Andrieux, Geneva CH
Roberto Monarca, Viterbo
Ada Moznich, Pordenone
Cristina Mussini, Modena
Silvia Nozza, Milano
Giuseppe Nunnari, Catania
Massimo Oldrini, Milano
Paolo Onorati, Roma
Alessandra Orlandini, Parma
Giancarlo Orofino, Torino
Lucia Palmisano, Roma
Giorgio Palù, Padova
Saverio Parisi, Padova
Giustino Parruti, Pescara
Alfredo Pennica, Roma
Carlo Federico Perno, Roma
Patrizia Perone, Roma
Silvia Petretti, London UK
Patrizio Pezzotti, Roma
Stefania Piconi, Milano
Teresa Pollicino, Messina
Tullio S. Prestileo, Palermo
Massimo Puoti, Milano
Tiziana Quirino, Busto Arsizio VA
Maria Carla Re, Bologna
Diego Ripamonti, Bergamo
Giuliano Rizzardini, Milano
James Rooney, Foster City USA
Stefano Rusconi, Milano
Asier Sáez Cirión, Paris F
Evangelista Sagnelli, Napoli
Matilde Sansone, Napoli
Maria Santoro, Roma
Loredana Sarmati, Roma
Filippo von Schloesser, Roma
Laura Sighinolfi, Ferrara
Guido Silvestri, Atlanta USA
Sabrina Spinosa Guzman, London UK
Maria Stagnitta, Firenze
Fabrizio Starace, Modena
Gaetana Sterrantino, Firenze
Valentina Svicher, Roma
Maria Grazia Tajè, Legnano MI



Gloria Taliani, Roma
 Enrica Tamburrini, Roma
 Giuseppe Tambussi, Milano
 Marcello Tavio, Ancona
 Carlo Torti, Catanzaro
 Georgios Tsiakalakis, Athens GR
 Ombretta Turriziani, Roma
 Emanuela Vaccher, Aviano PN
 Luca Valenti, Milano
 Stefano Vella, Roma
 Gabriella Verucchi, Bologna
 Francesca Vichi, Firenze
 Erica Villa, Modena
 Vincenzo Vullo, Roma
 Mauro Zaccarelli, Roma
 Maurizio Zazzi, Siena
 Anna Linda Zignego, Firenze

ABSTRACT REVIEWERS

Isabella Abbate, Roma
 Adriana Ammassari, Roma
 Mauro Andreotti, Roma
 Guido Antonelli, Roma
 Stefano Aquaro, Arcavacata di Rende CS
 Patrizia Bagnarelli, Ancona
 Claudia Balotta, Milano
 Dario Bartolozzi, Firenze
 Rita Bellagamba, Roma
 Teresa Bini, Milano
 Isabella Bon, Bologna
 Paolo Bonfanti, Lecco
 Stefano Bonora, Torino
 Marco Borderi, Bologna
 Vanni Borghi, Modena
 Federica Bozzano, Genova
 Michele Breveglieri, Verona
 Raffaele Bruno, Pavia
 Andrea Calcagno, Torino
 Leonardo Calza, Bologna
 Laura Camoni, Roma
 Maria Rosaria Capobianchi, Roma
 Antonella Castagna, Milano
 Anna Maria Cattelan, Padova
 Francesca Ceccherini-Silberstein, Roma

Alessandra Cerioli, Como
 Massimo Cernuschi, Milano
 Antonella Cingolani, Roma
 Paola Cinque, Milano
 Mario Clerici, Milano
 Cosimo Colletta, Omegna VB
 Giulio M. Corbelli, Roma
 Mario Cuccia, Catania
 Gabriella d'Ettore, Roma
 Gianpiero D'Offizi, Roma
 Gabriella De Carli, Roma
 Andrea De Luca, Siena
 Andrea De Maria, Genova
 Anita De Rossi, Padova
 Antonio Di Biagio, Genova
 Simona Di Giambenedetto, Roma
 Giovanni Di Perri, Torino
 Massimo Di Pietro, Firenze
 Margherita Errico, Milano
 Carlo Ferrari, Parma
 Daniela Francisci, Perugia
 Giovanni Battista Gaeta, Napoli
 Ivan Gardini, Roma
 Cristina Gervasoni, Milano
 Valeria Ghesetti, Torino
 Vania Giacomet, Milano
 Nicola Gianotti, Milano
 Enrico Girardi, Roma
 Andrea Gori, Monza
 Giovanni Guaraldi, Modena
 Maria Rosaria Iardino, Milano
 Giuseppe Lapadula, Monza
 Miriam Lichtner, Latina
 Giuseppina Liuzzi, Roma
 Sergio Lo Caputo, Firenze
 Olimpia Longo, Roma
 Daniela Lorenzetti, Roma
 Giordano Madeddu, Sassari
 Paolo Maggi, Bari
 Franco Maggiolo, Bergamo
 Ivana Maida, Sassari
 Marina Malena, Verona
 Giulia Carla Marchetti, Milano
 Bruno Marchini, Roma
 Simone Marcotullio, Roma

Renato Maserati, Pavia
 Claudio M. Mastroianni, Latina
 Alberto Matteelli, Brescia
 Sandro Mattioli, Bologna
 Stefano Menzo, Roma
 Ivano Mezzaroma, Roma
 Valeria Micheli, Milano
 Laura Monno, Bari
 Paola Nasta, Brescia
 Emanuele Nicastrì, Roma
 Silvia Nozza, Milano
 Giancarlo Orofino, Torino
 Lucia Palmisano, Roma
 Saverio Parisi, Padova
 Giustino Parruti, Pescara
 Massimo Puoti, Milano
 Vincenzo Puro, Roma
 Tiziana Quirino, Busto Arsizio VA
 Maria Carla Re, Bologna
 Agostino Riva, Milano
 Stefano Rusconi, Milano
 Caterina Sagnelli, Napoli
 Maria Santoro, Roma
 Annalisa Saracino, Bari
 Loredana Sarmati, Roma
 Filippo von Schloesser, Roma
 Paola Scognamiglio, Roma
 Alessandro Soria, Monza
 Nicola Squillace, Monza
 Gaetana Sterrantino, Firenze
 Valentina Svicher, Roma
 Gloria Taliani, Roma
 Giuseppe Tambussi, Milano
 Marcello Tavio, Ancona
 Camilla Tincati, Milano
 Carlo Torti, Catanzaro
 Daria Trabattoni, Milano
 Ombretta Turriziani, Roma
 Emanuela Vaccher, Aviano PN
 Gabriella Verucchi, Bologna
 Mauro Zaccarelli, Roma
 Bruna Zani, Bologna
 Maurizio Zazzi, Siena

Mission statement

The aim is to provide a forum of the highest standard for scientific (both clinical and basic), educational and social exchange between professionals involved in infectious diseases, liaising with patient organizations, in order to achieve progress in the clinical care of patients with HIV and Hepatitis.

SETTIMO CONGRESSO NAZIONALE



ICAR
Italian
Conference on
AIDS and
Retroviruses

The 7th ICAR 2015 conference draws the scientific community's attention to the importance of identifying diagnostic and treatment pathways for HIV infection that should be based on interactions between basic research, diagnostic and clinical research, and the specific needs of seropositive individuals.

The excellent results achieved to date with antiretroviral drugs, along with the experience in the management and customization of healthcare pathways, have prompted the search for new treatment strategies and innovative targets for intervention. Within this perspective, the topics addressed in the conference will include translational medicine, to promote the debate and exchange of knowledge between clinical practice and basic research, especially in the virological and immunological fields.

The new treatment opportunities for viral forms of hepatitis represent another therapeutic and healthcare challenge: the experience acquired in HIV can be useful in the management of both monoinfected and coinfecting patients.

Other important topics of this ICAR edition include gender medicine, not only from a female perspective, and the natural resistance to HIV infection and/or its progression as a key to understanding the pathogenesis of this infection and an instrument to identify new eradication strategies.

The Community of patient associations will be actively involved by contributing their experience on the needs and problems of HIV-infected people. The topic of prevention will be also discussed, with a review of both pharmacological and behavioral aspects. The sharing of experience is crucial to identify those sectors of research, whether clinical or basic, that may provide results which affect patients' quality of life.

A central feature of ICAR 2015 is the contribution of Italian young researchers, who will present mainly original works during the various sessions. This edition will also see the participation of foreign young researchers, with the purpose of promoting the sharing of research projects at the international level.

To support young researchers, the conference will host the second edition of the **ICAR-CROI Award** and other prizes granted by scientific societies.


Welcome to ICAR 2015!

Cristina Mussini



Cristina Mussini

The Chairs
Laura Sighinolfi



Laura Sighinolfi

Andrea Cossarizza



Andrea Cossarizza

WE CAN'T WE CAN

We can't promise that all breakthroughs in HIV therapy will happen in our labs.

We can promise to keep searching until there's a cure.



Constantly seeking solutions

Programme at a glance

DOMENICA 17	AUDITORIUM, CONCORDIA HALL	POLISSENA B HALL	GINEVRA HALL	VIOLANTE HALL
10:30	Secretariat Opening and Registration			
13:00 14:30	Lunch			
14:30 15:00		14:30 - 17:00 Pre-conference advanced course	14:30 - 17:00 Pre-conference advanced course	14:30 - 16:30 Pre-conference advanced course
15:00 16:30	15:00 - 17:00 Incontro Scuole "RaccontART HIV" Pag. 17	LA VIROLOGIA E L'IMMUNOLOGIA INCONTRANO LA CLINICA: I PARAMETRI VIROLOGICI E IMMUNOLOGICI DI FRONTIERA OGGI Pag. 14	IL RISCHIO DI INFEZIONE DA HIV E ALTRI PATOGENI A TRASMISSIONE EMATICA PER IL PERSONALE SANITARIO Pag. 15	DALLA RICERCA TRASLAZIONALE: BRAIN WAVE IN HIV. DIAGNOSI MIRATA E PRECOCE AL PAZIENTE CON DISTURBI NEUROCOGNITIVI Pag. 16
16:30 17:00				
17:00 19:45	<p style="text-align: center;">Opening Session <i>Auditorium, Concordia Hall</i></p> <p style="text-align: center;">17:00 - 17:30 Introducing ICAR 2015 Authorities' welcome addresses</p> <p style="text-align: center;">17:30 - 17:50 RaccontART HIV contest Award</p> <p style="text-align: center;">17:50 - 19:20 Opening Lectures <i>Nuclear architecture and the determinants for HIV latency - Mauro Giacca, Trieste</i> <i>A global approach: what can we learn from HIV in the HCV epidemics? - Isabelle Meyer-Andrieux, Geneva CH</i> <i>Italian research on HIV/AIDS: from the past to the future - Antonella d'Arminio Monforte, Milano</i> Pag. 21</p> <p style="text-align: center;">19:20 - 19:45 ICAR-CROI Awards 2015 for young Italian HIV investigators Pag. 22</p>			
19:45 22:30	<p style="text-align: center;">ICAR 2015 Welcome Reception Pag. 22</p>			

Programme at a glance

LUNEDÌ 18	AUDITORIUM, CONCORDIA HALL	CONCORDIA C HALL	POLISSENA A HALL	POLISSENA B HALL
08:30 10:00	<p>Keynote Lectures <i>Auditorium, Concordia Hall</i> Changing scenario in antiretroviral therapy - Massimo Andreoni, Roma Cross-talk between natural killer and dendritic cells in antiviral immune response - Guido Ferlazzo, Messina Recent advances in understanding mechanisms of HBV entry and replication - Maura Dandri, Hamburg D Pag. 23</p>			
10:00 11:00	<p>SYMPOSIUM ICAR-SIVIM-SIV Advanced diagnostic virology Pag. 23</p>	<p>SYMPOSIUM Doctor I feel old! Integration of clinical and patient related outcomes in the description of ageing as a health condition Pag. 27</p>	<p>ORAL COMMUNICATIONS Immunology: molecular and cellular aspects of viral infections Pag. 31</p>	<p>ORAL COMMUNICATIONS Community based studies Pag. 36</p>
11:00 12:30	<p>SYMPOSIUM Beyond the standard of care: HIV Pag. 24</p>	<p>ORAL COMMUNICATIONS Social and behavioural science Pag. 28</p>	<p>ORAL COMMUNICATIONS Clinical and epidemiological aspects Pag. 32</p>	<p>ORAL COMMUNICATIONS Comorbidities Pag. 37</p>
12:30 13:15	<p>SATELLITE SYMPOSIUM Patient needs and third agent choice: Dolutegravir, the innovative answer Pag. 24</p>			
13:20 14:05	<p>EXPERT MEETING Antiviral treatment for hepatitis C: the new challenge Pag. 24</p>	<p>EXPERT MEETING HIV and comorbidities: a total patient care approach for a long term success Pag. 29</p>		
14:10 14:55	<p>ORAL POSTER HIV clinical science Pag. 25</p>	<p>EXPERT MEETING One fibrosis stage, one therapy Pag. 29</p>	<p>ORAL POSTER Immuno-virological determinants Pag. 33</p>	<p>ORAL POSTER Basic science Pag. 38</p>
15:00 16:30	<p>Round Table PrEP: is it the right time to act? <i>Auditorium, Concordia Hall</i> Pag. 26</p>			
16:30 17:15	<p>SYMPOSIUM Viruses and cancers in HIV setting Pag. 26</p>	<p>SYMPOSIUM New therapeutic scenarios in patients with HIV-HCV coinfection Pag. 29</p>	<p>ORAL COMMUNICATIONS Clinical HIV Pag. 34</p>	<p>SYMPOSIUM New challenges in reproduction Pag. 39</p>
17:15 17:45		<p>ORAL COMMUNICATIONS Translational sciences Pag. 30</p>		
17:45 18:30				

19:30 - 20:30 ICAR RUN - Piazzale Ceccarini

Programme at a glance

MARTEDÌ 19	AUDITORIUM, CONCORDIA HALL	CONCORDIA C HALL	POLISSENA A HALL	POLISSENA B HALL
08:30 10:00	<p align="center">Keynote Lectures <i>Auditorium, Concordia Hall</i></p> <p align="center"><i>Ready to cure a broad spectrum of HCV patients: from the clinical trials to the field practice - Gloria Taliani, Roma</i> <i>Light and shadow in HIV therapeutic switch: criteria of virological evaluation and pharmacological options - Carlo Federico Perno, Roma</i> <i>From bench to bedside: what we have learnt from CCR5 - Lucia Lopalco, Milano</i></p> <p align="center">Pag. 40</p>			
10:00 11:00	<p align="center">SYMPOSIUM ICAR-AISF-SIMIT Beyond the standard of care: Hepatitis</p> <p align="center">Pag. 40</p>	<p align="center">ORAL COMMUNICATIONS Antiretroviral trials and observational studies</p> <p align="center">Pag. 45</p>	<p align="center">SYMPOSIUM WIN The adolescent perspective in HIV infection</p> <p align="center">Pag. 49</p>	<p align="center">ORAL POSTER Social, economical and clinical outcomes</p> <p align="center">Pag. 52</p>
11:00 12:30	<p align="center">ORAL COMMUNICATIONS HIV and HCV: which future?</p> <p align="center">Pag. 41</p>	<p align="center">ORAL COMMUNICATIONS Coinfections with hepatitis viruses</p> <p align="center">Pag. 46</p>	<p align="center">ORAL COMMUNICATIONS HIV transmission and primary HIV infection</p> <p align="center">Pag. 50</p>	<p align="center">ORAL COMMUNICATIONS Social vulnerability</p> <p align="center">Pag. 53</p>
12:30 13:15	<p align="center">EXPERT MEETING Tenofovir: yesterday, today and tomorrow</p> <p align="center">Pag. 42</p>			
13:20 14:05	<p align="center">EXPERT MEETING HCV between past and future: moving towards the cure</p> <p align="center">Pag. 42</p>	<p align="center">EXPERT MEETING The reliable individualization of today for the patients of tomorrow</p> <p align="center">Pag. 47</p>		
14:10 15:00	<p align="center">ORAL COMMUNICATIONS Clinical Hepatitis</p> <p align="center">Pag. 43</p>	<p align="center">ORAL COMMUNICATIONS Complication of HIV infection and antiretroviral therapy</p> <p align="center">Pag. 48</p>	<p align="center">ORAL COMMUNICATIONS Pathogenesis and immunopathogenesis</p> <p align="center">Pag. 51</p>	<p align="center">ORAL COMMUNICATIONS Clinical virology</p> <p align="center">Pag. 54</p>
15:00 16:00				
16:00 16:50	<p align="center">Wrap Up Session Highlights of the main topics from ICAR 2015 <i>Auditorium, Concordia Hall</i></p> <p align="center">Pag. 44</p>			
16:50 17:15	<p align="center">ICAR 2015 Awards and Closing remarks <i>Auditorium, Concordia Hall</i></p> <p align="center">Pag. 44</p>			



Oggi, il mondo di domani

Oggi il mondo di domani è l'impegno ad agire per un presente responsabile ed un futuro sostenibile. Per Bristol-Myers Squibb significa scoprire, sviluppare e offrire terapie innovative per aiutare i pazienti a sconfiggere malattie gravi. Ma significa anche avere la piena consapevolezza degli obblighi verso la comunità locale e globale, trasformandoli in impegno concreto. Il nostro impegno guarda al futuro e alle realtà più lontane ma inizia nel presente e dai luoghi a noi più vicini. **Oggi per il domani.**



ADVANCED COURSES

14:30 - 17:00

PRE-CONFERENCE ADVANCED COURSE LA VIROLOGIA E L'IMMUNOLOGIA INCONTRANO LA CLINICA: I PARAMETRI VIROLOGICI E IMMUNOLOGICI DI FRONTIERA OGGI

MODERATORI: **G. Antonelli** (Roma), **M. Clerici** (Milano)

DISCUSSANTS: **M.R. Capobianchi** (Roma), **M.C. Re** (Bologna), **L. Sarmati** (Roma)

Il precorso affronta aspetti importanti per una gestione ottimale del paziente con infezione cronica HIV-1, HCV od HBV, approfondendo gli aspetti traslazionali delle attuali conoscenze immunologiche e virologiche, e sviluppando un percorso applicativo alla clinica quotidiana delle tecniche/tecnologie virologiche e immunologiche più recentemente acquisite. Verranno inoltre evidenziate le eventuali criticità delle tecniche virologiche ed immunologiche e metodologiche cliniche in uso e saranno discusse le opzioni per l'applicazione di metodiche "di frontiera" attuali o future in ambito HIV-1, HCV, HBV tramite discussione con esperti della clinica, della virologia e dell'immunologia.

HBV e rischio di riattivazione

14:30 - 14:42 **Il punto di vista del virologo**

Valentina Svicher, Roma

14:42 - 14:54 **Il punto di vista dell'immunologo**

Carlo Ferrari, Parma

14:54 - 15:06 **Il punto di vista del clinico**

Vito Di Marco, Palermo

15:06 - 15:20 **Discussione**

HIV e il paziente difficile, oggi qual è?

15:20 - 15:32 **Il punto di vista del virologo**

Maurizio Zazzi, Siena

15:32 - 15:44 **Il punto di vista dell'immunologo**

Giulia Marchetti, Milano

15:44 - 15:56 **Il punto di vista del clinico**

Silvia Nozza, Milano

15:56 - 16:10 **Discussione**

HCV nell'era dei nuovi farmaci

16:10 - 16:22 **Il punto di vista del virologo**

Valeria Cento, Roma

16:22 - 16:34 **Il punto di vista dell'immunologo**

Andrea De Maria, Genova

16:34 - 16:46 **Il punto di vista del clinico**

Maurizia Brunetto, Pisa

16:46 - 17:00 **Discussione**

14:30 - 17:00

PRE-CONFERENCE ADVANCED COURSE IL RISCHIO DI INFEZIONE DA HIV E ALTRI PATOGENI A TRASMISSIONE EMATICA PER IL PERSONALE SANITARIOMODERATORI: **A. Bonini** (Milano), **M. Oldrini** (Milano), **M.G. Tajè** (Legnano, MI)

Il rischio per gli operatori sanitari di acquisire l'infezione da HIV è stato di stimolo per studi approfonditi sull'efficacia di trasmissione in seguito ad infortunio, i fattori favorenti, gli interventi di profilassi farmacologica ma soprattutto sulle possibili misure di prevenzione degli incidenti occupazionali. Il quadro epidemiologico oggi è mutato e il progresso scientifico, unitamente all'esperienza accumulata dall'inizio dell'epidemia, hanno radicalmente trasformato e ridotto il rischio occupazionale di infezione da HIV e da altri patogeni a trasmissione ematica.

Il Corso, destinato agli operatori sanitari, si propone un duplice obiettivo:

- 1) fornire una informazione corretta ed attuale sugli agenti a trasmissione ematica, sulle modalità di trasmissione di tali agenti in ambito sanitario e sulle precauzioni da adottare per prevenire le esposizioni;*
- 2) approfondire le misure da adottare dopo un'esposizione a rischio per prevenire le infezioni occupazionali, i controlli necessari e le opportunità terapeutiche, in modo da motivare correttamente gli operatori alla pronta notifica delle esposizioni.*

14:30 - 14:50	Il percorso infermieristico della persona con HIV a 30 anni dalla sua comparsa	Gianfranco Bocchi, Bologna
14:50 - 15:10	Il punto di vista del paziente nel rapporto con gli infermieri	Ada Moznich, Pordenone
15:10 - 15:30	Rischio professionale di infezione da HIV e altri patogeni a trasmissione ematica e gestione post-esposizione	Gabriella De Carli, Roma

La prevenzione delle esposizioni professionali

15:30 - 15:50	Rischio biologico occupazionale: aspetti organizzativi	Lorenza Camponovo, Monza
15:50 - 16:10	I dispositivi di sicurezza: loro scelta ed uso	Lorena Martini, Roma
16:10 - 17:00	Discussione	

14:30 - 16:30

PRE-CONFERENCE ADVANCED COURSE DALLA RICERCA TRASLAZIONALE: BRAIN WAVE IN HIV. DIAGNOSI MIRATA E PRECOCE AL PAZIENTE CON DISTURBI NEUROCOGNITIVIMODERATORI: **M. Andreoni** (Roma), **P. Onorati** (Roma)

Il complesso delle alterazioni neurocognitive associate ad HIV (HAND) provoca una disabilità funzionale, rilevata da una batteria di test neurocognitivi entrata nella pratica clinica, in grado di interferire in vario grado con le attività quotidiane condizionando negativamente la qualità della vita dei pazienti. In considerazione del noto ed immediato coinvolgimento del Sistema Nervoso Centrale (SNC) da parte di HIV diventa importante avere test diagnostici in grado di evidenziare il coinvolgimento del SNC ancor prima che questo si manifesti in una disabilità funzionale diagnosticabile dall'esame neuropsicologico.

LORETA (Low Resolution Electromagnetic Tomography) è un software di elaborazione delle sorgenti corticali EEG, già validato per la Malattia di Alzheimer ed il Morbo di Parkinson, che nel 2011 è stato introdotto in via sperimentale nella valutazione neurocognitiva dei soggetti HIVsieropositivi e si è rivelato sin da subito uno strumento valido e promettente. Le sorgenti corticali dei ritmi EEG a riposo sono promettenti biomarcatori delle alterazioni di HIV e degli effetti positivi della terapia antiretrovirale sul SNC, fornendo un ulteriore elemento a favore dell'inizio precoce del trattamento.

- 14:30 - 14:50 **Valutazione della funzione cerebrale mediante lo studio dei ritmi elettroencefalografici corticali** Claudio Babiloni, Roma
- 14:50 - 15:00 **Discussione**
- 15:00 - 15:20 **Le anomalie dei ritmi elettroencefalografici corticali nei pazienti HIV** Alfredo Pennica, Roma
- 15:20 - 15:30 **Discussione**
- 15:30 - 16:30 TAVOLA ROTONDA
Brain Wave in HIV: le sorgenti corticali dei ritmi EEG quali possibili biomarcatori delle alterazioni di HIV e degli effetti positivi della terapia antiretrovirale sul SNC
 Massimo Andreoni (Roma), Claudio Babiloni (Roma), Paolo Onorati (Roma), Alfredo Pennica (Roma)

15:00 - 17:00

INCONTRO SCUOLE "RaccontART HIV"MODERATORI: **A. Cossarizza** (Modena), **M. Errico** (Milano), **C. Mussini** (Modena), **L. Sighinolfi** (Ferrara)15:00 - 15:10 **Introduzione e obiettivi dell'incontro** *Cristina Mussini (Modena), Margherita Errico (Milano)*15:10 - 15:20 **Cosa ne sai? La Conoscenza dell'AIDS e delle MST** *Alessandro Battistella (Università Ca' Foscari e Ministero della Salute)*

15:20 - 16:30 **Presentazione delle Opere candidate al Concorso a cura dei Referenti Scolastici e degli Autori**

- Liceo Artistico Dosso Dossi, Ferrara - Ref. Scolastici Sandra Marinelli e Stefania D'Arcangelo
- Istituto Superiore L. Einaudi, Ferrara - Ref. Scolastico Pietro Benedetti
- Liceo Scientifico A. Einstein, Rimini - Ref. Scolastico Patrizia Mariani
- I.T.I.S. E. Fermi, Modena - Ref. Scolastico Giusi Mauceri e Francesca Negri
- I.T.I.S. Nullo Baldini, Ravenna - Ref. Scolastico Laura Bezzi
- Liceo Scientifico A. Tassoni, Modena - Ref. Scolastico Rosa Maria Coppelli
- Scuola Media Via Pascoli, Cesena - Ref. Scolastici Sabrina Rossi e Maurizio Mastrandrea

16:30 - 17:00 **Presentazione della Giuria Artistica**

LA GIURIA ARTISTICA

- **Andrea Adriatico** regista di teatro e di cinema
- **Alessandro Gottardo (alias Shout)** illustratore
- **Luigi Lo Cascio** attore e regista di teatro e cinema
- **Enzo Porcelli** produttore cinematografico
- **Massimo Pulini** storico d'arte e docente di pittura
- **Rocco Toscani** fotografo e videomaker

LA GIURIA SCIENTIFICA

- **Francesca Ceccherini-Silberstein** Università Tor Vergata di Roma
- **Andrea Cossarizza** Università degli Studi di Modena e Reggio Emilia
- **Silvia Nozza** IRCCS Ospedale S. Raffaele, Milano
- **Cristina Mussini** Azienda Ospedaliero-Universitaria Policlinico di Modena
- **Laura Sighinolfi** Azienda Ospedaliero-Universitaria di Ferrara
- **Michele Breveglieri** Arcigay, Verona
- **Alessandra Cerioli** LILA, Como
- **Margherita Errico** NPS Italia, Milano
- **Bruno Marchini** Anlaids, Roma
- **Simona Nasta** NPS sezione Sicilia, Palermo
- **Domenico Salierio** NPS sezione Campania, Napoli

ViiV Healthcare

Il nostro solo focus è L'HIV

Un impegno dedicato al 100% all'HIV, unico al mondo, un approccio innovativo nella ricerca di terapie efficaci, che si concretizza in un ampio portfolio di prodotti e una ricca e innovativa pipeline.

Comprendere le necessità delle persone sieropositive, rispondendo alle continue sfide che la malattia ci pone, per contribuire al miglioramento del loro futuro.





SCIENTIFIC PROGRAMME



17:00 - 17:30

ICAR 2015 OPENING SESSION

CHAIRS: **A. Cossarizza** (Modena), **C. Mussini** (Modena), **L. Sighinolfi** (Ferrara)

Introducing ICAR 2015

*Massimo Andreoni (SIMIT), Guido Antonelli (SIVIM), Andrea Cossarizza (SIICA),
Marco Marzioni (AISF), Stefano Vella (ISS)*

Adriano Lazzarin, Milano

Authorities' welcome addresses

17:30 - 17:50

"RaccontART HIV" CONTEST AWARD

CHAIRS: **G. Carosi** (Brescia), **R. Cauda** (Roma)

17:50 - 19:20

OPENING LECTURES

CHAIRS: **A. Antinori** (Roma), **S. Vella** (Roma)

- 17:50 - 18:20 **Nuclear architecture and the determinants for HIV latency**
18:20 - 18:50 **A global approach: what can we learn from HIV in the HCV epidemics?**
18:50 - 19:20 **Italian research on HIV/AIDS: from the past to the future**

Mauro Giacca, Trieste
Isabelle Meyer-Andrieux, Geneva CH
Antonella d'Arminio Monforte, Milano



19:20 - 19:45

ICAR-CROI AWARDS 2015 FOR YOUNG ITALIAN HIV INVESTIGATORSCHAIRS: **B. Hahn** (Philadelphia USA), **A. Lazzarin** (Milano), **G. Silvestri** (Atlanta USA)**Selected Italian Investigator:**

- Premature Aging and Immune Senescence in HIV-1-Infected Children
- Long-Term Consequences of Planned Treatment Interruption in HIV-1-Infected Children
- Regulation of IL-32 Expression by a Promoter Polymorphism and MicroRNA29b in HIV-1 Patients
- Declining Prevalence of HIV-Associated Neurocognitive Disorders in More Recent Years
- Invariant Natural Killer T-Cells in HIV-HBV co-infection
- sCD163 increase in HIV/CMV coinfecting subjects included in ICONA Cohort
- Heel Quantitative Ultrasound to Cut down on DXA Costs in HIVinfected Patients
- Cognitive Reserve and Neuropsychological Functioning in Older HIV-Infected People
- Neurocognitive Screening Tests Are Associated With Cardiovascular Risk and VACS Scores
- Complex HBV Quasispecies Affects Immunogenicity in Acute Hepatitis B Infection
- Determinants of Parathyroid Hormone Levels in HIV-positive Tenofovir-treated Patients with Normal Renal Function
- Integrase S119P mutation correlates with disease progression in HIV-1 naïve patients
- RANKL predicts 96-week BMD changes in ATV/r monotherapy: a MODAt trial sub-study
- Cerebrospinal fluid markers in long-term atazanavir/ritonavir monotherapy
- Incidence of extrahepatic complications in HIV/HCV patients who achieved SVR
- Residual Viremia Caused by Clonally Expanded Tumor-Infiltrating CD4+ Cells
- Monocytes activation characterizes immune failure but not cognitive impairment on ART

Ketty Giancesin, Padova
Riccardo Freguja, Padova
Carolina Scagnolari, Roma
Carmela Pinnetti, Roma
Matteo Basilissi, Milano
Serena Vita, Latina
Marilia Rita Pinzone, Catania
Benedetta Milanini, Roma
Andrea Calcagno, Torino
Valentina Svicher, Roma

Letizia Marinaro, Torino
Daniele Armenia, Roma
Vincenzo Spagnuolo, Milano
Francesca Ferretti, Milano
Sebastiano Leone, Monza
Francesco R. Simonetti, Milano
Antonio Muscatello, Monza

19:30 - 19:45 **ICAR-CROI Awards: Winner's lecture**

19:45 - 22:30

WELCOME RECEPTION

SETTIMO CONGRESSO NAZIONALE



ICAR
 Italian
 Conference on
 AIDS and
 Retroviruses



08:30 - 10:00**KEYNOTE LECTURES**CHAIRS: **A. Cossarizza** (Modena), **G. Di Perri** (Torino), **C. Ferrari** (Parma)08:30 - 09:00 **Changing scenario in antiretroviral therapy**

Massimo Andreoni, Roma

09:00 - 09:30 **Cross-talk between natural killer and dendritic cells in antiviral immune response**

Guido Ferlazzo, Messina

09:30 - 10:00 **Recent advances in understanding mechanisms of HBV entry and replication**

Maura Dandri, Hamburg D

10:00 - 11:00**SYMPOSIUM ICAR-SIVIM-SIV ADVANCED DIAGNOSTIC VIROLOGY**CHAIRS: **M. Clementi** (Milano), **M. Zazzi** (Siena)DISCUSSANT: **S. Parisi** (Padova)

In the era of highly efficacious novel therapeutic strategies for HIV and viral hepatitis, several grey areas remain still to be addressed, particularly regarding the eradication and functional cure of HIV and HBV. The objective of the symposium is therefore focused on comparing similarities and differences between HIV and HBV reservoirs, and to understand the role of HIV and HBV DNA as markers of therapy outcome, persistence, viral replication, viral reactivation, and carcinogenesis. Moreover, it will be discussed if in the era of individualized medicine versus simplification approach, the resistance test can still be relevant in the management and choice of antiviral treatments.

10:00 - 10:15 **Resistance test: if, when, how**

Francesca Ceccherini-Silberstein, Roma

Comparing reservoir10:15 - 10:30 **HIV: HIV DNA and its prognostic role**

Ombretta Turriziani, Roma

10:30 - 10:45 **HBV: which prognostic markers?**

Massimo Levrero, Roma

10:45 - 11:00 **Discussion**

11:00 - 12:30**SYMPOSIUM BEYOND THE STANDARD OF CARE: HIV**CHAIRS: **A. Lazzarin** (Milano), **S. Marcotullio** (Roma)DISCUSSANTS: **S. Bonora** (Torino), **A. De Luca** (Siena), **L. Palmisano** (Roma)

The introduction of active antiretroviral therapy (ART) has reduced morbidity and mortality rates in HIV infected individuals. Nowadays the management of HIV patients according to guidelines obtains a prolonged efficacy in the majority of chronically infected patients. However the therapeutical approach to several clinical situations is still debated. Acute infection, viral persistence, high viremia and viral failure could need management interventions beyond the standard of care, in order to obtain a durable treatment success.

Objective of the Symposium is to enhance information about new strategies, to highlight uncertainties and to explore innovative clinical and treatment interventions in ameliorating HIV patient's management.

11:00 - 11:15	Introduction	Maria Santoro, Roma
11:15 - 11:30	Acute infection: is it a real option for cure?	Giuseppe Tambussi, Milano
11:30 - 11:45	Viral persistence: an obstacle for cure	Javier Martinez-Picado, Barcelona E
11:45 - 12:00	Does high viremia change perspectives?	Antonio Di Biagio, Genova
12:00 - 12:15	New paradigms in viral failure	Antonella Castagna, Milano
12:15 - 12:30	Discussion	

12:30 - 13:15**SATELLITE SYMPOSIUM PATIENT NEEDS AND THIRD AGENT CHOICE:
DOLUTEGRAVIR, THE INNOVATIVE ANSWER**CHAIRS: **A. Antinori** (Roma), **A. Lazzarin** (Milano)

The setting of ARV is increasingly driven by the choice of the third agent. There are common needs both of patients and IDs in terms of efficacy, durability and tolerability. The results of Dolutegravir Phase III Trials offer new opportunities to address these needs.

12:30 - 12:50	Efficacy and durability in long term treatment goal	Antonella Castagna, Milano
12:50 - 13:10	Tolerability and convenience as guarantee of patients expectations	Massimo Andreoni, Roma
13:10 - 13:15	Discussion	

Sponsored by ViiV Healthcare

13:20 - 14:05**EXPERT MEETING ANTIVIRAL TREATMENT FOR HEPATITIS C: THE NEW CHALLENGE**CHAIRS: **C.F. Perno** (Roma), **M. Puoti** (Milano)

Numerous interferon- and ribavirin-free DAA combinations are emerging and all promise HCV cure rates above 95%. The revolution of HCV therapy is taking place at an incredible pace leaving little room for further optimization indeed, but challenges remain for some patient populations in which HCV treatment often represents a high priority. HCV therapy in genotype infected HCV patients is still challenging; not all of the newly available DAAs have activity against genotype 3 further limiting treatment choices in this patient group. HIV/HCV coinfecting subjects are 3 times more likely to develop cirrhosis or liver decompensation than HCV monoinfected. It's time to identify oral IFN- and RBV-free therapies, highly effective, safe and well tolerated, with a predictable DDI profile and compatible with a wide range of ARVs, so HIV/HCV coinfecting individuals will actually no longer be regarded as special patient population.

13:20 - 13:40	HCV treatment for genotype 3 and HIV/HCV coinfecting patients	Giovanni Di Perri, Torino
13:40 - 14:00	New DAA based therapies: the French experience	Christophe Hézode, Paris F
14:00 - 14:05	Discussion	

Unrestricted educational grant of Bristol-Myers Squibb

14:10 - 14:55

ORAL POSTER HIV CLINICAL SCIENCE

CHAIRS: **G. Madeddu** (Sassari), **T.S. Prestileo** (Palermo)

- OP 1 **An Organizational Model to Prevent HIV/AIDS in a Community Context: The Case "AIDS Commission"**
M. Boni, G. De Angelis, M.M. Daglio, A. Canale, C. Mussini, G. Fattori
Commissione AIDS provincia di Modena
- OP 2 **Outreach program of HIV rapid testing among people at higher risk of HIV living in Italy: preliminary results**
P. Scognamiglio¹, **G. Chiaradia**¹, M. Oldrini², M. Breveglieri³, E. Albertini³, A. Camposeragna⁴, M. Farinella⁵, D. Lorenzetti⁶, L. Rancilio⁷, M.G. Pompa⁸, E. Girardi¹, G. Ippolito¹
¹Istituto Nazionale Malattie Infettive "L. Spallanzani", IRCCS, Roma, ²Lila, ³Arcigay, ⁴CNCA, ⁵Circolo Mario Mieli, ⁶ANLAIDS, ⁷Caritas, ⁸Ministero della Salute
- OP 3 **Cost-Effectiveness of Optimized Therapies in Virologically-Suppressed, HIV-positive Patients in 2013 and 2014: a Comparison**
A. Borghetti¹, S. La Monica¹, A. D'Avino¹, I. Fanti¹, R. Gagliardini¹, A. Mondì¹, F. Pallavicini¹, R. Cauda¹, A. De Luca², M. Fabbiani¹, S. Di Giambenedetto¹
¹Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Policlinico Gemelli, Rome, ²UOC, University Infectious Disease, Azienda Ospedaliera Universitaria Senese, Siena
- OP 4 **Six-month efficacy and safety of switching from branded to generic antiretrovirals**
LB N. Gianotti¹, A. Poli², L. Galli¹, M. Franzin³, P. Tadini³, C. Uberti-Foppa¹, G. Tambussi¹, M. Cernuschi¹, P. Scarpellini¹, P. Cinque¹, A. Lazzarin^{1,2}, A. Castagna^{1,2}
¹Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy, ²Università Vita-Salute San Raffaele, Milano, Italy, ³Pharmacy, San Raffaele Scientific Institute, Milano, Italy
- OP 5 **Comparison of virologic and immunologic outcome between patients on a stable tenofovir/emtricitabine-containing regimen continuing tenofovir/emtricitabine or switching to an abacavir/lamivudine containing regimen**
LB C. Bianco^{1,2}, A. Vergori¹, S. Di Giambenedetto², B. Bruzzone³, I. Vicenti⁴, A. Zoncada⁵, D. Francisci⁶, A. Di Biagio⁷, M. Colafigli⁶, M. Pecorari⁸, A.R. Pignataro⁹, A. Giacometti¹⁰, M. Zazzi⁴, A. De Luca¹, B. Rossetti^{1,2} for the ARCA Collaborative Group
¹University Infectious Diseases Clinic, Azienda Ospedaliera Universitaria Senese, Siena, ²Clinic of Infectious Diseases, Catholic University of Sacred Heart, Roma, ³Hygiene Unit, IRCCS AOU San Martino-IST, Genova, ⁴Department of Medical Biotechnologies, University of Siena, Siena, ⁵Infectious Diseases Clinic, Cremona Hospital, Cremona, ⁶Infectious Diseases Clinic, Perugia University Hospital, Perugia, ⁷Infectious Diseases Unit, IRCCS AOU San Martino-IST, Genova, ⁸Laboratory of Microbiology and Virology, Modena University Hospital, Modena, ⁹Laboratory of Microbiology, Ospedale San Raffaele, IRCCS, Milano, ¹⁰Infectious Diseases Clinic, Ancona Hospital, Ancona
- OP 6 **Late presentation in HIV infected intravenous drug users admitted in a Romanian regional center**
I. Ianache¹, C. Oprea^{1,2}
¹"Victor Babes" Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania, ²"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania

15:00 - 16:30**ROUND TABLE PREP: IS IT THE RIGHT TIME TO ACT?**CHAIRS: **G.M. Corbelli** (Roma), **E. Girardi** (Roma), **C. Mussini** (Modena)

There is an increasing scientific evidence on the possibility to prevent the acquisition of HIV infection with antiretroviral drugs i.e. pre-exposure prophylaxis (PrEP). At present, we think that it is time at least to discuss how to go further with this in European Health Systems. The round table will put together all stakeholders: researchers who will present the scientific evidence from trials and the impact of PrEP in clinical practice in the US, a EMA representative, a drug-company representative, HIV-positive representatives and a representative from a lesbian, gay and transgender organization.

15:00 - 15:10	Results from the PROUD study	Sheena McCormack, London UK
15:10 - 15:20	Results from the IPERGAY study	Eric Cua, Nice F
15:20 - 15:30	The American experience	Roy M. Gulick, New York USA
15:30 - 15:40	EMA: Regulatory perspective	Sabrina Spinosa Guzman, London UK

PRO & CONS in Italy

15:40 - 15:50	People living with HIV perspective	Maria Rosaria Iardino, Milano
15:50 - 16:00	Non-infected perspective	Alberto Bignardi, Modena
16:00 - 16:30	Discussion	
A. Bignardi (Modena), G.M. Corbelli (Roma), E. Cua (Nice F), E. Girardi (Roma), R.M. Gulick (New York USA), M.R. Iardino (Milano), S. McCormack (London UK), C. Mussini (Modena), J. Rooney (Foster City USA), S. Spinosa Guzman (London UK)		

16:30 - 17:45**SYMPOSIUM VIRUSES AND CANCERS IN HIV SETTING**CHAIRS: **C.F. Perno** (Roma), **E. Vaccher** (Aviano PN)DISCUSSANT: **M.R. Capobianchi** (Roma)

The etiological factors that contribute to cancers pathogenesis in HIV infected people are multifactorial. Persons living with HIV/AIDS are susceptible to infection by oncogenic viruses, and EBV, HHV-8, HPV, HBV and HCV, all implicated in HIV malignancies by altering mechanisms of apoptosis and cell cycle regulation, activating oncogenes, and inhibition of tumor suppressor genes, are more prevalent in HIV infected individuals than in general population. Antiretroviral therapy may change the HIV/AIDS natural history to that of a chronic disease, but the risk of cancer persistently affect even HIV treated population, and how oncogenic viruses, HIV, and CD4 T-cell lymphocytes interact to promote malignancies remains to be completely elucidated.

16:30 - 16:50	HIV malignancies in the late antiretroviral era	Andrea Antinori, Roma
16:50 - 17:10	Gene signaling networks and transcriptional signatures in immune and neoplastic tissues: translational prospects for HIV-associated tumors	Davide Bedognetti, Doha Q
17:10 - 17:30	Role of EBV and HIV cooperation in lymphomagenesis	Riccardo Dolcetti, Aviano PN
17:30 - 17:45	Discussion	



10:00 - 11:00**SYMPOSIUM DOCTOR I FEEL OLD! INTEGRATION OF CLINICAL AND PATIENT RELATED OUTCOMES IN THE DESCRIPTION OF AGEING AS A HEALTH CONDITION**CHAIRS: **P. Cinque** (Milano), **F. von Schloesser** (Roma)DISCUSSANTS: **A.M. Cattelan** (Padova), **M.L. Cosmaro** (Milano)

The symposium analyzes the tools used in clinical trials and measured health aspects in order to identify and classify the same tools, which measure the effects of treatment in clinical studies comparing the different classes of ARV drugs. Although there is no consensus on the optimal patient-reported outcome instruments, a typical battery includes a multidimensional HRQL measure together with one or more symptom measurements. Other tools are validated measurement of sleep, depression, anxiety and psychiatric symptoms, beliefs on ARVs, HIV symptoms, ageing well, stress and burden reported by caregivers as possible elements of old and new taxonomies.

10:00 - 10:20 **Frailty index in the risk prediction of ageing trajectories and its application in the clinical management of HIV patients**

Giovanni Guaraldi, Modena

10:20 - 10:30 **Perspective of HIV patients on positive and negative aspect of ageing with HIV**

Margherita Errico, Milano

10:30 - 10:40 **The importance of patient related outcomes in the description of health outcomes and Quality of Life in Ageing cohorts**

Fabrizio Starace, Modena

10:40 - 11:00 **Discussion**

11:00 - 12:30

ORAL COMMUNICATIONS SOCIAL AND BEHAVIOURAL SCIENCECHAIRS: **A. Chirianni** (Napoli), **C. Contini** (Ferrara)DISCUSSANTS: **A. Cerioli** (Como), **P. Filippini** (Napoli)11:00 - 11:15 **HCV: Patients' perspectives and access to new drugs**

Massimiliano Conforti, Roma

11:15 - 11:30 **HCV: Physicians' perspectives**

Cosimo Colletta, Omegna VB

OC 1 Cost of HIV rapid testing in community sites in Italy**C. Angeletti**¹, **P. Scognamiglio**¹, **G. Chiaradia**¹, **M. Oldrini**², **E. Albertini**³, **A. Camposeragna**⁴, **M. Farinella**⁵, **D. Lorenzetti**⁶, **M.R. Parisi**⁷, **M.G. Pompa**⁸, **L. Rancilio**⁹, **A. Lazzarin**⁷, **E. Girardi**¹, **G. Ippolito**¹¹Istituto Nazionale Malattie Infettive "L. Spallanzani", IRCCS, Roma, ²Lila, ³Arcigay, ⁴CNCA, ⁵Circolo Mario Mieli, ⁶ANLAIDS, ⁷Dipartimento di Malattie Infettive, Fondazione San Raffaele Milano, ⁸Ministero della Salute, ⁹Caritas**OC 2 Feasibility of Periconception Antiretroviral Pre-Exposure Prophylaxis (PrEP-C)****G. De Carli**¹, **A. Palummieri**¹, **G. Liuzzi**¹, **A. Ammassari**¹, **S. Cicalini**¹, **R. Libertone**¹, **S. Mosti**¹, **C. Pinnetti**¹, **A. Sampaolesi**¹, **M. Zaccarelli**¹, **A. Cingolani**², **E. Tamburrini**², **G. Maffongelli**³, **V. Puro**¹¹National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy, ²Department of Infectious Diseases, Catholic University, Rome, Italy, ³Clinical Infectious Diseases, Tor Vergata University, Rome, Italy**OC 3 Would you use PrEP? Trends among MSM between 2013 and 2015****G.M. Corbelli**^{1,2}, **S. Mattioli**¹, **M. Degli Esposti**, **S. Pieralli**¹, **P. Gorgoni**¹¹Plus onlus, ²European AIDS Treatment Group**OC 4 Free HIV test access in unconventional setting****A. Bianchi**¹, **A. Antonino**¹, **G. Fracca**¹, **V. Meneghin**¹, **R. Repossi**¹, **F. Esposito**¹, **M. Cernuschi**^{1,2}¹ASA Associazione Solidarietà Aids Onlus, Milano, Italy, ²Infectious Diseases Department, San Raffaele Scientific Institute, Milano, Italy**OC 5 The European HIV Testing Week in Italy: characteristics of organizations and users****G.M. Corbelli**^{1,2}, **M. Lichtner**³, **L. Nigro**⁴, **M. Oldrini**⁵, **N. Orchi**⁶, **S. Patrucco**⁷, **M. Poli**⁸, **G. Sartori**⁹, **C. Sfara**¹⁰¹Plus Onlus, ²European AIDS Treatment Group, ³Università Sapienza/Ospedale SM Goretti, ⁴LILA Catania, ⁵Fondazione LILA Milano, ⁶Istituto Nazionale Malattie Infettive L. Spallanzani, Roma, ⁷Arcobaleno Aids, ⁸LILA Trentino, ⁹Circolo Tondelli LGBTI, Bassano del Grappa, ¹⁰Anlaids Umbria-Cabs-Cabiria**OC 6 Physician conception about PrEP: an italian surveys****LB** **A. Di Biagio**¹, **A. Gori**², **R. Maserati**³, **G. Strano**⁴, **T. Quirino**⁵, **D. Ripamonti**⁶, **T. Bini**⁷, **D. Bartolozzi**⁸, **M.C. Rossi**⁹, **S. Martini**¹⁰, **G. Mazzola**¹¹, **F. Castelnuovo**¹², **D. Francisci**¹³, **S. Nozza**¹⁴, **N. Ladisa**¹⁵, **A. Saracino**¹⁶, **S. Bonora**¹⁷, **S. Lo Caputo**¹⁸¹Malattie Infettive, IRCCS AOU San Martino-IST di Genova, ²Malattie Infettive, Ospedale San Gerardo, Monza, ³Malattie Infettive, Ospedale San Matteo, Pavia, ⁴Malattie infettive, Ospedale di Messina, ⁵Malattie Infettive, Ospedale di Busto Arsizio, ⁶Malattie Infettive, Ospedale di Bergamo, ⁷Malattie Infettive, San Paolo, Milano, ⁸Malattie Infettive, Ospedale Careggi, Firenze, ⁹Malattie Infettive, Ospedale "S. Maria di Ca' Foncello", Treviso, ¹⁰Malattie Infettive, Napoli, ¹¹Malattie Infettive, Ospedale di Palermo, ¹²Malattie Infettive, Spedali Civili di Brescia, ¹³Malattie Infettive, Ospedale di Terni, ¹⁴Malattie Infettive, IRCCS San Raffaele, Milano, ¹⁵Malattie infettive, Policlinico di Bari, ¹⁶Malattie Infettive, università degli Studi di Bari, ¹⁷Malattie Infettive, Università degli Studi di Torino, ¹⁸Malattie Infettive, Ospedale dell'Annunziata, Firenze

13:20 - 14:05**EXPERT MEETING HIV AND COMORBIDITIES: A TOTAL PATIENT CARE APPROACH FOR A LONG TERM SUCCESS**CHAIR: **G. Guaraldi** (Modena) - SPEAKER: **E. Martinez** (Barcelona E)

People living with HIV who have access to antiretroviral therapy (ART) are living longer. The clinical management of these patients is evolving towards a new spectrum of comorbidities. Current antiretroviral drugs show improved side effect profiles and can afford new opportunities for ART optimization and toxicity management in long term. There is a greater awareness of increased risks of non AIDS-defining comorbidities than HIV-uninfected individuals. Diseases of the cardiovascular system, kidneys, liver, cognitive function, malignancies, and metabolic bone disease appear to be more common among HIV-infected patients. Some infections continue to be a significant cause of comorbidities in such patients, including viral hepatitis and human papilloma virus; yet new agents to treat hepatitis C virus (HCV) infection will dramatically alter the prognosis of coinfecting individuals. Physicians caring for people living with HIV must consider not only HIV treatment but also the management of other comorbidities in the context of HIV.

Unrestricted educational grant of MSD Italy

14:10 - 14:55**EXPERT MEETING ONE FIBROSIS STAGE, ONE THERAPY**CHAIR: **A. Aghemo** (Milano)

Individualization of HCV therapy has become compelling today, due to the availability of new direct-acting antivirals (DAA) also in Italy and AIFA definition of access criteria to treatment. In particular, analyzing the results available in literature, data of the real-life experience and sustainability of national healthcare system, it is possible to identify the right therapy for every single patient. The educational symposium aims to point out the benefits of early treatment of patient with HCV infection (reduced incidence of HCC and decompensated liver disease, liver transplantation, extrahepatic manifestations) and the priority to treat patients with advanced liver disease.

- 14:10 - 14:30 **The option in early treatment**
 14:30 - 14:50 **The Optimist choice for advanced and cirrhotic patients**
 14:50 - 14:55 **Discussant**

Tarik Asselah, Paris F
 Peter Buggisch, Hamburg D

Unrestricted educational grant of Janssen

16:30 - 17:15**SYMPOSIUM NEW THERAPEUTIC SCENARIOS IN PATIENTS WITH HIV-HCV COINFECTION**CHAIR: **G. Taliani** (Roma)

HCV treatment has always been considered a critical issue in HIV-HCV coinfecting patients. Accelerating the progression of liver disease caused by hepatitis C virus, and the immunodeficiency typically associated to HIV, HIV-HCV coinfection determines a more severe clinical condition than HCV-monoinfection.

About 30-40% of Italian patients with HIV infection are also HCV-infected. These subjects should be regarded as a population at high risk of disease progression and with an elevated need for HCV antiviral treatment. Today it is extremely relevant to obtain the eradication of hepatitis C virus with the new antiviral therapies and cure the infection, as HIV may be controlled but not eradicated.

- 16:30 - 16:35 **Chair's introduction**
 16:35 - 16:50 **Therapy of patients with coinfection: what is new?**
 16:50 - 17:05 **DDI in patients with coinfection: is the real problem?**
 17:05 - 17:15 **Discussion and take home messages**

Raffaele Bruno, Pavia
 Massimo Puoti, Milano

17:15 - 18:30

ORAL COMMUNICATIONS TRANSLATIONAL SCIENCES

CHAIRS: **C.M. Mastroianni** (Latina), **L. Valenti** (Milano)DISCUSSANT: **M. Tavio** (Ancona)17:15 - 17:30 **Why is it so difficult to develop an HCV vaccine**

Sergio Abrignani, Milano

OC 7 **Pharmacokinetics of switching from twice-daily 150 mg maraviroc to once-daily 300 mg in combination with darunavir/ritonavir in HIV-positive patients****L. Marinaro**¹, S. Nozza², J. Cusato¹, C. Alcantarini¹, M. Simiele¹, S. Raviolo¹, M. Milesi¹, M.C. Tettoni¹, L. Trentini¹, A. Calcagno¹, A. D'Avolio¹, A. Lazzarin², G. Di Perri¹, S. Bonora¹¹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, ²Department of Infectious Diseases, OSR Scientific Institute, Milan, ItalyOC 8 **Tenofovir Pharmacokinetics and Early Tubular Safety in HIV-positive Patients Switching to Tenofovir/emtricitabine/rilpivirine****M. Ferrara**, L. Marinaro, G. Vendemiati, M. Simiele, M.C. Tettoni, L. Trentini, A. Calcagno, A. D'Avolio, G. Di Perri, S. Bonora

Unit of Infectious Diseases, Department of Medical Sciences, University of Torino

OC 9 **Impact of PNPLA3 variants on the liver histology of 168 patients with HIV infection and chronic hepatitis C****C. Sagnelli**¹, M. Merli², C. Uberti-Foppa², H. Hasson², G. Cirillo³, A. Gradone³, S. Salpietro², C. Minichini⁴, E. Miraglia Del Giudice³, A. Lazzarin², E. Sagnelli⁴, N. Coppola⁴¹Department Experimental Medicine and Surgery "F. Magrassi e A. Lanzara", Second University of Naples, Naples, Italy, ²Department of Infectious Diseases, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy, ³Department of Pediatrics, Second University of Naples, Naples, Italy, ⁴Department Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, ItalyOC 10 **Influence of HIV-1 co-receptor tropism on liver fibrosis progression in HIV-HCV co-infected patients****A. Saracino**, G. Bruno, N. Ladisa, G. Punzi, A. Lagioia, E. Cinori, L. Monno, G. Angarano

Clinic of Infectious Diseases, University of Bari, Italy

OC 11 **Viro-Immunological Response in Treatment-Experienced HIV-1 Infected Patients Starting a Maraviroc Containing Regimen in Clinical Practice****D. Di Carlo**¹, D. Armenia¹, C. Gori², A. Bertoli^{1,3}, F. Forbici², V. Borghi⁴, V. Svicher¹, C. Alteri¹, G. Berno², M. Zaccarelli², E. Nicastrì², M. Andreoni^{1,3}, C. Mussini⁴, A. Antinori², F. Ceccherini-Silberstein¹, C.F. Perno², M.M. Santoro¹¹University of Rome Tor Vergata, Rome, Italy, ²L. Spallanzani Hospital, Rome, Italy, ³University Hospital Tor Vergata, Rome, Italy, ⁴Modena University Hospital, Modena, ItalyOC 12 **HIV-1 transcriptional silencing caused by TRIM22 inhibition of Sp1 binding to the promoter****F. Turrini**^{1,2}, A. Kajaste-Rudnitski¹, S.S. Marelli¹, C. Van Lin³, A.T. Das⁴, B. Berkout⁴, E. Vicenzi¹¹Viral Pathogens and Biosafety Unit, Division of Immunology, Transplantation and Infectious Diseases, Ospedale San Raffaele, Milan, Italy, ²Università Vita-Salute San Raffaele, School of Medicine, Milan, Italy, ³University of Bruxelles, Gosselies, Belgium, ⁴Center for Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, The Netherlands

10:00 - 11:00

ORAL COMMUNICATIONS IMMUNOLOGY: MOLECULAR AND CELLULAR ASPECTS OF VIRAL INFECTIONSCHAIRS: **F. Baldelli** (Perugia), **A. De Maria** (Genova)DISCUSSANT: **G. d'Etторе** (Roma)

- 10:00 - 10:15 **HIV DNA reservoirs, immune response and remission of HIV infection: results from the Visconti study** *Asier Sáez Cirión, Paris F*
- OC 13 **Myeloid derived suppressor cells increase during the early phases of primary HIV infection**
A. Sacchi, N. Tumino, M.T. Bilotta, C. Pinnetti, F. Turchi, I. Abbate, R. Casetti, V. Bordoni, E. Cimini, C. Agrati, M.R. Capobianchi, A. Antinori, A. Ammassari, F. Martini
 National Institute for Infectious Diseases "Lazzaro Spallanzani"
- OC 14 **Genome-wide analysis of the effect of CCL2 neutralization in primary human macrophages reveals modulation of host genes associated with HIV-1 infection**
D.A. Covino¹, J. Lu², C. Purificato¹, A.O. Rinaldi², M. Sabbatucci¹, M. Pellegrini², L. Fantuzzi¹
¹Istituto Superiore di Sanità, Department of Hematology, Oncology and Molecular Medicine, Rome, Italy, ²Department of Molecular, Cell, and Developmental Biology, University of California Los Angeles, Los Angeles, California, USA
- OC 15 **Extracellular ATP induces the rapid release of HIV-1 from virus containing compartments of human macrophages**
F. Graziano^{1,2}, M. Desdouts³, L. Garzetti⁴, P. Podini⁴, M. Alfano¹, R. Furlan⁴, P. Benaroch³, G. Poli^{1,2}
¹AIDS Immunopathogenesis Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy, ²Vita-Salute San Raffaele University, School of Medicine, Milano, Italy, ³Institut Curie, Inserm U932 Transport Intracellulaire et Immunité, Paris, France, ⁴Department of Neuroscience, Institute of Experimental Neurology, San Raffaele Scientific Institute, Milan, Italy
- OC 16 **Phenotypic and functional alterations of iNKT cells in HIV+ patients with low CD4/CD8 ratio after successful treatment**
S. De Biasi¹, M. Nasi¹, E. Bianchini², M. Digaetano³, L. Gibellini¹, S. Pecorini¹, R. Bartolomeo¹, V. Borghi³, M. Pinti², C. Mussini^{1,3}, A. Cossarizza¹
¹Department of Surgery, Medicine, Dentistry and Morphological Sciences, University of Modena and Reggio Emilia, ²Department of Life Sciences, University of Modena and Reggio Emilia, ³Infectious Diseases Clinics, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy

11:00 - 12:30

ORAL COMMUNICATIONS CLINICAL AND EPIDEMIOLOGICAL ASPECTSCHAIRS: **A.C. Finarelli** (Bologna), **L. Sighinolfi** (Ferrara)DISCUSSANT: **S. Di Giambenedetto** (Roma)11:00 - 11:15 **Lights and shadows of generic antiretrovirals***Dario Cattaneo, Milano*11:15 - 11:30 **Access and costs in HIV***Giuliano Rizzardini, Milano***OC 17 Trend and causes of hospitalizations among patients with HIV entering care in Italy: a 15 years study from the Icona cohort****A. Mammine¹**, A. Cingolani², M. Lichtner³, A. Di Biagio⁴, P. Caramello⁵, F. Baldelli⁶, P. Bonfanti⁷, G. Angarano⁸, A. Antinori⁹, M. Puoti¹⁰, A. d'Arminio Monforte¹¹, E. Girardi¹, ICONA Foundation Study Group¹National Institute for Infectious Diseases IRCCS 'L. Spallanzani', Department of Epidemiology and ²Clinical Department, Rome, Italy, ³Catholic University, Institute of Infectious Diseases, Rome, Italy, ⁴University of Rome La Sapienza, Department of Infectious Diseases, Rome, Italy, ⁵San Martino University Hospital, Infectious Diseases Unit, Genoa, Italy, ⁶Amedeo di Savoia Hospital, Department of Infectious Diseases, Turin, Italy, ⁷University of Perugia, Section of Infectious Diseases, Department of Experimental Medicine and Biochemical Sciences, Perugia, Italy, ⁸Azienda Ospedaliera Lecco, Department of Infectious Diseases, Lecco, Italy, ⁹University of Bari, Clinic of Infectious Diseases, Bari, Italy, ¹⁰Niguarda Hospital, Infectious Diseases Department, Milan, Italy, ¹¹University of Milan, Clinic of Infectious and Tropical Diseases, Department of Health Sciences, Milan, Italy**OC 18 What are the death causes of people with AIDS?****E. Grande¹**, F. Grippo¹, M. Pappagallo¹, L. Frova¹, A. Zucchetto², M. Taborelli², S. Virdone², D. Serraino², L. Camoni³, V. Regine³, B. Suligo³¹Istituto Nazionale di Statistica (ISTAT), ²Centro Riferimento Oncologico (CRO) di Aviano, ³Istituto Superiore di Sanità (ISS)**OC 19 The HIV treatment and care cascade in Italy: successes and disparities****L. Camoni**, M. Raimondo, P. Pezzotti, M. Dorrucchi, B. Suligo and Gruppo di Studio CARPHA (G. Rizzardini, C. Atzori, C. Paternoster, C. Mussini, V. Borghi, A. Antinori, A. Giannetti, M. Chimenti, F. Baldelli, D. Francisci, G. Borgia, G. Di Filippo, T. Fontana, R. Losappio, G. Parruti, P. Di Stefano, M.S. Mura, G. Madeddu, E.M. Farinella, C. Occhino, V. Portelli)*Istituto Superiore di Sanità, Roma***OC 20 Rapid HIV Testing versus "conventional" Voluntary Counseling & Testing: comparison of clients' characteristics****P. Scognamiglio¹**, G. Chiaradia¹, F.M. Fusco¹, E. Piscitelli², O. Bruzzi², G. Di Stefano², A. Palummieri¹, M. Sanè Schepisi¹, N. Orchi¹, S. Pittalis¹, G. De Carli¹, C. Pinnetti², I. Abbate³, V. Puro¹, C. Angeletti¹, G. Ippolito¹, E. Girardi¹¹Department of Epidemiology and ²Clinical Department and ³Virology Laboratory, National Institute for Infectious Diseases "Lazzaro Spallanzani", Rome, Italy**OC 21 Risk of HCV transmission among individuals undergoing non-occupational antiretroviral post-exposure prophylaxis****G. De Carli¹**, E. Schifano¹, L. Signorini², F. Niero³, A. Franco⁴, A. Agresta¹, P. Piselli¹, V. Puro¹ on behalf of the Italian Registry of Antiretroviral Post-Exposure Prophylaxis (IRAPEP) group¹National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy, ²A.O. Spedali Riuniti, Brescia, Italy, ³A.O. L. Sacco, Milan, Italy, ⁴AORN Ospedali dei Colli, Naples, Italy**OC 22 Predictors of retention in care for HIV-infected patients: data from San Martino Hospital cohort in Genoa****R. Prinapori¹**, B. Giannini², G. Mazzarello¹, A. Alessandrini¹, M. Giacomini², A. Di Biagio¹¹University of Genoa (DISSA)-Infectious Diseases Unit, AOU IRCCS San Martino-IST, Genoa, Italy, ²Department of Informatics, Bioengineering, Robotics and System Engineering (DIBRIS), University of Genoa, Genoa, Italy

14:10 - 14:55

ORAL POSTER IMMUNO-VIROLOGICAL DETERMINANTS

CHAIRS: **B.M. Celesia** (Catania), **M. Zaccarelli** (Roma)

- OP 7 **Direct acting anti-viral (DAA) therapeutic options in HIV/HCV co-infected individuals seen for care in Italy: an estimate using data from ICONA and HepalCONA cohorts**
M. Puoti¹, M. Shanyinde², A. Cozzi-Lepri², A. Antinori³, A. Castagna⁴, E. Nicastrì³, S. Bonora⁵, F. Castelli⁷, A. Chiodera⁶, C. Pinnetti⁴, A. d'Arminio Monforte⁸ on the behalf of ICONA and HepalCONA study groups
¹Niguarda ca Grande Hospital, Milano, Italy, ²Royal Free Hospital University College London, UK, ³INMI Spallanzani Roma, Italy, ⁴San Raffaele Hospital Milan, Italy, ⁵Clinical Infectious Diseases University of Turin, Italy, ⁶Macerata Hospital, Infectious Diseases, Macerata, Italy, ⁸San Paolo Hospital Milan, Italy
- OP 8 **Role of mucosal-associated invariant T (MAIT) cells in HIV/HCV co-infection**
M. Cerrone¹, B. van Wilgenburg², L. Swadling², A. De Bona¹, A. d'Arminio Monforte¹, G. Marchetti¹, P. Klenerman²
¹Clinic of Infectious Diseases, Department of Health Sciences, San Paolo University Hospital, University of Milan, ²Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK
- OP 9 **Increased CD4 and CD8 T cells apoptosis in HCV infected patients treated by first-generation protease inhibitor triple therapy**
C. Mascia¹, P. Zuccalà¹, M. Lichtner², A. Ermocida¹, M. Campagna², T. Tieghi², F. Mengoni¹, S. Vita¹, R. Marocco², C.M. Mastroianni², V. Vullo¹
¹Sapienza University of Rome, ²Sapienza University of Rome, Polo Pontino, Latina, Italy
- OP 10 **Analysis of HIV-1 Coreceptor Tropism Evolution During Treatment Interruption**
M.M. Santoro¹, D. Armenia¹, M. Nasi², M.C. Bellocchi¹, L. Carioti¹, F. Continenza³, D. Di Carlo¹, M. Digaetano⁴, A. Cossarizza², C.F. Perno¹, F. Ceccherini-Silberstein¹, C. Mussini⁴
¹University of Rome Tor Vergata, Rome, ²University of Modena and Reggio Emilia School of Medicine, Modena, ³National Institute for Infectious Diseases I Spallanzani - IRCCS, Rome, ⁴Clinic of Infectious Disease, AOU Modena, Modena
- OP 11 **Evolution of HIV-1 Transmitted Drug Resistance in Italy in the 2009-2013 Period: a Weighted Analysis**
M. Franzetti¹, A. De Luca², F. Ceccherini-Silberstein³, V. Spagnuolo⁴, E. Nicastrì⁵, C. Mussini⁶, A. Antinori⁵, L. Monno⁷, J. Vecchiet⁸, G. Rizzardini⁹, V. Micheli¹⁰, I. Fantì¹¹, A. d'Arminio Monforte¹², C. Balotta¹ on behalf of the ICONA Foundation Study Group
¹Department of Biomedical and Clinical Sciences 'L. Sacco', University of Milan, Milan, Italy, ²Siena University Hospital, Infectious Diseases Unit, Siena, Italy, ³University of Rome Tor Vergata, Department of Experimental Medicine and Surgery, Rome, Italy, ⁴San Raffaele Scientific Institute, Infectious Diseases, Milan, Italy, ⁵National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy, ⁶Clinic of Infectious Disease, University Hospital, Modena, Italy, ⁷University of Bari, Department of Biomedical Science and Oncology, Bari, Italy, ⁸University of Chieti, Infectious Diseases Clinic, Italy, ⁹L. Sacco Hospital, Department of Infectious Diseases, Milan, Italy, ¹⁰L. Sacco Hospital, Unit of Microbiology, Milan, Italy, ¹¹Catholic University of Sacred Heart, Clinical Infectious Diseases, Rome, Italy, ¹²San Paolo University Hospital Milan, Clinic of Infectious and Tropical Diseases, Milan, Italy
- OP 12 **CD4/CD8 ratio and pregnancy outcome: a useful immunological biomarker in resource limited settings**
F. Bisio¹, A. Calzi¹, L.A. Nicolini¹, F.A. Mayinda Mbougou², A.C. Nzagou², **B. Bruzzone**³, C. Viscoli¹
¹Clinica Malattie Infettive, IRCCS A.O.U. San Martino-IST, Università di Genova (DiSSal), Italy, ²Hopital Régional des Armées, Pointe Noire, République del Congo, ³Istituto di Igiene, IRCCS A.O.U. San Martino-IST, Università di Genova (DiSSal), Italy
- 14:50 - 14:55 **AVIRALIA Awards: Characterization of gp41 Mutations in Patients with Virological Failure on Protease Inhibitors**
A. Lai¹, M. Franzetti¹, N. Gianotti², F. Binda¹, F. Saladini³, G. Punzi⁴, V. Spagnuolo², C. Mussini⁵, A. Castagna², L. Monno⁴, M. Zazzi³, C. Balotta¹
¹Department of Biomedical and Clinical Sciences 'L. Sacco', University of Milan, Milan, Italy, ²Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy, ³Department of Medical Biotechnologies, University of Siena, Siena, Italy, ⁴Department of Biomedical Science and Human Oncology, University of Bari, Bari, Italy, ⁵Clinic of Infectious Diseases, University Hospital, Modena, Italy

16:30 - 18:30

ORAL COMMUNICATIONS CLINICAL HIVCHAIRS: **N. Abrescia** (Napoli), **F. Castelli** (Brescia)DISCUSSANTS: **D. Francisci** (Perugia), **S. Lo Caputo** (Firenze)16:30 - 16:45 **The changing face of HIV treatment**

Andrea Gori, Monza

OC 23 Effectiveness and Durability of ATV/r- and DRV/r-Based cART in Naïve HIV-infected Patients: retrospective analysis of the INMI Clinical Cohort (ICC)**C. Pinnetti**, P. Lorenzini, A. Ammassari, A. Giannetti, M. Zaccarelli, R. Libertone, S. Mosti, S. Ottou, M.M. Plazzi, A. Gallo, A. Antinori
Clinical Department, National Institute For Infectious Diseases, Lazzaro Spallanzani, Rome, Italy**OC 24 Virological response to modern first-line antiretroviral regimens in HIV-infected patients enrolled in a large cohort according to their pre-therapy viral load and type of regimen started**C. Mussini¹, A. d'Arminio Monforte², A. Antinori³, A. Castagna⁴, S. Lo Caputo⁵, F. Maggiolo⁶, M. Andreoni⁷, J. Vecchiet⁸, C. Ferrari⁹, E. Nicastrì³, G. Pellizzer¹⁰, A. De Luca¹¹, **A. Cozzi-Leperi**¹² for the Icona Foundation Study¹Clinic of Infectious Diseases, University of Modena, Italy, ²Clinic of Infectious and Tropical Diseases, San Paolo Hospital, University of Milan, Milan, Italy,³National Institute of Infectious Diseases, L Spallanzani, Rome, Italy, ⁴Clinic of Infectious Diseases, University of Vita-Salute, HSR Milan, Italy,⁵Department of Infectious Diseases, SM Annunziata Hospital, Bagno a Ripoli, Italy, ⁶Department of Infectious Diseases, Riuniti Hospital, Bergamo,Italy, ⁷Infectious Diseases, University Tor Vergata, Rome, Italy, ⁸Clinic of Infectious Diseases, University of Chieti, Chieti, Italy, ⁹Clinic of InfectiousDiseases, University of Parma, Parma, Italy, ¹⁰Department of Infectious and Tropical Diseases, Vicenza Hospital, Vicenza, Italy, ¹¹University of Siena, Italy, ¹²University College London, UK**OC 25 Efficacy and safety Rilvopirine/tenofovir/emtricitabine in HIV-infected naive patients: results from SCOLTA Project****P. Bagella**¹, M. Bellacosa², G.C. Orofino³, G. Penco⁴, F. Vichi⁵, C. Martinelli⁶, G.V.L. De Socio⁷, S. Di Giambenedetto⁸, G. Parruti⁹, A. Di Biagio¹⁰, B.M. Celesia¹¹, L. Valsecchi¹², R. Libertone¹³, C. Dentone¹⁴, L. Carenzi¹², E. Ricci¹⁵, L. Calza¹⁶, M. Franzetti¹², K. Falasca¹⁷, N. Squillace¹⁸, P. Bonfanti¹⁹, B. Menzaghi²⁰, G. Madeddu¹ on behalf of the CISAI Study Group¹Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Italy ²Infectious Disease Clinic, University ofBari, Italy, ³Department of Infectious Diseases, Amedeo di Savoia Hospital, Turin, Italy, ⁴Unit of Infectious Diseases, Galliera Hospital, Genoa, Italy, ⁵Unitof Infectious Diseases, Santa Maria Annunziata Hospital, Firenze, Italy, ⁶Unit of Infectious Diseases, Careggi Hospital, Firenze, Italy, ⁷Unit of InfectiousDiseases, Santa Maria Hospital, Perugia, Italy, ⁸Unit of Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy, ⁹Department ofInfectious Diseases, Pescara Hospital, Italy, ¹⁰Infectious Diseases, IRCCS San Martino Hospital, University of Genoa, Italy, ¹¹Unit of InfectiousDiseases, Garibaldi Hospital, Catania, Italy, ¹²Department of Infectious Diseases, L. Sacco Hospital, Milan, Italy, ¹³National Institute for InfectiousDiseases "Lazzaro Spallanzani", Rome, Italy, ¹⁴Unit of Infectious Diseases, San Remo Hospital, Italy, ¹⁵EPI2004 Milano, Italy, ¹⁶Unit of InfectiousDiseases, Policlinico S. Orsola, Bologna, Italy, ¹⁷Unit of Infectious Diseases, Chieti-Pescara University, Italy, ¹⁸Unit of Infectious Diseases, San GerardoHospital, Monza, Italy, ¹⁹Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy, ²⁰Unit of Infectious Diseases, Busto Arsizio Hospital, Busto

Arsizio, Italy

OC 26 Detectable HIV-RNA after 24 weeks of treatment and risk of virological failure of first-line antiretroviral therapy**G. Lapadula**, A. Soria, A. Bandera, A. Muscatello, N. Squillace, S. Costarelli, M. Fabbiani, A. Gori

Clinic of Infectious Diseases, AO San Gerardo of Monza, University of Milano-Bicocca, Italy

OC 27 Virological and immunological response to treatment of naïve HIV-1 positive patients with viral load > 500,000 copies / ml: do we need personalized treatment for this class of patients?**G. Sterrantino**¹, A. Boschi², A. Degli Antoni³, F. Prati⁴, G.V. De Socio⁵, L. Sighinolfi⁶, L. Calza⁷, V. Borghi⁸¹Tropical and Infectious Diseases Unit, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy, ²Infectious Diseases Unit, Azienda Sanitaria diRimini, Rimini, Italy, ³Infectious Diseases Unit, Azienda Ospedaliera-Universitaria Parma, Parma, Italy, ⁴Infectious Diseases Unit, IRCCS Santa MariaNuova, Reggio Emilia, Italy, ⁵Clinica di Malattie Infettive, Azienda Ospedaliera-Universitaria di Perugia, Perugia, Italy, ⁶Infectious Diseases Unit,Azienda Ospedaliera-Universitaria di Ferrara, Ferrara, Italy, ⁷Infectious Diseases Unit, Policlinico S. Orsola-Malpighi, University of Bologna, Bologna, Italy,⁸Infectious Diseases Unit, Azienda Ospedaliera-Universitaria di Modena, Modena, Italy

- OC 28 **Rates of viral rebound (VR) >200 copies/mL after a viral load (VL) ≤50 copies/mL according to period and duration of viral suppression on first-line cART**
G. Marchetti¹, A. Cozzi-Lepri², M. Galli³, G. Rizzardini⁴, F. Maggiolo⁵, A. Antinori⁶, T. Quirino⁷, P.E. Manconi⁸, M.R. Capobianchi⁹, F. Ceccherini-Silberstein¹⁰, A. d'Arminio Monforte¹¹ for the Itona Foundation Study Group
¹Clinic of Infectious Dis, Dept of Health Sciences, University of Milan - San Paolo Hospital, ²University College London, ³Clinic of Infectious Dis, University of Milan, L Sacco Hospital, ⁴Div di Mal Infettive, AO L Sacco, Milano, ⁵Malattie Infettive, A.O. Ospedale Riuniti di Bergamo, Bergamo, Italy, ⁶Dipartimento Clinico, IRCCS L Spallanzani, Rome, Italy, ⁷Malattie Infettive, Dipartimento Sanitario Aziendale di Medicina, Busto Arsizio, Varese, Italy, ⁸Medicina Interna, Allergologia ed Immunologia clinica, Azienda Ospedaliera Universitaria di Cagliari, Cagliari, Italy, ⁹Laboratory of Virology National Institute for Infectious Diseases "L. Spallanzani", ¹⁰Department of Experimental Medicine and Surgery University of Rome Tor Vergata, ¹¹Clinic of Infectious Dis, Dept of Health Sciences, University of Milan- San Paolo Hospital
- OC 29 **Greater durability of 3TC compared to other drugs in PI/r-based dual therapies**
A. Mondì¹, A. Borghetti¹, V. Borghi², C. Pinnetti³, M. Zaccarelli³, A. D'Avino¹, A. Latini⁴, G. Sterrantino⁵, R. Cauda¹, S. Di Giambenedetto¹, M. Fabbiani¹
¹Institute of Clinical Infectious Disease, Catholic University of Sacred Heart, Rome, Italy, ²Infectious Diseases Unit, Azienda Ospedaliera-Universitaria di Modena, Modena, Italy, ³Clinical Department, National Institute for the Infectious Diseases "Lazzaro Spallanzani", Rome, Italy, ⁴Clinic of Dermatology and Infectious Diseases, "San Gallicano" Institute, Rome, Italy, ⁵Division of Infectious Diseases, "Careggi" Hospital, Florence, Italy
- OC 30 **Triple Therapies with Unboosted Atazanavir are Associated to a Higher Risk of Virological Failure but to Better Tolerability Compared to ATV/r-based Regimens in a Cohort of Virologically-Controlled, Treatment-experienced HIV-infected Patients**
A. Borghetti¹, I. Fanti¹, A. D'Avino¹, A. Mondì¹, G. Baldin¹, S. Lamonica¹, R. Gagliardini¹, F. Pallavicini¹, N. Ciccarelli¹, B. Milanini¹, R. Cauda¹, M. Fabbiani¹, A. De Luca², S. Di Giambenedetto¹
¹Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Policlinico Gemelli, Rome, ²UOC, University Infectious Disease, Azienda Ospedaliera Universitaria Senese, Siena
- OC 31 **Efficacy and Safety of Eviplera in naïve and cART-experienced HIV positive patients: data from a clinical setting**
L. Gazzola, **F. Bai**, M. Trunfio, V. Cogliandro, N. Iannotti, T. Bini, G. Marchetti, A. d'Arminio Monforte
Department of Health Sciences, University of Milan, Clinic of Infectious Diseases, S. Paolo Hospital, Milan
- OC 32 **Health transitions in HIV-seropositive individuals undergoing NRTI-based and NRTI-sparing treatment strategies**
S. Zona¹, T.D. Brothers², S. Kirkland³, A. Malagoli¹, C. Stentarelli¹, C. Mussini¹, J. Falutz⁴, K. Rockwood⁵, G. Guaraldi¹
¹Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy, ²Faculty of Medicine, Dalhousie University, Halifax, Canada, ³Department of Community Health & Epidemiology, Dalhousie University, Halifax, Canada, ⁴Chronic Viral Illness Service, McGill University Hospital Center, Montreal, Canada, ⁵Department of Medicine (Geriatric Medicine & Neurology), Dalhousie University, Halifax, Canada

10:00 - 11:00

ORAL COMMUNICATIONS COMMUNITY BASED STUDIES

CHAIRS: **A. Boschini** (Rimini), **C. Cancellieri** (Forlì)DISCUSSANTS: **M. Breveglieri** (Verona), **G. Orofino** (Torino)

- OC 33 **Multiple Pill Regimens and Single Tablet Regimens: which is the patients point of view? Evidence from the STRaQ Study**
E. Foglia¹, F. Maggiolo², T. Quirino³, P. Bonfanti⁴, F. Scolari¹, E. Garagiola¹, L. Ferrario¹, D. Bernasconi⁴, R. Visonà³, Davide Croce^{1,5}
¹Centre for Research on Health Economics, Social and Health Care Management – Carlo Cattaneo – LIUC University, Castellanza, Italy, ²Infectious Diseases Department, Papa Giovanni 23th Hospital Authority, Bergamo, Italy, ³Infectious Diseases Department, Ospedale di Circolo Hospital Authority, Busto Arsizio, Italy, ⁴Infectious Diseases Department, Alessandro Manzoni Hospital Authority, Lecco, Italy, ⁵School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- OC 34 **2014 – One Year of Community-Based Testing Activities in Milan, Italy**
M. Oldrini¹, M.L. Cosmaro¹, S. Penon¹, S. Giudici¹, S. Curridori¹, M. Giannelli¹, M. Angarini¹, D. Guarini¹, S. Colombo¹, D. Savarino¹, N. Ceserani², S. Chiappetta³, M.R. Parisi³, A. Lazzarin³, S. Nozza³
¹Fondazione LILA Milano ONLUS, ²Azienda Ospedaliera Treviglio, ³Ospedale San Raffaele
- OC 35 **Patient Satisfaction With Antiretroviral Therapy (ARV) – Results of Multicentre Italian Study**
A. Muscatello¹, S. Nozza², C. Mussini³, F. Vichi⁴, E. Focà⁵, A. Chiriani⁶, B.M. Celesia⁷, A.M. Cattelan⁸, M. Cernuschi⁹, A. Lazzarin², M. Quartaroli¹⁰, F. Maggiolo¹¹, A. Di Biagio¹²
¹San Gerardo, Monza, ²San Raffaele, Milano, ³Univ. Modena, ⁴S.M. Annunziata, Firenze, ⁵Spedali Civili, Brescia, ⁶Osp. Cotugno, Napoli, ⁷Osp. Garibaldi/Nesima, Catania, ⁸Osp. Tre Martiri, Rovigo, ⁹ASA Onlus Milano, ¹⁰ViiV Healthcare Italy, ¹¹Osp. Papa Giovanni XXIII, Bergamo, ¹²Osp. San Martino, Genova
- OC 36 **Determinants of social cost: The social condition of patients living with HIV in Italy**
A. Battistella, M. Errico, D. Cattaneo, M. Cascio, **A.M. Vasile**
Centro studi "Gianni Grosso" Nps Italia onlus, Milan, Italy, NPS Italia Onlus, Milan, Italy, Luigi sacco Hospital, Milan, Italy, European Aids Group Treatment, NPS sezione Sicily, Palermo, Italy
- OC 37 **Determinants of social cost: an empirical survey in the HIV+ setting**
L. Ferrario¹, M. Errico², G. Rizzardini³, S. Rusconi^{3,4}, M. Medaglia³, E. Foglia¹, D. Croce^{1,5}, **E. Garagiola**¹
¹Centre for Research on Health Economics, Social and Health Care Management – Carlo Cattaneo – LIUC University, Castellanza, Italy, ²NPS Italia – Network Persone Sieropositive, ³Luigi Sacco Hospital Authority, Milan, Italy, ⁴University of Milan, Italy, ⁵School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- OC 38 **The impact of the introduction of the generic drug among patients with HIV / AIDS**
A. Battistella, M. Errico, D. Cattaneo, **A. Cavassi**
Centro Studi "Gianni Grosso" di NPS Italia Onlus, NPS Italia Onlus – Network of People Living with Hiv, Luigi Sacco Hospital Authority, Milan, Italy, NPS Emilia Romagna – Network of People Living with Hiv- sezione Emilia Romagna



11:00 - 12:30

ORAL COMMUNICATIONS COMORBIDITIES

CHAIRS: **M. Libanore** (Ferrara), **P. Pezzotti** (Roma)DISCUSSANT: **P. Maggi** (Bari)

- OC 39 **NRTI-sparing regimen with Maraviroc plus a boosted PI in proactive switch for experienced HIV/HCV coinfecting patients: data of a multicenter study**
S. Martini¹, N. Coppola¹, L. Alessio¹, A. Tartaglia², S. Ferrara², M. Macera¹, A. Cascone¹, B. Grisorio², P. Filippini¹
¹UOS Diagnosi e Terapia Immunodeficienza Acquisita della Seconda Università Degli Studi di Napoli, ²UOC di Malattie Infettive della AOU Ospedali Riuniti di Foggia
- OC 40 **Achievement of virological success as a risk factor for non-AIDS events in patients on HAART: A delay (> 6 months) of plasma viremia response to HAART correlates with a higher number of non-AIDS events in a population of HIV patients at first line of treatment**
V. Malagnino¹, G. Maffongelli¹, C. Cerva¹, M. Viscione¹, D. Leoni¹, E. Teti¹, A. Bianchi, E. Gentilotti¹, C. Alteri², A. Bertoli², M. Santoro², A. Ricciardi¹, L. Dori¹, C.F. Perno², M. Andreoni¹, L. Sarmati¹
¹Clinical Infectious Diseases, Tor Vergata University of Rome, Italy, ²Department of Experimental Medicine and Surgery, University of Tor Vergata, Rome
- OC 41 **Prognosis of AIDS and non-AIDS related lymphoma in a cohort of HIV infected patients treated with chemotherapy in cART era. A cohort study**
A. Cascavilla¹, L. Scudeller³, M. Bartoletti¹, S. Tedeschi¹, G. Vandì¹, E. Magistrelli¹, N. Girometti¹, V. Stefoni², P. Zinzani², P. Viale¹
¹Infectious Disease Unit and ²Institute of Hematology "Seragnoli", S. Orsola-Malpighi Hospital, University of Bologna, ³Clinical Epidemiology Unit, IRCCS San Matteo Foundation, University of Pavia
- OC 42 **Vaccine-targeted HPV infections in an anal cancer screening program for MSM in Italy: implications for an immunization program**
A.R. Garbuglia, M. Gentile, D. Lapa, F. Lupi, P. Lorenzini, C. Pinnetti, **R. Libertone**, S. Cicalini, M.R. Capobianchi, A. Ammassari
National Institute for Infectious Diseases "Lazzaro Spallanzani"
- OC 43 **Incidence of Sexually Transmitted Diseases in large single site cohort of HIV-infected patients over calendar years: an increasing emergency**
A. D'Avino¹, **G. Baldin¹**, R. Gagliardini¹, I. Fanti¹, F. Pallavicini¹, A. Borghetti¹, A. Mondì¹, R. Cauda¹, A. De Luca², S. Di Giambenedetto¹, M. Fabbiani¹
¹Istituto di Clinica delle Malattie Infettive-Università Cattolica del Sacro Cuore Roma, ²Dipartimento di Malattie Infettive, Policlinico Universitario Le Scotte-Siena
- OC 44 **Solid organ transplantation in HIV infected patients: a single center experience**
S. Gruttadauria¹, D. Pagano¹, A. Mularoni², **G. Panarello³**, V. Lamona⁴, F. Cardinale⁴, M. Spada¹, D. Cintorino¹, M. Pilato⁵, A. Bertani⁶, A. Arcadipane³, G. Vizzini⁷, P. Grossi⁸, A. Luca⁹, B. Gridelli¹⁰
¹Abdominal Surgery and Organ Transplantation Unit, Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (ISMETT), Palermo, Italy, ²Infectious Diseases Unit, Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, ISMETT, Palermo, Italy, ³Intensive Care Unit, Department of Anesthesia and Intensive Care, ISMETT, Palermo, Italy, ⁴Department of Laboratory Medicine and Advanced Biotechnologies, ISMETT, Palermo, Italy, ⁵Cardiac Surgery Unit, Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, ISMETT, Palermo, Italy, ⁶Thoracic Surgery Unit, Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, ISMETT, Palermo, Italy, ⁷Hepatology Unit, Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, ISMETT, Palermo, Italy, ⁸Infectious Diseases Section, Department of Surgical and Morphological Sciences, University of Insubria, Varese, Italy, ⁹Radiology Service, Department of Diagnostic and Therapeutic Services, ISMETT, Palermo, Italy, ¹⁰Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, ISMETT, Palermo, Italy
- OC 45 **Elevated levels of coagulation and fibrinolysis markers in cerebrospinal fluid of patients with HIV-associated dementia**
M. Alfano¹, V. Longo¹, L. Passeri¹, M. Gisslen², R.W. Price³, A. D'Angelo¹, A. Lazzarin¹, **P. Cinque¹**
¹San Raffaele Scientific Institute, ²University of Goteborg, Sweden, ³University of California at San Francisco
- OC 46 **Blood Brain Barrier Impairment is Associated with Cerebrospinal Fluid Markers of Neuronal Damage in HIV-positive Patients**
A. Calcagno¹, C. Atzori², A. Romito³, D. Vai², M.L. Stella¹, C. Montrucchio¹, D. Imperiale², G. Di Perri¹, S. Bonora¹
¹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, ²Unit of Neurology, Ospedale Maria Vittoria, ASLTO2, ³Laboratory of Immunology, Ospedale Maria Vittoria, ASLTO2, Torino, Italy
- OC 47 **The effects of CCR5 Antagonist Maraviroc on the carotid intima media thickness (IMT) in HIV-1/HCV coinfecting patients**
G. Bruno, **P. Maggi**, A. Saracino, A. Volpe, G. Punzi, C. Santoro, N. Ladisa, L. Monno, G. Angarano
Clinic of Infectious Diseases, University of Bari, Italy

14:10 - 14:55

ORAL POSTER BASIC SCIENCE

CHAIRS: **G. Nunnari** (Catania), **L. Palmisano** (Roma)

- OP 13 **Genetic elements clustered in specific immune active regions of HBsAg drive HBV reactivation under immunosuppression: an extensive analysis of HBV genome**
R. Salpini¹, L. Colagrossi¹, A. Battisti¹, M.C. Bellocchi¹, C. Alteri¹, D. Armenia¹, F. Di Santo¹, L. Carioti¹, M. Pollicita¹, A. Ricciardi², M. Lichtner³, C. Mastroianni⁴, M. Paoloni⁵, M. Marignani⁶, S. Maylin⁷, C. Delaugerre⁷, F. Morisco⁸, N. Coppola⁹, A. Marrone¹⁰, D. Di Paolo¹¹, C. Sarrecchia², L. Sarmati², M. Andreoni², M. Angelico¹¹, C.F. Perno¹, V. Svicher¹
¹Tor Vergata University, Department of Experimental Medicine and Surgery, Rome, Italy, ²Tor Vergata University Hospital, Infectious Diseases Unit, Rome, Italy, ³Sapienza University, Department of Public Health and Infectious Disease, Rome, Italy, ⁴Sapienza University, Rome, Italy, ⁵S.S. Filippo e Nicola Hospital, Infectious Disease Unit, Avezzano, Italy, ⁶S. Andrea Hospital, Department of Gastroenterology, Rome, Italy, ⁷AP-HP Hopital Saint-Louis, Laboratoire de Virologie, Paris, France, ⁸University of Naples Federico II, Section of Infectious Diseases, Department of Clinical Medicine and Surgery, Naples, Italy, ⁹Second University of Naples, Department of Mental Health and Public Medicine, Section of Infectious Diseases, Naples, Italy, ¹⁰Second University of Naples, Internal Medicine and Hepatology Unit, Naples, Italy, ¹¹Tor Vergata University Hospital, Hepatology Unit, Rome, Italy
- OP 14 **Comparative study of RAVs prevalence in NS3 and NS5A genes in different Hepatitis C virus sub-genotypes, in liver and plasma specimens in patients with HCC / transplanted and not**
M.C. Sorbo¹, V.C. Di Maio¹, M. Manuelli², I. Lenci³, D. Sforza², F.P. Antonucci¹, D. Di Paolo³, F. De Leonardis³, A. Abedrabbo³, V. Cento¹, M. Aragri¹, A. Bertoli¹, M. Tontodonati⁴, C. Pasquazzi⁵, V. Micheli⁶, C. Magni⁷, C. Sarrecchia⁸, M. Milano³, T. Manzia², V.P. Palitti⁴, A. Pieri⁴, A. Pellicelli⁹, S. Babudieri¹⁰, P. Cacciatore⁴, G. Taliani¹¹, A. Di Biagio¹², M. Siciliano¹³, M. Puoti¹⁴, G. Parruti⁴, G. Rizzardini⁷, M. Andreoni⁸, M. Angelico³, G. Tisone², C.F. Perno¹, F. Ceccherini-Silberstein¹
¹Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy, ²Liver Transplant Centre, Policlinico Tor Vergata, Tor Vergata University, Rome, Italy, ³Hepatology Unit, Policlinico Tor Vergata, Tor Vergata University, Rome, Italy, ⁴Infectious Disease Unit, Pescara General Hospital, Pescara, Italy, ⁵Infectious Diseases, Sant'Andrea Hospital – "La Sapienza" University, Rome, Italy, ⁶Unit of Microbiology, Hospital Sacco of Milan, Milan, Italy, ⁷Division of Infectious Disease, Hospital Sacco of Milan, Milan, Italy, ⁸Infectious Disease, University Hospital of Rome "Tor Vergata", Rome, Italy, ⁹Hepatology Unit, San Camillo Forlanini Hospital, Rome, Italy, ¹⁰Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Sassari, Italy, ¹¹"La Sapienza" University, Rome, Italy, ¹²S. Martino Hospital, Genova, Italy, ¹³Gastroenterology, Catholic University of Rome, Rome, Italy, ¹⁴Hospital Niguarda Ca'Granda, Milan, Italy
- OP 15 **Pharmacologically Induced Functional Cure of Simian AIDS is Associated with Cell-mediated Anti-Gag Immunity as a Likely Result of "Bottleneck Effect"**
I.L. Shytaj
 A. Savarino
 Istituto Superiore di Sanità
- OP 16 **IFNL4 rs368234815 TT/ G polymorphism is not associated with the expression levels of Interferon Stimulated Genes and the clinical outcome of HIV-1 infection**
K. Monteleone¹, G. Cacciotti¹, C. Selvaggi¹, G. Corano¹, A. Fantauzzi², G. d'Ettore³, I. Mezzaroma², F. Falasca¹, V. Vullo³, G. Antonelli¹, C. Scagnolari¹
¹Pasteur Institute-Cenci Bolognetti Foundation, Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, ²Department of Clinical Medicine, Sapienza University of Rome, ³Department of Public Health and Infectious Diseases, Sapienza University of Rome
- OP 17 **Plasma and PBMC miRNA Profile in Sexually HIV- Exposed Seronegative Individuals**
I. Saule¹, S. Yahyaeei¹, M. Biasin¹, M. De Luca¹, F. Gnudi¹, A. Berzi¹, M. Garziano¹, M. Masetti¹, D. Trabattoni¹, S. Lo Caputo², F. Mazzotta², M. Clerici³
¹Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, ²S. Maria Annunziata Hospital Florence, Italy, ³Don Gnocchi Foundation Milan, Italy
- OP 18 **A Pseudo-glycodendrimer Inhibits DC-SIGN-Mediated HIV Trans-Infection and Interferes with DC-SIGN Signal**
A. Berzi¹, S. Ordanini², M. Masetti¹, I. Saule¹, M. Garziano¹, M. Biasin¹, D. Trabattoni¹, A. Bernardi², M. Clerici^{3,4}
¹Chair of Immunology, Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, ²Department of Organic and Industrial Chemistry, University of Milan, Milan Italy, ³Department of Pathophysiology and Transplantation, University of Milan, ⁴Don C. Gnocchi Foundation, IRCCS, Milano, Italy

17:15 - 18:30**SYMPOSIUM NEW CHALLENGES IN REPRODUCTION**CHAIRS: **M. Malena** (Verona), **E. Tamburrini** (Roma)DISCUSSANTS: **T. Quirino** (Busto Arsizio VA), **F. Vichi** (Firenze)

Vaginal delivery is recommended for women with HIV on ARV treatment with an undetectable viral load at week 36 of pregnancy. The Italian guidelines on HIV state that women who have started labour and for whom a vaginal delivery have begun to establish the criteria for inclusion and exclusion from vaginal delivery in clinical terms. However, you will also have an opportunity to discuss your individual birth plan with your midwife and doctor at the antenatal clinic. HIV in itself does not mean that pregnant women with HIV should be treated as high risk. Women with HIV who are low risk in all other respects should be offered the same choices about where and how they deliver. This includes being looked after by midwives in a midwifery led unit. Doctors and midwives try to normalize the birth experience for women with HIV as much as possible.

- 17:15 - 17:30 **The safety of reproduction in the undetectable era**
 17:30 - 17:45 **Vaginal delivery in HIV+ persons**
 17:45 - 18:00 **Is post-exposure prophylaxis in new born still useful?**
 18:00 - 18:15 **Patients' experiences**
 18:15 - 18:30 **Discussion**

*Giuseppina Liuzzi, Roma
 Matilde Sansone, Napoli
 Carlo Giaquinto, Padova
 Patrizia Perone, Roma*

08:30 - 10:00**KEYNOTE LECTURES**CHAIRS: **G. Antonelli** (Roma), **M. Galli** (Milano), **E. Villa** (Modena)

08:30 - 09:00	Ready to cure a broad spectrum of HCV patients: from the clinical trials to the field practice	<i>Gloria Taliani, Roma</i>
09:00 - 09:30	Light and shadow in HIV therapeutic switch: criteria of virological evaluation and pharmacological options	<i>Carlo Federico Perno, Roma</i>
09:30 - 10:00	From bench to bedside: what we have learnt from CCR5	<i>Lucia Lopalco, Milano</i>

10:00 - 11:00**SYMPOSIUM ICAR-AISF-SIMIT BEYOND THE STANDARD OF CARE: HEPATITIS**CHAIRS: **G. Verucchi** (Bologna), **A.L. Zignego** (Firenze)DISCUSSANT: **G.B. Gaeta** (Napoli)

Regarding the world of viral hepatitis, today, the new therapeutic challenge is surely represented from the recent and extraordinary opportunity of hepatitis C cure in many patients, near at all different stages of disease. Nevertheless, the issue of the hidden world of viral infections, particularly in fragile populations, such as the immigrants still remains very important. Often this people come from countries with high prevalence of viral hepatitis infections, and often they come infected with different genotypes, less frequent in Italy, however more pathogenic and oncogenic. For all of these reasons, the objective of the symposium is to create a space of discussion to enhance knowledge about new strategies of appropriate diagnosis, prevention of disease progression and treatment intervention in ameliorating the management of hepatitis infected patients.

10:00 - 10:15	Prevalence and clinical significance of viral hepatitis B and Delta in the immigrant population in Italy	<i>Gioacchino Angarano, Bari</i>
10:15 - 10:30	The importance of genotype in HBV, HCV and HDV	<i>Teresa Pollicino, Messina</i>
10:30 - 10:45	HCV-related cryoglobulinemia in the era of DAA	<i>Massimo Galli, Milano</i>
10:45 - 11:00	Discussion	



11:00 - 12:30

ORAL COMMUNICATIONS HIV AND HCV: WHICH FUTURE?

CHAIRS: **A. De Rossi** (Padova), **G. Silvestri** (Atlanta USA)DISCUSSANT: **M. Clerici** (Milano)11:00 - 11:25 **Dissecting HIV-1 Transmission: understanding transmitted founder virus biology** *Beatrice Hahn, Philadelphia USA*OC 48 **Natural HCV resistance may impact the fast and deep HCV-RNA decay in cirrhotic HCV-1 patients treated with paritaprevir/r-ombitasvir, dasabuvir and ribavirin**V. Cento¹, M. Aragri¹, E. Biliotti², E. Teti³, D. Di Paolo⁴, F. Fiore⁵, R. Alfieri⁶, F.P. Antonucci¹, D. Palazzo², K. Yu La Rosa¹, V.C. Di Maio¹, M. Milana⁴, P. Perinelli², L. Sarmati³, L. Milanesi⁶, C. Pasquazzi⁵, M. Angelico⁴, G. Taliani², M. Andreoni³, C.F. Perno¹, **F. Ceccherini-Silberstein**¹¹Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy, ²Infectious and Tropical diseases, "Umberto I" Hospital, Rome, Italy, ³Infectious Diseases, University Hospital of Rome "Tor Vergata", Rome, Italy, ⁴Hepatology, University Hospital of Rome "Tor Vergata", Rome, Italy, ⁵Infectious Diseases, Sant'Andrea Hospital, Rome, Italy, ⁶Institute for Biomedical Technologies, National Research Council, Segrate (MI), ItalyOC 49 **"Full" viral suppression, residual viremia and low level viremia in HIV-1 ART- treated patients: risk of virological failure and association with inflammation markers and HIV-1 DNA****F. Falasca**¹, E. Palermo¹, I. Mezzaroma², A. Fantauzzi², G. D'Ettore³, F. Fimiani², L. Mazzuti¹, I. Bon⁴, G. Tranquilli¹, M. Bucci¹, V. Vullo³, G. Antonelli¹, O. Turriziani¹¹Department of Molecular Medicine, ²Department of Clinical Medicine, ³Department of Public Health and Infectious Disease, Sapienza University, Rome, ⁴Microbiology Section of the Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine, University of BolognaOC 50 **Clonal Populations of HIV-Infected Cells are Well Distributed across Anatomical Sites: Intra-Host Analysis in a Patient with Comorbid Squamous Cell Carcinoma****F.R. Simonetti**^{1,2}, M. Gouzoulis¹, R. Gorelick⁴, S. Hill¹, S.A. Watters¹, W. Shao³, D. Wells⁴, X. Wu⁴, M. Piatak Jr⁴, J.M. Coffin⁵, J.W. Mellors⁶, S.H. Hughes¹, F. Maldarelli¹¹NCI, NIH, Frederick, MD, ²Department of Biomedical and Clinical Sciences L. Sacco, Milan, Italy, ³ABCC, Leidos Biomed. Res., Inc. Frederick, MD, ⁴Leidos Biomedical Research, Frederick, MD, ⁵Tufts U, Boston, MA, ⁶U. of Pittsburgh, Pittsburgh, PAOC 51 **Thiazolides Elicit Anti-Viral Innate Immunity and Drastically Reduce HIV Replication In Vitro****M. Masetti**¹, D. Trabattoni¹, F. Gnudi¹, S.V. Ibba¹, I. Saulle¹, M. Garziano¹, A. Berzi¹, M. Biasin¹, J.-F. Rossignol², M. Clerici^{3,4}¹Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Italy, ²Romark Laboratories, L.C., Tampa, Florida, USA, ³Department of Physiopathology and Transplants, University of Milan, Italy, ⁴Don C. Gnocchi Foundation, Milan, ItalyOC 52 **ALVAC-, but not NYVAC- based vaccination significantly protects Rhesus macaques from SIVmac251 intravaginal challenge****G. Gorini**^{1*}, S. Gordon^{2*}, N. Liyanage¹, M.N. Doster¹, L. Schifanella¹, M. Vaccari¹, R. Washington-Parks¹, V. Galli¹, D. Brown¹, N. Binello¹, M. Ferrari⁴, J. Treece⁴, A. Cristillo⁴, R. Pal⁴, D. Fuller⁷, S. Santra³, M. Agy⁷, H. Chung⁴, S. Orndoff⁴, X. Pallermo⁷, M.G. Katze⁷, L. Law⁷, G. Tomaras⁸, S. Shen⁸, C. Labranche⁸, D. Venzon⁵, N. Miller⁶, G. Franchini¹¹Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA, ²GlaxoSmithKline R&D, Infectious Diseases, Research Triangle Park, NC, USA, ³Beth Israel Deaconess Medical Center, Boston MA 02215, USA, ⁴Advanced Bioscience Laboratories, Rockville, MD, USA, ⁵Bioinformatics and Data Management Section, National Cancer Institute, Bethesda, MD, USA, ⁶Division of AIDS, Preclinical Research and Development Branch, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, ⁷Washington National Primate Research Center, University of Washington, Seattle, WA, USA, ⁸Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA * These authors contributed equally to this workOC 53 **Frequency and homing potential of blood circulating plasmablasts in different SIV/SHIV vaccine strategies and the systemic-inflammation induced by the vaccines****L. Schifanella**, N. Binello, S.N. Gordon, M. Vaccari, N.P.M. Liyanage, G. Gorini, M.N. Doster, M. Blackburn, F. Caccuri, A.M. Xenophontos, R. Washington Parks, D. Venzon, G. Franchini

National Institutes of Health, National Cancer Institute, Animal Models & Retroviral Vaccine Section

12:30 - 13:15**EXPERT MEETING TENOFOVIR: YESTERDAY, TODAY AND TOMORROW**CHAIR: **A. Chirianni** (Napoli)

From the beginning of the HAART era, nucleoside backbone remains a fundamental part of antiretroviral therapy. In particular, TDF/FTC backbone has shown widely its efficacy and tolerability in many studies and even more in clinical practice. Thanks to the TDF/FTC combination, HIV therapy marked a big step forward. Recently the research is focused on alternative strategies, including backbone sparing. At this time we wonder what the future holds: a therapeutic strategy based on the backbone sparing or newer nucleotide analogues that are an evolution of the existing ones?

12:30 - 12:50 **The role of tenofovir/emtricitabine in the history of ARV therapy**

Sergio Lo Caputo, Firenze

12:50 - 13:10 **Can we imagine a future without tenofovir?**

Andrea Antinori, Roma

13:10 - 13:15 **Discussion**

Unrestricted educational grant of Gilead Sciences

13:20 - 14:05**EXPERT MEETING HCV BETWEEN PAST AND FUTURE: MOVING TOWARDS THE CURE**CHAIR: **A. d'Arminio Monforte** (Milano)

The educational symposium aims to provide an overview of major advances in the treatment of HCV infection, focusing on their impact on current clinical practice. Rapid progresses, the availability of new DAAs and therapeutic strategies are increasing the need for the most up-to-date information on management of patients with hepatitis C virus. Experts will summarize the available results in order to offer point of discussion with current HCV therapy and how the availability of new drugs has changed the clinical practices.

13:20 - 13:40 **Sofosbuvir: bridging the gap between treatment and cure**

Franco Maggiolo, Bergamo

13:40 - 14:00 **STR: when the cure becomes simple**

Massimo Galli, Milano

14:00 - 14:05 **Discussion**

Unrestricted educational grant of Gilead Sciences



14:10 - 16:00

ORAL COMMUNICATIONS CLINICAL HEPATITIS

CHAIRS: **R. Bruno** (Pavia), **E. Sagnelli** (Napoli)DISCUSSANT: **G. D'Offizi** (Roma)14:10 - 14:25 **Post-EASL 2015: HBV treatment update**

Pietro Lampertico, Milano

14:25 - 14:40 **Post-EASL 2015: Focus on HCV**

Erica Villa, Modena

OC 54 **Acute HBV infections: the changing pattern of HBV epidemiology in Italy****S. Menzo**¹, D. Vincenti², F. Iacomì³, G. D'Offizi³, M.R. Capobianchi²¹Dipartimento di Scienze Biomediche e Sanità Pubblica, Università Politecnica delle Marche, Ancona, ²Laboratorio di Virologia, Istituto Nazionale per le Malattie Infettive "L. Spallanzani", Roma, ³1° Divisione, Istituto Nazionale per le Malattie Infettive "L. Spallanzani", RomaOC 55 **Specific HBsAg mutations significantly correlate with hepatocellular carcinoma by reducing HBsAg secretion and enhancing cell proliferation in vitro****M. Surdo**¹, R. Salpini¹, N. Warner², M.F. Cortese¹, C. Mirabelli^{1,3}, D. Colledge², S. Soppe², P. Saccomandi¹, M. Pollicita¹, R. Longo⁴, S. Romano⁴, G. Cappiello⁴, A. Spanò⁴, P. Trimoulet⁵, H. Fleury⁵, J. Vecchiet⁶, N. Iapadre⁷, A. Barlattani⁸, A. Bertoli¹, T. Mari⁹, C. Pasquazzi¹⁰, G. Missale¹¹, C. Sarrecchia¹², E. Orecchini¹³, A. Michienzi¹³, M. Andreoni¹², S. Francioso¹⁴, M. Angelico¹⁴, F. Ceccherini-Silberstein¹, S. Locarnini², C.F. Perno¹, V. Svircher¹¹Department of Experimental Medicine, University of Rome "Tor Vergata" Rome, Italy, ²Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia, ³Institut Pasteur, Unité de Biologie des virus entériques, Paris, France, ⁴"S. Pertini Hospital", Rome, Italy, ⁵Hôpital Pellegrin Tripode, Bordeaux, France, ⁶"SS Annunziata" Hospital, Chieti, Italy, ⁷"S Salvatore" Hospital, L'Aquila, Italy, ⁸"S Giacomo" Hospital, Rome, Italy, ⁹"Regina Margherita" Hospital, Rome, Italy, ¹⁰"S Andrea" Hospital, Rome, Italy, ¹¹Hospital of Parma, Parma, Italy, ¹²Tor Vergata University Hospital, Infectious Diseases Unit, Rome, Italy, ¹³Department of Biomedicine and Prevention, University of Rome "Tor Vergata" Rome, Italy, ¹⁴Tor Vergata University Hospital, Hepatology Unit, Rome, ItalyOC 56 **Analysis of genetic and viral determinants of HBsAg levels in chronic carriers****A. Vergori**¹, B. Rossetti¹, I. Vicenti², G. Meini², G. Lentini³, M.G. Cusi³, M. Zazzi² e A. De Luca¹¹University Infectious Diseases Unit, Siena University Hospital, Siena, ²Medical Biotechnology Department, University of Siena, Siena, ³Microbiology Unit, Siena University Hospital, SienaOC 57 **Potential Epigenetic effects of NAs Therapies in Chronic Hepatitis B patients****S. Ortu**¹, G. Madeddu¹, M. Melis¹, I. Maida¹, A.A. Muredda¹, G. Garrucciu², S. Babudieri¹, M.S. Mura¹¹Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, ²Unit of Internal Medicine, Azienda Ospedaliero-Universitaria, SassariOC 58 **Low four weeks entecavir plasma concentration is associated with a higher HBV DNA decay after three months of therapy**C.S. Cardellino¹, **A. De Nicolò**², L. Boggione¹, L. Baietto², M. Simiele², P. Cariti¹, G. Di Perri¹, A. D'Avolio²¹Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin, Turin, Italy, ²Laboratory of Clinical Pharmacology and Pharmacogenetics, Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin, Turin, ItalyOC 59 **Clinical Usefulness of HCV Sequencing for Genotype and Subtype Determination in the Era of New Direct Antiviral Agents****V.C. Di Maio**¹, M. Aragri¹, D. Di Paolo², V. Cento¹, F. De Leonardis², L. Gianserra³, M. Tontodonati⁴, V. Micheli⁵, S. Landonio⁶, A. Manunta⁷, A. Bertoli¹, M. Ciotti⁸, M.C. Bellocchi¹, F.P. Antonucci¹, R. Campoli¹, M.C. Sorbo¹, F. De Luca¹, F. Deodati¹, I. Lenci², S. Francioso², L.A. Nicolini⁹, S. Marengo⁹, C. Cerva¹⁰, V. Malagnino¹⁰, L. Lambiase³, F. Santopaolo², M. Milana², I. Maida⁷, A. Di Biagio⁹, A. Pellicelli¹¹, L. Nosotti¹², S. Grieco¹³, P. Cacciatore⁴, D. Romagnoli¹⁴, M. Siciliano¹⁵, G. D'Etorre¹³, S. Babudieri⁷, M. Lichtner¹⁶, U. Vespasiani-Gentilucci¹⁷, M. Romano¹⁸, C. Sarrecchia¹⁰, A. Grieco¹⁵, F. Morisco¹⁹, C. Mastroianni¹⁶, J. Vecchiet²⁰, M. Puoti²¹, A. Mangia²², E. D'Amico²³, N. Caporaso¹⁹, A. Gasbarrini¹⁵, S. Bruno²⁴, C. Magni⁶, M.S. Mura⁷, G. Taliani¹³, A. Picciotto², G. Parruti⁴, C. Pasquazzi³, G. Rizzardini⁶, M. Andreoni¹⁰, M. Angelico², C.F. Perno^{1,8}, F. Ceccherini-Silberstein¹¹Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy, ²Hepatology Unit, University Hospital of Rome "Tor Vergata", Rome, Italy, ³Infectious Diseases, San'Andrea Hospital - "La Sapienza" University, Rome, Italy, ⁴Infectious Disease Unit, Pescara General Hospital, Pescara, Italy, ⁵Unit of Microbiology, Hospital Sacco of Milan, Milan, Italy, ⁶Division of Infectious Disease, Hospital Sacco of Milan, Milan, Italy, ⁷Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Sassari, Italy, ⁸Molecular Virology Unit, University Hospital of Rome "Tor Vergata", ⁹S. Martino Hospital, Genova, Italy, ¹⁰Infectious Disease, University Hospital of Rome "Tor Vergata", Rome, Italy, ¹¹Hepatology Unit, San Camillo Forlanini Hospital, Rome, Italy, ¹²Hepatology Unit, National Institute of Health, Migration and Poverty, Rome, Italy, ¹³"La Sapienza" University, Rome, Italy, ¹⁴Department of Biomedical, Metabolic and Neural Sciences, NOCSAE Baggiovara, ¹⁵Gastroenterology, Catholic University of Rome, Rome, Italy, ¹⁶Infectious Diseases, "La Sapienza" University, Latina, Italy, ¹⁷Campus Biomedico, Rome, Italy, ¹⁸S. Pertini Hospital, Rome, Italy, ¹⁹Università «Federico II», Napoli, Italy, ²⁰Infectious Disease Clinic, Chieti, Italy, ²¹Hospital Niguarda Ca'Granda, Milan, Italy, ²²Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy, ²³Hepatology Unit, Ospedale San Massimo, Penne, Italy, ²⁴Internal Medicine, Gastroenterology and Hepatology, Azienda Ospedaliera Fatebenefratelli e Oftalmico, Milan ItalyOC 60 **Optimization of simeprevir triple therapy: A multivariate logistic regression model using baseline predictors****G. D'Offizi**¹, C. Cammà², M. Schlag³, K. Weber³, R. DeMasi⁴, K. Janssen⁴, J. Witek⁴, R. Lionetti¹¹National Institute for Infectious Diseases "L. Spallanzani" I.R.C.C.S., Rome, Italy, ²Section of Gastroenterology, Di.Bi.M.I.S., University of Palermo, Italy, ³Janssen-Cilag, Vienna, Austria, ⁴Janssen R&D LLC, Titusville, USA

16:00 - 16:50**WRAP UP SESSION HIGHLIGHTS OF THE MAIN TOPICS FROM ICAR 2015**CHAIRS: **A. Cossarizza** (Modena), **C. Mussini** (Modena), **L. Sighinolfi** (Ferrara)

16:00 - 16:10 **Epidemiology**
 16:10 - 16:20 **Basic Science**
 16:20 - 16:30 **Clinical HIV**
 16:30 - 16:40 **Clinical Hepatitis**
 16:40 - 16:50 **Community**

Patrizio Pezzotti, Roma
Miriam Lichtner, Latina
Stefano Rusconi, Milano
Alessandra Orlandini, Parma
Michele Breveglieri, Verona

16:50 - 17:05**ICAR 2015 AWARDS**CHAIRS: **A. Cossarizza** (Modena), **C. Mussini** (Modena), **L. Sighinolfi** (Ferrara)**ICAR - SIMIT**

3 Awards for the best abstracts of Clinical, Basic Science and Social-Epidemiological

*Massimo Andreoni, Roma***ICAR - SIVIM**

1 Award for the best abstract of Basic and Clinical Virology

*Adriano Lazzarin, Milano***ICAR - Fondazione AVIRALIA**

2 Scholarships for the best abstracts of Virology

*Riccardo Massari, Roma***17:05 - 17:15****CLOSING REMARKS****A. Cossarizza** (Modena), **C. Mussini** (Modena), **L. Sighinolfi** (Ferrara)

10:00 - 11:00

ORAL COMMUNICATIONS ANTIRETROVIRAL TRIALS AND OBSERVATIONAL STUDIES

CHAIRS: **P. Bonfanti** (Lecco), **C. Gervasoni** (Milano)DISCUSSANT: **N. Gianotti** (Milano)

- OC 61 **A NRTI sparing two- drugs switch strategy maintains HIV suppression and is well tolerated (PROBE study)**
F. Maggiolo, D. Valenti, A. Callegaro, E. Di Filippo, M. Rizzi
 AO Papa Giovanni XXIII, Bergamo
- OC 62 **Randomized clinical trial comparing the safety and efficacy of the use of fixed-dose combination efavirenz/tenofovir/emtricitabine on alternate days versus continuous treatment**
E. Nicastrì, R. Bellagamba, C. Tommasi, A.L. Gallo, M. Tempestilli, C. Angeletti, M. Zaccarelli, A. Ammassari, C. Pinnetti, A. Antinori, P. Narciso and the ATAD study group (T. Ascoli Marchetti, E. Boumis, C. Cerva, S. Cicalini, A. Corpolongo, M.L. Giancola, P. De Nardo, S. Fazio, E. Gentilotti, G. Liuzzi, P. Mencarini, L. Pucci, A. Sampaolesi, C. M. Stella, M. Viscione)
 National Institute of Infectious Diseases Lazzaro Spallanzani, Rome, Italy
- OC 63 **Response to first-line ritonavir-boosted protease inhibitors (PI/r) based regimens in late presenting patients enrolled in a large cohort of HIVinfected individuals**
 A. d'Arminio Monforte¹, **A. Cozzi Lepri**², F. Maggiolo³, G. Rizzardini⁴, P.E. Manconi⁵, N. Gianotti⁶, T. Quirino⁷, C. Pinnetti⁸, S. Rusconi⁹, A. De Luca¹⁰, A. Antinori⁸ on behalf of the Icona Foundation Study cohort
¹University of Milan, San Paolo Hospital, Milan, Italy, ²University College, London, UK, ³Spedali Riuniti, Bergamo, Italy, ⁴L Sacco Hospital, Milan, Italy, ⁵University of Cagliari, Cagliari, Italy, ⁶San Raffaele Hospital, Milan, Italy, ⁷Busto Arsizio Hospital, Varese, Italy, ⁸INMI L Spallanzani, Rome, Italy, ⁹University of Milan, Sacco Hospital, Milan, Italy, ¹⁰University of Siena, Siena, Italy
- OC 64 **Safety of switching to Co-Formulated Rilpivirine/Emtricitabine/Tenofovir (RPV/FTC/TDF) in Virologically Suppressed Patients: One Year of Observation from a Multicenter Cohort**
 C. Pinnetti¹, S. Di Giambenedetto², F. Maggiolo³, M. Fabbiani², G. Sterrantino⁴, A. Latini⁵, P. Lorenzini¹, A. Ammassari¹, L. Loiacono¹, R. Bellagamba¹, E. Boumis¹, R. Cauda², A. Antinori¹, **M. Zaccarelli**¹
¹National Institute for the Infectious Disease "Lazzaro Spallanzani", IRCCS, Rome, ²Department of Infectious Diseases, Catholic University of the Sacred Heart, Rome, ³Division of Infectious Diseases, Ospedali Riuniti, Bergamo, ⁴Division of Infectious Diseases, 'Careggi' Hospital, Florence, ⁵San Gallicano Institute, IRCCS, Rome

10:45 - 11:00 **Trials, cohorts and real live: where is the break even point?**

Franco Maggiolo, Bergamo

11:00 - 12:30

ORAL COMMUNICATIONS COINFECTIONS WITH HEPATITIS VIRUSES

CHAIRS: **V. Borghi** (Modena), **F. Mazzotta** (Firenze)DISCUSSANTS: **L. Calza** (Bologna), **G. Sterrantino** (Firenze)11:00 - 11:15 **Treatment of hepatitis C in persons living with HIV: new drugs and new treatment strategies**

Massimo Puoti, Milano

- OC 65 **Characteristics of HIV/HCV co-infected individuals seen for care in Italy: a description using data from ICONA and HepalCONA cohorts**
M. Shanyinde¹, A. Cozzi-Lepri¹, A. Antinori², C. Uberti Foppa³, N. Abrescia⁴, P. Bonfanti⁵, G. Angarano⁶, S. Bonora⁷, A. d'Arminio Monforte⁸, M.C. Moiola⁹ on behalf of ICONA and HepalCONA study groups
¹Royal Free Hospital University College London, UK, ²Dept Infectious Diseases, INMI Spallanzani Roma, Italy, ³San Raffaele Hospital Milano, Italy, ⁴Cotugno Hospital, Napoli, Italy, ⁵Lecco Hospital, Lecco, Italy, ⁶Clinic Infectious Diseases, University of Bari, Italy, ⁷Clinical Infectious Diseases University of Turin, Italy, ⁸Clinic Infectious Diseases, San Paolo Hospital Milano, Italy, ⁹Dept Infectious Diseases, Niguarda ca Grande Hospital, Milano, Italy
- OC 66 **HCV coinfection in HIV-infected pregnant women: data from a national study in Italy**
G. Liuzzi¹, S. Baroncelli², M.F. Pirillo², R. Amici², E. Tamburrini³, O. Genovese⁴, M. Ravizza⁵, A. Maccabruni⁶, G. Masuelli⁷, G. Guaraldi⁸, C. Pinnetti¹, V. Giacomel⁹, A. Degli Antoni¹⁰, A. Vimercati¹¹, S. Dalzero⁵, V. Sacchi⁵, M. Florida² on behalf of The Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy
¹I.N.M.I. Lazzaro Spallanzani, Rome, Italy, ²Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy, ³Department of Infectious Diseases, Catholic University, Rome, Italy, ⁴Department of Paediatrics, Catholic University, Rome, Italy, ⁵Department of Obstetrics and Gynaecology, DMSD San Paolo Hospital Medical School, University of Milan, Italy, ⁶University of Pavia, Department of Paediatrics, IRCCS Policlinico San Matteo, Pavia, Italy, ⁷Department of Obstetrics and Neonatology, Città della Salute e della Scienza Hospital, and University of Turin, Italy, ⁸Department of Medical Specialties, Infectious Diseases Clinic, University of Modena and Reggio Emilia, Modena, Italy, ⁹Department of Paediatrics, Luigi Sacco Hospital and University of Milan, Italy, ¹⁰Department of Infectious Diseases and Hepatology, Azienda Ospedaliera di Parma, Italy, ¹¹Department of Obstetrics and Gynaecology and Policlinic Hospital, University of Bari, Italy
- OC 67 **The treatment cascade of chronic hepatitis C in HIV co-infected patients: data from the Clinic of Infectious Diseases in Modena, Italy**
G. Cuomo, C. Puzzolante, C. Lazzaretti, G. Guaraldi, C. Mussini, V. Borghi
 Clinic of Infectious Disease, AOU Modena, Italy
- OC 68 **A Prospective Study on Immune Response to Hepatitis B Vaccination in HIV Infected Individuals with Isolated Antibodies to HBV Core Antigen, Final Results**
 G. Morsica¹, **S. Bagaglio**^{1,2}, L. Della Torre¹, L. Galli¹, S. Salpietro¹, E. Messina¹, M. Merli¹, H. Hasson¹, M. Maillard¹, S. Nozza¹, V. Spagnuolo¹, A. Castagna¹, A. Andolina¹, A. Lazzarin^{1,2}, C. Uberti-Foppa¹
¹Infectious Diseases Dept., San Raffaele, Scientific Institute, Milan, Italy and ²University Vita-Salute Milan, Italy
- OC 69 **Magnetic Resonance Spectroscopy, dual-phase and multi-echo gradient-echo MRI in the quantitative assessment of hepatic steatosis in HIV infected patients**
C. Stentarelli, G. Besutti, L. Nocetti, G. Ligabue, S. Zona, R. Scaglioni, P. Torricelli, G. Guaraldi
 University of Modena and Reggio Emilia



13:20 - 14:05**EXPERT MEETING THE RELIABLE INDIVIDUALIZATION OF TODAY FOR THE PATIENTS OF TOMORROW**CHAIR: **A. De Luca** (Siena)

Thanks to the available treatment options, ARV treatment efficacy it's already a fulfilled unmet need. Considering that in an infectious disease like HIV there is few investment in preventing it, this is not enough. The ambitious aim is to improve patient quality of life and guarantee a viral load suppression for everyone. The fundamental aspects in which the research is working are: the optimization of the take in care of the diagnosed patient and his/her engagement during the treatment pathway. Showing the importance of the treatment, providing supportive services in the centers, giving the patient all the needed information about the treatment pathway that will last for his/her entire life, are crucial elements that can improve the efficacy of the entire HIV cascade. Considering the chronicity of the therapies, it is important to take into account drugs that guarantee long term reliability. Among the available therapeutic options, the Protease Inhibitors can assure the reliability of a versatile solution, widely employed in the clinical practice, effective and suitable to individualize the therapy according to patient needs.

13:20 - 13:40 **Reliable therapeutic choices for naïve patients**
 13:40 - 14:00 **Treatment individualization for a reliable retention in care**
 14:00 - 14:05 **Discussion**

Carlo Federico Perno, Roma
 Diego Ripamonti, Bergamo

Unrestricted educational grant of Janssen

14:10 - 16:00

ORAL COMMUNICATIONS COMPLICATION OF HIV INFECTION AND ANTIRETROVIRAL THERAPY

CHAIRS: **R. Maserati** (Pavia), **V. Vullo** (Roma)DISCUSSANTS: **M. Gargiulo** (Napoli), **G. Mazzola** (Palermo)

14:10 - 14:25 **Antiretroviral drug concentrations in the central nervous system: scarce, enough or too much?**

Andrea Calcagno, Torino

OC 70 **eGFR Trajectories in HIV-Infected Patients Treated with Different PIs and TDF or ABC**

N. Gianotti¹, L. Galli¹, A. Poli¹, S. Salpietro¹, S. Nozza¹, A. Carbone^{1,2}, M. Merli^{1,2}, M. Ripa^{1,2}, N. Galizzi^{1,2}, V. Spagnuolo¹, A. Lazzarin^{1,2}, A. Castagna^{1,2}

¹Infectious Diseases, San Raffaele Scientific Institute, Milano, Milano, Italy, ²Università Vita-Salute San Raffaele, Milano, Milano, Italy

OC 71 **Prevalence, predictors and management of low Bone Mineral Density in a single cohort of HIV-infected patients: results of a multidisciplinary experience**

A. D'Avino¹, A.P. Lassandro¹, R. Gagliardini¹, S. Lamonica¹, G. Baldin¹, F. Pallavicini¹, A. Mondì¹, A. Borghetti¹, R. Cauda¹, A. De Luca², M. Fabbiani¹, S. Di Giambenedetto¹

¹Istituto di Clinica delle Malattie Infettive-Università Cattolica del Sacro Cuore Roma, ²Dipartimento di Malattie Infettive, Policlinico Universitario Le Scotte-Siena

OC 72 **Parasympathetic tone and its adaptation to moderate intensity aerobic training in HIV patients on combination anti-retroviral therapy**

G. Merati^{1,2}, M. Bonato¹, **G. Pavei**³, A. La Torre¹, L. Agnello¹, S. Bossolasco⁴, L. Galli⁴, P. Cinque⁴

¹Department of Biomedical Sciences for Health, Università degli Studi, Milan, Italy, ²Don C. Gnocchi Foundation, Milan, Italy, ³Department of Pathophysiology and Transplantation, Università degli Studi, Milan, Italy, ⁴Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy

OC 73 **TB occurrence in a cohort of patients with HIV infection screened for latent tuberculosis with QuantiFERON-TB Gold In-Tube**

M. Sañé Schepisi¹, M.P. Parracino¹, A. Mammone¹, R. Bellagamba², C. Pinnetti², S. Cicalini², A. Sampaolesi², A. Ammassari², F. Martini¹, D. Goletti¹, E. Girardi¹

¹Department of Epidemiology and Preclinical Research and ²Clinical Department, National Institute for Infectious Diseases (INMI) L. Spallanzani, IRCCS, Rome, Italy

OC 74 **Changes in Inflammatory Markers in Patients Initiating Antiretroviral Therapy with Protease Inhibitors**

N. Squillace¹, A. Bandera¹, D. Trabatton², A. Muscatello¹, F. Sabbatini¹, A. Maloberti³, C. Giannattasio⁴, A. Soria¹, M. Clerici², A. Gori¹

¹Division of Infectious Diseases "San Gerardo" Hospital University of Milano-Bicocca, Monza, Italy, ²Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, ³Clinica Medica, "San Gerardo" Hospital University of Milano-Bicocca, Monza, Italy, ⁴Cardiology IV, Cardiovascular "A.De Gasperis" Department, Niguarda Ca' Granda Hospital, Milan, Italy,

OC 75 **New insights on HIV associated bone disease pathogenesis: traditional risk factors or not?**

A. D'Abramo, M.A. Zingaropoli, A. Oliva, C. D'Agostino, S. Al Moghazi, G. De Luca, M. Iannetta, M.R. Ciardi, C.M. Mastroianni, V. Vullo
Department of Public Health and Infectious Diseases, "Sapienza" University of Rome

OC 76 **Prevalence of neurocognitive impairment in a large cohort of HIV-positive patients on stable EFV/FTC/TDF regimen and relationship with plasmatic EFV levels and treatment adherence**

M.L. Giancola, P. Balestra, A. Ammassari, C. Angeletti, M. Ricottini, R. Bellagamba, C. Tommasi, A.L. Gallo, M. Tempestilli, M. Zaccarelli, P. Lorenzini, C. Pinnetti, P. Narciso, A. Antinori, E. Nicastri and the ATAD study group (E. Boumis, C. Cerva, S. Cicalini, A. Corpolongo, P. De Nardo, S. Fazio, E. Gentilotti, G. Liuzzi, P. Mencarini, L. Pucci, A. Sampaolesi, C.M. Stella, M. Viscione)

National Institute for Infectious Diseases "Lazzaro Spallanzani", IRCCS



10:00 - 11:00

SYMPOSIUM THE ADOLESCENT PERSPECTIVE IN HIV INFECTIONCHAIRS: **A. Ammassari** (Roma), **A. Castagna** (Milano), **A. d'Arminio Monforte** (Milano)DISCUSSANTS: **T. Bini** (Milano), **A. Cingolani** (Roma)

There are globally 2 million HIV-1 infected subjects aged between 10 and 19 years of age. Adolescents and young adults are at increased risk for HIV due to the many developmental, psychological, social, and structural transitions that converge in this period of the lifespan. One of the key challenges for any HIV-positive person is disclosing the condition to others (e.g. to a partner, family members and friends). Youth with HIV infection may face additional barriers in disclosing their status, adhering to HIV services and treatment; moreover data on long-term outcomes of antiretroviral options and strategies in HIV-1 infected adolescents are limited. This session will debate how to promote the well being in this population and how to face with adolescent-centred interventions, taking advantages of the innovations and technologies that youth have easily incorporated into their daily lives.



Ernesto Caffo, Modena
Caroline Foster, London UK
Vania Giacomet, Milano

10:00 - 10:10 **Promoting well-being in adolescents**10:10 - 10:20 **Interventions to help HIV-disclosure in adolescents**10:20 - 10:30 **Antiretroviral therapy in adolescents: lights and shadows**10:30 - 11:00 **ROUND TABLE Taking care of adolescents with HIV**

A. Ammassari (Roma), T. Bini (Milano), E. Caffo (Modena), A. Castagna (Milano), A. Cingolani (Roma), A. d'Arminio Monforte (Milano), C. Foster (London UK), V. Giacomet (Milano)

11:00 - 12:30

ORAL COMMUNICATIONS HIV TRANSMISSION AND PRIMARY HIV INFECTION

CHAIRS: **P. Bassi** (Ravenna), **G. Magnani** (Reggio Emilia)DISCUSSANT: **A. Cascio** (Messina)

- OC 77 **Prevalence of recent HIV infection (RHI) and characterisation of the RHI population in a cohort of patients seen for care in Italy over 1997-2014**
S. Nozza¹, A. Cozzi-Lepri², S. Rusconi³, A. Gori⁴, P. Cinque¹, A. Ammassari⁵, P. Caramello⁶, G. Tambussi¹, A. D'Arminio Monforte³, G. Marchetti³ for ICONA Study Group
¹San Raffaele Scientific Institute, Milano, Italy, ²Research Department of Infection and Population Health, University College London, London, UK, ³Università degli Studi di Milano, Milano, Italy, ⁴Division of Infectious Diseases, Department of Internal Medicine, "San Gerardo" Hospital, University of Milan-Bicocca, Monza, Italy, ⁵INMI Spallanzani, Roma, Italy, ⁶Department of Infectious Diseases, Amedeo di Savoia Hospital, Torino, Italy
- OC 78 **Identification of Recent Transmission Clusters of HIV-1 C and CRF17_BF Strains with evidence of NNRTI-related mutations among Newly Diagnosed Men in Central Italy**
L. Fabeni¹, C. Alteri², N. Orchi¹, C. Gori¹, A. Bertoli^{2,3}, F. Forbici¹, F. Montella⁴, A. Pennica⁵, G. De Carli¹, M. Giuliani⁶, F. Continenza¹, C. Pinnetti¹, E. Nicastrì¹, F. Ceccherini-Silberstein², C.M. Mastroianni⁷, E. Girardi¹, M. Andreoni³, A. Antinori¹, M.M. Santoro², C.F. Perno¹
¹National Institute for Infectious Diseases L. Spallanzani - IRCCS, Rome, Italy, ²University of Rome Tor Vergata, Rome, Italy, ³University Hospital Tor Vergata, Rome, Italy, ⁴S. Giovanni Addolorata Hospital, Rome, Italy, ⁵S. Andrea Hospital, Sapienza University of Rome, Italy, ⁶IRCSS San Gallicano, Rome, Italy, ⁷Infectious Diseases Unit, Sapienza University, Polo Pontino, Latina, Italy
- OC 79 **IN ACTION study group: retrospective interim analysis of Primary HIV Infections in Italy between 2008 and 2014**
A. Muscatello^{1*}, M. Ripa^{2*}, A. Bandera¹, M. Fabbiani¹, S. Nozza², S. Chiappetta², S. Rusconi³, G.M. Bottani³, R. Gulminetti⁴, G. Tambussi², A. Gori¹ on behalf of IN ACTION study group. *equally contributing authors.
¹San Gerardo Hospital, Monza, ²San Raffaele Hospital, Milano, ³Sacco Hospital - Milano University, Milano, ⁴San Matteo IRCCS, Pavia
- OC 80 **Early HIV-RNA decay kinetics support the use of intensified cART in primary HIV when compared to chronic infection**
A. Ammassari¹, A. Amendola², **C. Pinnetti**¹, I. Abbate², V. Bordoni³, G. Rozera², N. Orchi⁴, L. Alba¹, A. Corpolongo¹, A. Abeddaim¹, P. Pierro¹, P. Lorenzini¹, R. Libertone¹, A. Antinori¹, M.R. Capobianchi²
¹Clinical Department, National Institute For Infectious Diseases, Lazzaro Spallanzani, Rome, Italy, ²Laboratory of Virology, National Institute For Infectious Diseases, Lazzaro Spallanzani, Rome, Italy, ³Cellular Immunology Laboratory, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy, ⁴Epidemiology Department, National Institute For Infectious Diseases, Lazzaro Spallanzani, Rome, Italy
- OC 81 **More pronounced decline of proviral load in peripheral lympho-monocytes is associated with cART started during acute compared to recent primary HIV infection**
G. Rozera¹, C. Pinnetti², I. Abbate¹, A. Amendola¹, N. Orchi³, P. Pierro², P. Lorenzini², V. Bordoni⁴, A. Antinori², M.R. Capobianchi¹, A. Ammassari²
¹Laboratory of Virology, National Institute for Infectious Diseases "L.Spallanzani", ²Clinical Department, National Institute for Infectious Diseases "L.Spallanzani", ³AIDS Referral Centre and Epidemiology Department, National Institute for Infectious Diseases "L.Spallanzani", ⁴Cellular Immunology Laboratory, National Institute for Infectious Diseases "L.Spallanzani"
- OC 82 **Acute HIV infection in women. Rome, 2004-2013**
N. Orchi¹, A. Navarra¹, A. Palummieri¹, I. Abbate², C. Pinnetti³, V. Puro¹, A. Antinori³, M.R. Capobianchi², A. Ammassari³, E. Girardi¹ and on behalf of the Sendih study group
¹Dipartimento di Epidemiologia, Istituto Nazionale Malattie Infettive L. Spallanzani, Roma, ²Laboratorio di Virologia, Istituto Nazionale Malattie Infettive L. Spallanzani, Roma, ³Dipartimento Clinico, Istituto Nazionale Malattie Infettive L. Spallanzani, Roma
- OC 83 **Epidemiological scenarios of recent HIV infection and seroconversions in Modena HIV surveillance system during period 2005-2014**
C. Lazzaretti, S. Zona, G. Giovanni, C. Mussini, V. Borghi
Infectious disease clinic, AOU Policlinico Modena, Italy
- OC 84 **Induction with a 4-drug cART followed by a simplified GRT-guided maintenance in Primary HIV Infection: preliminary data on feasibility and early efficacy**
C. Pinnetti¹, N. Orchi², R. Libertone¹, L. Alba¹, A. Corpolongo¹, P. Pierro¹, I. Abbate¹, C. Gori³, M.R. Capobianchi³, A. Antinori¹, A. Ammassari¹
¹Clinical Department, National Institute For Infectious Diseases, Lazzaro Spallanzani, Rome, Italy, ²Epidemiology Department, National Institute For Infectious Diseases, Lazzaro Spallanzani, Rome, Italy, ³Laboratory of Virology, National Institute For Infectious Diseases, Lazzaro Spallanzani, Rome, Italy, ⁴Antiretroviral Drug Monitoring Unit, National Institute For Infectious Diseases, Lazzaro Spallanzani, Rome, Italy



14:10 - 16:00

ORAL COMMUNICATIONS PATHOGENESIS AND IMMUNOPATHOGENESIS

CHAIRS: **G. Palù** (Padova), **C. Torti** (Catanzaro)DISCUSSANTS: **A. Bandera** (Monza), **S. Piconi** (Milano)14:10 - 14:25 **Immunological map of HIV infection by mass cytometry**

Antonio Cosma, Paris F

- OC 85 **Overexpression of MAVS and STING and downregulation of NLRX1 in HIV patients assuming efficient antiretroviral therapy**
M. Nasi¹, M. Digaetano², S. De Biasi¹, E. Bianchini³, S. Pecorini¹, R. Bartolomeo¹, M. Pinti³, L. Gibellini¹, V. Borghi², C. Mussini^{1,2}, A. Cossarizza¹
¹Department of Surgery, Medicine, Dentistry and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, ²Infectious Diseases Clinics, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy, ³Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy
- OC 86 **Residual HIV-RNA, Foxp3, IL17 levels and microbial translocation markers in HIV monoinfected and HIV/HCV coinfecting patients**
P. Sacchi¹, S. Cima¹, **P. Columpsi¹**, C. Sarda¹, V. Zuccaro¹, S. Paolucci², G. Comolli², F. Baldanti², M. Mariconti¹, R. Bruno¹
¹Dipartimento di Malattie Infettive, Fondazione IRCCS Policlinico San Matteo, Pavia, ²Unità di Virologia Molecolare, S.C. di Microbiologia e Virologia, Fondazione IRCCS Policlinico San Matteo, Pavia
- OC 87 **NKG2D detuning in CD8+ T cells of a patients with chronic HIV-1 infection**
E. Giuliani¹, L. Vassena¹, M.G. Desimio¹, A.R. Buonomini², V. Malagnino², M. Andreoni², M. Doria¹
¹Laboratory of Immunoinfectology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy, ²Department of Medicine of Systems, Tor Vergata University, Rome, Italy
- OC 88 **Study of Gut-Homing and Th17 CD4+ Subpopulations in cART-Naive Individuals with Different Responses to Treatment**
M. Basilissi, C. Tincati, A. Smedile, E. Merlini, S. Cannizzo, F. Cazzaniga, A. d'Arminio Monforte, G. Marchetti
Department of Health Sciences, Clinic of Infectious Diseases and Tropical Medicine, "San Paolo" Hospital, University of Milan, Italy
- OC 89 **Highly frequencies of Th17 and Tc17 in gut associated lymphoid tissue despite sustained immune-activation and type I interferon response in chronic HIV-1 positive patients**
I. Schietroma¹, C. Scagnolari², G. Ceccarelli¹, M. Andreotti³, N. Giustini¹, S. Serafino¹, C. Selvaggi², G. Nunnari⁴, G. Antonelli², G. d'Ettore¹, V. Vullo¹
¹Department of Public Health and Infectious Diseases, University of Rome "Sapienza", Rome, Italy, ²Department of Molecular Medicine, Laboratory of Virology, University of Rome "Sapienza", Rome, Italy, ³Department of Therapeutic Research and Medicines Evaluation, Italian Institute of Health, Rome, Italy, ⁴Department of Clinical and Molecular Biomedicine, Division of Infectious Diseases, University of Catania, Italy
- OC 90 **Persistent expansion of Inflammatory Monocytes despite virological suppression through HAART in both AIDS presenters and non AIDS presenters**
S. Savinelli¹, M. Lichtner², S. Vita¹, C. Mascia¹, R. Rossi¹, R. Marocco², M. Iannetta³, G. d'Ettore¹, F. Schiavone², C.M. Mastroianni², V. Vullo¹
¹Sapienza University of Rome, ²Sapienza University of Rome, Polo Pontino, Latina, Italy, ³INSERM u1016, Paris, France
- OC 91 **ISG15 expression correlates with HIV-1 viremia and selected factors regulating T cell response**
C. Scagnolari¹, K. Monteleone¹, C. Selvaggi¹, G. Cacciotti¹, A. Pierangeli¹, G. D'Ettore², I. Mezzaroma³, O. Turriziani¹, M. Gentile¹, V. Vullo², G. Antonelli¹
¹Pasteur Institute-Cenci Bolognetti Foundation, Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, ²Department of Public Health and Infectious Diseases, Sapienza University of Rome, ³Department of Clinical Medicine, Sapienza University of Rome
- OC 92 **Immune activation is present in HIV-1 Exposed Seronegative Individuals (HESN) and is independent from microbial translocation**
M. Garziano, I. Saule, F. Gnudi, M. Masetti, A. Berzi, V. Rainone, S. Lo Caputo, F. Mazzotta, D. Trabattoni, M. Biasin, M. Clerici
University of Milan, Biomedical and Clinical Sciences, Milan, Italy, Santa Maria Annunziata Hospital, Infection Disease, Florence, Italy, Don Gnocchi Foundation, Milan, Italy

10:00 - 11:00

ORAL POSTER SOCIAL, ECONOMICAL AND CLINICAL OUTCOMES

CHAIRS: **M. Borderi** (Bologna), **S. Mattioli** (Bologna)

- OP 19 **Incidence of renal toxicity after a 12-month follow-up in naïve patients starting tenofovir/emtricitabine associated with darunavir/ritonavir, atazanavir/ritonavir or raltegravir**
L. Calza¹, E. Magistrelli¹, V. Colangeli¹, M. Borderi¹, I. Bon², M.C. Re², P. Viale¹
¹Infectious Diseases Unit and ²Microbiology Unit, S.Orsola-Malpighi Hospital, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna
- OP 20 **Prospective evaluation of Urinary Neutrophil gelatinase-associated lipocalin levels as a marker of subclinical renal impairment in HIV-infected patients**
F. Sabbatini¹, G. Castoldi², A. Bandera¹, V. Perlangeli³, P. Mariani², N. Squillace¹, M. L. Carati³, A. Stella², A. Gori¹
¹Infectious Diseases Unit, St Gerardo Hospital, University of Milano-Bicocca, Monza (Italy), ²Department of Health Sciences, Nephrology Unit, St Gerardo Hospital, University of Milano-Bicocca, Monza (Italy), ³Clinical Chemistry Laboratory, St Gerardo Hospital, Monza, (Italy)
- OP 21 **Peripheral and CSF viro-immunological features of HIV infected patients with elevated CSF HIV-RNA: a longitudinal study**
E. Merlini¹, F. Iannuzzi¹, A. Calcagno², M. Trunfio¹, F. Bai¹, F. Cazzaniga¹, T. Bini¹, S. Bonora², A. d'Arminio Monforte¹, G. Marchetti¹
¹Department of Health Sciences, University of Milan, Milan, Italy, ²Department of Medical Sciences, University of Torino, Turin, Italy
- OP 22 **HPV anal and pharyngeal infection in HIV positive Men who Have sex with Men (MSM): a cross sectional and longitudinal study over eight years**
S.G. Parisi¹, R. Scaggiante², S. Andreis¹, A. Barelli³, C. Boldrin¹, F. Dal Bello F¹, M. Cruciani⁴, C. Mengoli¹, M. Basso¹, G. Palù¹
¹Department of Molecular Medicine, University of Padova, Padova, Italy, ²Infectious Disease Unit, Padova Hospital, Padova, Italy, ³Infectious Disease Unit, Venezia-Mestre Hospital, Venezia, Italy, ⁴Center of Preventive Medicine & HIV Outpatient Clinic, Verona, Italy
- OP 23 **Adverse skin reactions in course of combined antiretroviral therapy**
L. Taramasso¹, E. Ricci², G. Orofino³, G. Penco⁴, F. Vichi⁵, C. Martinelli⁶, G.V. De Socio⁷, G. Parruti⁸, B.M. Celesia⁹, S. Rusconi¹⁰, L. Carezzi¹⁰, G. Madeddu¹¹, P. Bonfanti¹², T. Quirino¹³, A. Di Biagio¹ on behalf of the CISAI Study Group
¹Unit of Infectious Diseases, San Martino Hospital, University of Genoa, Italy, ²Epi2004, Milan, Italy, ³Department of Infectious Diseases, Amedeo di Savoia Hospital, Turin, Italy, ⁴Unit of Infectious Diseases, Galliera Hospital, Genoa, Italy, ⁵Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Firenze, Italy, ⁶Unit of Infectious Diseases, Careggi Hospital, Firenze, Italy, ⁷Unit of Infectious Diseases, Santa Maria Hospital, Perugia, Italy, ⁸Department Of Infectious Diseases, Pescara Hospital, Italy, ⁹Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy, ¹⁰Department of Infectious Diseases, L. Sacco Hospital, Milan, Italy, ¹¹Unit of Infectious Diseases, University of Sassari, Italy, ¹²Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy, ¹³Unit of Infectious Diseases, Busto Arsizio Hospital, Busto Arsizio, Italy
- OP 24 **AIDS presentation in the antiretroviral treatment era: characteristics and outcome**
G. Lapadula, S. Biraghi, A. Soria, A. Bandera, M. Rossi, A. Dolara, G. Migliorino, S. Foresti, L. Bisi, S. Costarelli, F. Sabbatini, N. Squillace, A. Muscatello, A. Cappelletti, L. Alagna, A. Gori
 Clinic of Infectious Diseases, AO San Gerardo di Monza, University of Milano-Bicocca, Italy
- OP 25 **Early treatment in HIV patients: a cost-utility analysis from the Italian perspective**
 A. Marcellusi^{1,2}, R. Viti¹, S. Russo¹, M. Andreoni³, A. Antinori⁴, **F.S. Mennini**^{1,5}
¹Economic Evaluation and HTA (CEIS-EEHTA) - IGF Department, Faculty of Economics, University of Rome "Tor Vergata", Italy, ²Department of Demography, University of Rome "La Sapienza", Italy, ³University of Rome "Tor Vergata", ⁴INMI "Lazzaro Spallanzani" IRCCS, Roma, ⁵Institute for Leadership and Management in Health - Kingston University London, London, UK
- OP 26 **Patients' needs: preliminary results of the OSR Counseling service**
 A. Bianchi², A. Poli¹, **A. Antonino**², G. Ardenghi², V. Meneghin², D. Zandonà¹, R. Rossi², M. Drusiani², N. Gianotti¹, S. Bossolasco¹, V. Spagnuolo^{1,3}, S. Nozza¹, P. Cinque¹, G. Tambussi¹, M. Cernuschi^{1,2}, A. Lazzarin^{1,3}, A. Castagna¹
¹Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy, ²ASA Associazione Solidarietà AIDS Onlus, Milan, Italy, ³Università Vita-Salute San Raffaele, Milan, Italy



11:00 - 13:15

ORAL COMMUNICATIONS SOCIAL VULNERABILITY

CHAIRS: **S. D'Amato** (Roma), **D. Lorenzetti** (Roma)DISCUSSANTS: **A. Franco** (Siracusa), **B. Marchini** (Roma), **M. Stagnitta** (Firenze)

- 11:00 - 11:15 **Women, cultural diversity and HIV: the role of peer education** *Silvia Petretti, London UK*
- 11:15 - 11:30 **HIV treatment and care among Italian inmates** *Roberto Monarca, Viterbo
Mario Cascio, Palermo*
- 11:30 - 11:45 **Early access to new DAA drugs for HIV/HCV coinfected patients** *Massimo Cernuschi, Milano*
- 11:45 - 12:00 **The transgender person well-being: HIV/AIDS information and prevention** *Porpora Marcasciano, Bologna*
- 12:00 - 12:15 **Access issues to treatment in Greece** *Georgios Tsiakalakis, Athens GR*

OC 93 **The epidemiology of HIV, hepatitis B and C infections, Syphilis and tuberculosis in a major Italian correctional house: a one year Infectious Diseases screening experience****A. Foschi¹**, R. Ranieri¹, M. Casana¹, A. Radice¹, D. Pavani², V. Acquaviva², O. Turri³, R. Baccalini³, A. d'Arminio Monforte⁴¹Consulenti Infettivologi, Casa di Reclusione Milano, Opera, A.O. San Paolo, Milano, ²S.E.R.T., Casa di Reclusione Milano, Opera, A.O. San Paolo, Milano, ³Unità di Biologia Molecolare e Sierologia, A.O. San Paolo, Milano, ⁴Direttore U.O. Malattie Infettive, Cattedra Malattie Infettive, A.O. San Paolo, MilanoOC 94 **QuestionAids: HIV and Stigma in Italy - a survey on a sample of 11,588 participants****M.L. Cosmaro¹**, A. Cerioli¹, M. Oldrini¹, P. Perone¹, L. Pietrantonio², G. Prati², D. Scudiero¹, B. Zani²¹LILA Onlus, Lega Italiana per la Lotta contro l'AIDS, ²Dipartimento di Psicologia, Università di BolognaOC 95 **From the HIV Patient Journey to the determinants of social and health care HIV related costs: what's new?****E. Garagiola¹**, G. Rizzardini², S. Rusconi^{2,3}, M. Medaglia², M. Errico⁴, L. Ferrario¹, D. Croce^{1,5}, **E. Foglia¹**¹Centre for Research on Health Economics, Social and Health Care Management – Carlo Cattaneo – LIUC University, Castellanza, Italy, ²Luigi Sacco Hospital Authority, Milan, Italy, ³University of Milan, Italy, ⁴NPS Italia – Network Persone Sieropositive, ⁵School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaOC 96 **Students whose parents are not Italian are at greater risk of never having received information on the existence of HIV: the results of a study conducted in 5782 high school students in the metropolitan areas of Rome, Milan and Bologna****G. Del Bene¹**, R. Galipò², T. Ferrario¹, P. Ferri², E. Magistrelli³, M. Ghenzer², D. Bragadin³, L. Oreni¹, **M. Galli¹** for the ANLAIDS National Project for HIV/AIDS Prevention in Schools¹Anlaids Sezione Lombardia, ²Anlaids ONLUS Sezione Laziale, ³Anlaids Emilia-Romagna ONLUSOC 97 **It's safe to defer the CD4 cell count monitoring in stable patients on HAART with more than 350 or 500 CD4 lymphocyte/ l?****B.M. Celesia¹**, M. Gussio, R. Bruno, M. Maresca, G. Nunnari, S. Piacenti, S. Sofia, F. Palermo, B. Cacopardo

Unit of Infectious diseases, University of Catania, ARNAS Garibaldi Catania, Italy

OC 98 **Quality of life in patients living with HIV infection: lack of association with psychiatric disorders, neurocognitive impairment and viro-immunological factors****F. Iannuzzi¹**, M. Trunfio¹, L. Borghi², F. Bai¹, E. Merlini¹, T. Bini¹, A. d'Arminio Monforte¹, G. Marchetti¹¹Clinic of Infectious and Tropical Disease, Department of Health Sciences, University of Milan, San Paolo Hospital, Milan, Italy, ²Unit of Clinical Psychology, Department of Health Sciences, University of Milan, San Paolo Hospital, Milan, Italy

15:00 - 16:00

ORAL COMMUNICATIONS CLINICAL VIROLOGY

CHAIRS: **M. Arlotti** (Rimini), **G. Parruti** (Pescara)DISCUSSANT: **C. Balotta** (Milano)

- OC 99 **AVIRALIA Awards: Study of archived HIV-1 resistance mutations in pluri-experienced HIV-1-infected patients treated with a salvage regimen: 4-years follow-up**
L. Mazzuti¹, F. Falasca¹, N. Alvaro¹, A. Fantauzzi², E. Cella³, I. Mezzaroma¹, D. Di Carlo¹, P. Maida¹, G. Antonelli¹, O. Turriziani¹
¹Department of Molecular Medicine, ²Department of Clinical Medicine, Sapienza University of Rome, Italy, ³Department of Infectious Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Rome, Italy
- OC 100 **The RT polymorphism A98S increases the response to TDF+FTC containing HAART both in vivo and in vitro**
C. Alteri¹, M. Surdo¹, F. Di Santo¹, V.C. Di Maio¹, G. Costa², L. Parrotta², C. Gori³, I. Romeo², C. Pinnetti³, N. Orchi³, A. Latini⁴, A. Bertoli⁵, E. Girardi³, S. Alcaro², M. Giuliani⁴, M. Andreoni^{1,5}, A. Antinori³, A. d'Arminio Monforte⁶, A. Artese², F. Ceccherini-Silberstein¹, C.F. Perno⁵, V. Svicher¹
¹University of Rome "Tor Vergata", ²University "Magna Graecia" of Catanzaro, Germaneto (CZ), Italy, ³INMI "L. Spallanzani", Rome, Italy, ⁴San Gallicano Hospital, Rome, Italy, ⁵University Hospital of Rome "Tor Vergata", Rome, Italy, ⁶University of Milan, Italy
- OC 101 **Prevalence of resistance mutations to Integrase Inhibitors in INI-naïve and INI-experienced HIV-1 infected patients in a large Italian cohort**
B. Rossetti^{1,2}, A. Vergori¹, C. Bianco^{1,2}, L. Monno³, G. Punzi⁴, V. Borghi⁵, M. Pecorari⁶, D. Francisci⁷, L.I. Bellazzi⁸, S. Paolucci⁹, B. Bruzzone¹⁰, L. Toscano¹¹, F. Saladini¹², M. Zazzi¹², A. De Luca¹ for the ARCA Collaborative Group
¹University Infectious Diseases Clinic, Azienda Ospedaliera Universitaria Senese, Siena, ²Clinic of Infectious Diseases, Catholic University of Sacred Heart, Roma, ³Infectious Diseases Clinic, Bari University Hospital, Bari, ⁴Unit of Microbiology and Virology, Bari University Hospital, Bari, ⁵Infectious Diseases Clinic, Modena University Hospital, Modena, ⁶Unit of Microbiology and Virology, Modena University Hospital, Modena, ⁷Infectious Diseases Clinic, Perugia University Hospital, Perugia, ⁸Infectious Diseases Clinic, S. Matteo Hospital, Pavia ⁹Laboratory of Virology, S. Matteo Hospital, Pavia, ¹⁰Hygiene Unit, IRCCS AOU San Martino-IST, Genova, ¹¹Infectious Diseases and Hepatology Clinic, Azienda Ospedaliera Universitaria Senese, Siena, ¹²Department of Medical Biotechnologies, University of Siena, Siena
- OC 102 **How Genotypic Resistance Test in PBMC (Proviral DNA) May Help to Identify Hidden Resistance in patients with Low Level or Undetectable HIVRNA?**
M. Zaccarelli¹, M.M. Santoro², D. Armenia², C. Gori¹, F. Forbici¹, A. Giannetti¹, M. Andreoni³, C. Mastroianni⁴, C. Mussini⁵, C.F. Perno^{1,2}, A. Antinori¹
¹National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy, ²University of Rome Tor Vergata, Rome, Italy, ³University Hospital Tor Vergata, Rome, Italy, ⁴La Sapienza University, Polo Pontino, Latina, Italy, ⁵Modena University Hospital, Modena, Italy
- OC 103 **HIV-DNA levels in patients on suppressive HAART is affected by LTR genetic variability**
C. Alteri¹, S. Barbaliscia¹, R. Scutari¹, A. Bertoli¹, M. Pollicita¹, M. Montano¹, G. Maffongelli², M. Andreoni^{1,2}, C.F. Perno^{1,2}, V. Svicher¹
¹University of Rome "Tor Vergata", ²University Hospital of Rome "Tor Vergata", Rome, Italy



POSTER



IMPORTANTI OBIETTIVI TERAPEUTICI.



FARMACI INNOVATIVI.



CURE MIGLIORI.

Combattiamo patologie gravi.

In Gilead applichiamo il meglio della scienza biofarmaceutica per creare medicinali innovativi che portino nuove speranze nella lotta contro l'HIV/AIDS, patologie del fegato e gravi patologie cardiovascolari e respiratorie.

Superando gli attuali standard terapeutici.

Stiamo sviluppando nuovi farmaci di maggiore efficacia, migliore profilo di resistenza, migliore indice di sicurezza e con schemi di dosaggio più semplici. Grazie ad ogni progresso nelle terapie, cerchiamo di migliorare significativamente la cura del paziente e la vita umana.



GILEAD

Advancing Therapeutics.
Improving Lives.

ANTIRETROVIRAL THERAPY STUDIES

- P 1 **Darunavir/ritonavir-based dual and mono therapy in a cohort of treatment experienced HIV-positive patients: a multicenter study**
 V. di Biase¹, F. Barchiesi², B. Canovari³, M. Tavio⁴, R. Del Gobbo⁴, A. Costantini⁵, C.V. Martinelli⁶, C. Pallotto¹, F. Baldelli¹, D. Francisci¹
¹Clinica delle Malattie Infettive, Università degli Studi di Perugia, Perugia, Italia, ²Istituto Malattie Infettive e Medicina Pubblica, Università Politecnica delle Marche, Ancona, Italia ³Malattie Infettive, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Presidio Ospedaliero San Salvatore, Pesaro, Italia, ⁴Clinica delle Malattie Infettive, Azienda Ospedaliero-universitaria Ospedali Riuniti, Ancona, Italia, ⁵Immunologia Clinica, Azienda Ospedaliero-universitaria Ospedali Riuniti, Ancona, Italia, ⁶Clinica delle Malattie Infettive, Università di Firenze, Firenze Italia
- P 2 **Pill refill to estimate level of adherence in a cohort of HIV-positive patients in cART**
 C. Burla¹, L. Consalvi¹, S. Lo Caputo², F. Vichi², L. Rabatti¹, A. Poggi², B. Del Pin², A. Degli Esposti², F. Mazzotta²
¹Pharmacy Unit S.M. Annunziata Hospital, ²Infectious Disease Unit S. M Annunziata Hospital Florence
- P 3 **Simplification strategies in virologically suppressed patients: comparison between switching to co-formulated Rilpivirine/Emtricitabine/Tenofovir (EPA) vs boosted-PI (PI/r) plus lamivudine (3TC)**
 A. Mondì¹, R. Gagliardini¹, A. Borghetti¹, B. Milanini¹, I. Fanti¹, A. D'Avino¹, G. Baldin¹, S. Lamonica¹, F. Pallavicini¹, N. Ciccarelli¹, R. Cauda¹, A. De Luca², S. Di Giambenedetto¹, M. Fabbiani¹
¹Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, ²UOC University Infectious Disease, Azienda Ospedaliera Universitaria Senese, Siena
- P 4 **The switch to generic antiretroviral drugs: safety, efficacy and patients' feeling**
 D. Segala¹, G. Fabbri¹, M. Barotto², C. Palladino², S. Bianchi², L. Sighinolfi¹
¹Infectious Diseases Unit and ²Pharmacy Unit, Azienda Ospedaliero Universitaria, Ferrara
- P 5 **Virological Responses by Gender in an Italian Observational Study in Darunavir-naïve Patients**
 A. Antinori¹, T. Bini², E. Colella³, P. Meraviglia⁴, C. Mussini⁵, G. Sterrantino⁶, G. Airoidi⁷, D. Mancusi⁸, R. Termini⁸
¹Clinical Department, National Institute for Infectious Diseases "L. Spallanzani," Roma, Italy, ²Department of Medicine, Surgery and Dentistry - University of Milan, Clinic of Infectious Diseases, "San Paolo" Hospital, Milan, Italy, ³Infectious Diseases Unit, DIBIC Luigi Sacco, Milan, Italy, ⁴Department of Infectious Disease, "L.Sacco" University Hospital, Milan, Italy, ⁵Institute of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy, ⁶Division of Infectious Diseases, "Careggi" Hospital, Florence, Italy, ⁷Studio Associato Airoidi, Cicogna, Ghirri - Milan, Italy, ⁸Janssen Italy, Medical Affairs, Cologno Monzese - Milan, Italy
- P 6 **Evaluation of Cell Toxicity and Matrix Metalloproteinase-9 Inhibition by combination of Antiretroviral Drugs in Cultured Primary Astrocytes. Implication for the treatment of neuroAIDS**
 I. Pati¹, T. Latronico¹, A. Fasano¹, R. Ciavarella¹, M. Lichtner³, F. Mengoni², V. Vullo², C.M. Mastroianni³, G.M. Liuzzi¹
¹Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, Bari, ²Sapienza University, Rome, ³Sapienza University Polo Pontino, Latina Italy
- P 7 **UGT1A1 and PPARA as genetic predictors of liver abnormalities in HIV infected patients on atazanavir treatment**
 F.S. Falvella¹, E. Clementi¹, E. Ricci², S. Cheli¹, C. Resnati², C. Gervasoni², M. Galli², A. Riva²
¹Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences L. Sacco, "Luigi Sacco" University Hospital, Università di Milano, Milan, Italy, ²Infectious Diseases Unit, Department of Biomedical and Clinical Sciences L. Sacco, "Luigi Sacco" University Hospital, Università di Milano, Milan, Italy
- P 8 **Switching to stribild in HIV positive virologically suppressed patients: a real life scenario**
 C. Abeli, M. Farinazzo, R. Visonà, B. Menzaghi, T. Quirino
 Infectious Diseases Department Busto Arsizio Hospital
- P 9 **Maraviroc plus Protease Inhibitor as a Switching Regimen in Clinical Practice**
 M. Menozzi¹, F. Maggiolo², S. Rusconi³, S. Nozza⁴, S. Bonora⁵, A. Saracino⁶, G. D'Etto⁷, V. Svicher⁸, S. Martini⁹, A. Di Biagio¹⁰, C. Mussini¹
¹Infectious Disease - AOU Policlinico di Modena, ²Infectious Disease Azienda Ospedaliera Papa Giovanni XXIII, ³Infectious Disease - Dipartimento di Scienze Biomediche e Cliniche "Luigi Sacco" - University of Milan, ⁴Infectious Disease - San Raffaele Hospital - Milan, ⁵Infectious Disease, University of Turin, ⁶Infectious Disease - University of Foggia, ⁷Infectious Disease, University of Rome La Sapienza, ⁸Infectious Disease - University of Rome Tor Vergata, ⁹Infectious Diseases Division, Second University of Naples, ¹⁰Infectious Disease Clinic - IRCCS Azienda Ospedaliera Universitaria San Martino - IST di Genova
- P 10 **Backbone switch to abacavir/lamivudine fixed-dose combination: implications for antiretroviral therapy optimization**
 A. Fantauzzi¹, M. Floridia², F. Falasca³, O. Turriziani³, V. Vullo⁴, I. Mezzaroma¹
¹Department of Clinical Medicine, Sapienza, University of Rome, Rome, Italy, ²Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità (ISS), Rome, Italy, ³Department of Molecular Medicine, Sapienza, University of Rome, Rome, Italy, ⁴Department of Public Health and Infectious Diseases, Sapienza, University of Rome, Rome, Italy

- P 11 Switching from Non-Nucleoside Reverse-Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI)-based regimens to a rilpivirine/emtricitabine/tenofovir disoproxil fumarate-based Single-Tablet Regimen is effective, safe and saves costs**
G. Sterrantino¹, M. Masini², R. Banfi³, S. di Matteo⁴, A. Bartoloni^{2,5}
¹Azienda Ospedaliera-Universitaria Careggi, Clinic for Infectious and Tropical Diseases, Florence, Italy, ²Florence University, Department of Clinical and Experimental Medicine, Florence, Italy, ³Azienda Ospedaliera-Universitaria Careggi, Pharmacy, Florence, Italy, ⁴Studio Analysis Economic Evaluation, Milan, Italy, ⁵Florence University, Clinic for Infectious and Tropical Diseases, Florence, Italy
- P 12 Simplification of antiretroviral treatment: PI/Rt-based LDR regimens in routine clinical practice**
A. Mastroianni, E. Briganti, F. Allegrini, S. Di Cesare, C. Grosso, S. Brighi, C. Antonini, C. Cancellieri
Unità Operativa Malattie Infettive, P.O. "G.B. Morgagni – L.Pierantoni, Forlì & Unità Operativa Malattie Infettive, P.O. "M. Bufalini", Cesena, Azienda USL della Romagna
- P 13 Virological suppression, safety and tolerability of Eviplera switch in HIV positive patients**
P. Carboni, V. Barocci, G. Ruggieri, F. Vignale, C. Ucciferri, F. Ricci, K. Falasca, J. Vecchiet
Clinic of Infectious Diseases, G. d'Annunzio University of Chieti-Pescara
- P 14 Virologic and immunologic outcome in treatment-experienced HIV-1 infected patients receiving Raltegravir containing regimens**
LB A. Vergori¹, C. Bianco^{1,2}, S. Di Giambenedetto², P. Meraviglia³, D. Bartolozzi⁴, G. Filice⁵, L. Monno⁶, G. Penco⁷, V. Borghi⁸, P. Almi⁹, L. Butini¹⁰, P. Castelli¹¹, M. Zazzi¹², A. De Luca¹, B. Rossetti^{1,2} for the ARCA Collaborative Group
¹University Infectious Diseases Clinic, Azienda Ospedaliera Universitaria Senese, Siena, ²Clinic of Infectious Diseases, Catholic University of Sacred Heart, Roma, ³1st Division of Infectious Diseases, 'Luigi Sacco' Hospital, Milano, ⁴SOD Infectious Diseases, Azienda Ospedaliera Universitaria Careggi, Firenze, ⁵Department of Infectious Diseases, University of Pavia, IRCCS Policlinico San Matteo, Pavia, ⁶Infectious Diseases Clinic, Bari University Hospital, Bari, ⁷Unit of Infectious Diseases, Galliera Hospital, Genoa, ⁸Infectious Diseases Clinic, Modena University Hospital, Modena, ⁹Tropical and Infectious Diseases Unit, Massa Hospital, Massa, ¹⁰Clinical Immunology Unit, Ancona Hospital, Ancona, ¹¹Infectious Diseases Clinic, Macerata Hospital, Macerata, ¹²Department of Medical Biotechnologies, University of Siena, Siena
- P 15 Alternate-day TDF/FTC/EFZ single tablet regimen as maintenance therapy in virologically suppressed HIV individuals. The Day-On Day-Off (DODO) pilot study**
C. Tontini, A. Costantini, M. Cognigni, A. Marchionni, L. Marinangeli, M.C. Sielli, L. Butini
Servizio Regionale di Immunologia Clinica e Tipizzazione Tessutale, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona

PEDIATRICS, ADOLESCENTS, MATERNAL, FETAL

- P 16 Procreation medically assisted (PMA) for couples with HIV: five years activities at the Reggio Emilia hospital**
F. Prati¹, G. Zoboli¹, M.T. Villani², A.I. Falbo², I. Rondini³, B. Valli³, A. Nicoli³, G.B. La Sala², G. Magnani¹
¹Infectious Diseases, A.O. Arcispedale S.Maria Nuova, IRCCS, Reggio Emilia, ²Department of Obstetrics, Gynecology and Pediatrics, A.O. Arcispedale S. Maria Nuova, IRCCS, Reggio Emilia, ³P.M.A. Laboratory, Department of Obstetrics and Gynecology and Pediatrics, A.O. Arcispedale S. Maria Nuova, IRCCS, Reggio Emilia

AIDS AND NON-AIDS RELATED MALIGNANCIES

- P 17 Characteristics of AIDS and non-AIDS cancers in two North-East Italian Hospitals: a retrospective study**
L. Sasset¹, M. Franzetti², R. Scaggiante², F. Barbaro², A.M. Cattelan²
¹S.Maria della Misericordia Hospital, Azienda ULSS 18, Rovigo, ²General Hospital of Padova, Azienda Ospedaliera and University of Padova, Italy
- P 18 Evaluation of Toxicity in HIV-associated Lymphomas: a Matched Cohort Study**
A. Bandera¹, L. Verga², F. Farina², E. Pollastri¹, M. Rossi¹, P. Pioltelli², A. Gori¹
¹Clinic of Infectious Diseases, AO San Gerardo di Monza, University of Milano-Bicocca, Italy, ²Haematology Unit, AO San Gerardo di Monza, University of Milano-Bicocca, Italy

- P 19 Survival with AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort**
 P. Schommers¹, M. Hentrich², C. Hoffmann³, D. Gillor¹, A. Zoufaly⁴, B. Jensen⁵, J.R. Bogner⁶, J. Thoden⁷, J.C. Wasmuth⁸, T. Wolf⁹, M. Oette¹⁰, M. Muller¹¹, S. Esser¹², J.J. Vehreschild^{1,13}, C. Wyen¹, G. Fätkenheuer^{1,13}
¹First Department of Internal Medicine, University of Cologne, ²Department of Hematology, Oncology and Palliative Medicine, Harlaching Hospital, Munich, ³IPM Study Center, Hamburg and University of Schleswig Holstein, Campus Kiel, ⁴Department of Medicine I, University Medical Center Hamburg-Eppendorf, Hamburg, ⁵Department of Gastroenterology, Hepatology, and Infectiology, University of Dusseldorf, ⁶Department of Internal Medicine IV, University of Munich, ⁷Private Practice of Rheumatology and Infectious Diseases, Freiburg, ⁸Department of Internal Medicine I, University of Bonn, ⁹Department of Medicine III, University of Frankfurt, ¹⁰Department of General Medicine, Gastroenterology, and Infectious Diseases, Augustinerinnen Hospital, Cologne, ¹¹Department of Infectious Diseases, Vivantes Auguste-Viktoria-Hospital, Berlin, ¹²Department of Dermatology, University of Essen, ¹³German Centre for Infection Research (DZIF), Cologne, Germany
- P 20 Prognostic role and impact on survival of inflammatory prognostic scores in HIV infected subjects after diagnosis of hepatocellular carcinoma: a population-based study**
 S. Amadasi¹, A. Ferraresi¹, E. Raffetti², E. Quiros-Roldan¹, F. Donato², F. Castelli¹
¹University Division of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy, ²Unit of Hygiene, Epidemiology and Public Health, University of Brescia, Brescia, Italy
- P 21 A very rare presentation of Kaposi's Sarcoma leading to HIV diagnosis**
 O. Tambaro, G. Palmiero, A.E. Maraolo, M. Cotugno, F. Borrelli, G. Bonadies
 Department of Clinical Medicine, Unity of Viral Diseases Including AIDS Day Hospital, University of Naples
- P 22 Prevalence of anal HPV infection in a cohort of HIV+ MSM patients**
 E. Magistrelli¹, L. Calza¹, V. Colangeli¹, R. Manfredi¹, S. Venturoli², M.L. Prosperi³, P. Viale¹
¹Department of Medical and Surgical Sciences, Infectious Diseases Unit, S. Orsola-Malpighi Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy, ²Unit of Microbiology, Department of Diagnostic Medicine and Prevention, S. Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy, ³"F. Addarii" Institute of Oncology and Transplantation Pathology, S.Orsola-Malpighi Hospital, Bologna University, Bologna, Italy

COMPLICATION OF HIV INFECTION AND ANTIRETROVIRAL THERAPY

- P 23 Initiating Protease Inhibitor-only therapy is associated with increased subcutaneous adipose tissue PPARG expression, reduced mitochondrial stress together with altered expression of insulin signalling genes**
 R.T. Maughan¹, E.R. Feeney¹, E. Cape², J. Capeau², P. Domingo³, F. Villarroya⁴, J.M.A. Lange^{5,6,†}, P. Phanuphak^{6,7}, D.A. Cooper⁸, P. Reiss^{5,6}, P.W.G. Mallon¹
¹HIV Molecular Research Group, School of Medicine and Medical Science, University College Dublin, Ireland, ²University Paris 6, INSERM UMR5 938, Paris, France, ³Hospital de la Santa Creu/Sant Pau, Barcelona, Spain, ⁴Universitat de Barcelona, Barcelona, Spain, ⁵Academic Medical Center, Department of Global Health and Division of Infectious Diseases, Amsterdam, Netherlands, ⁶The HIV-Netherlands Australia Thailand Research Collaboration (HIV-NAT) - Thai Red Cross Aids Research Center (TRCARC), Bangkok, Thailand, ⁷Chulalongkorn University, Bangkok, Thailand, ⁸Kirby Institute, University of New South Wales, Sydney, Australia, [†]Deceased July 17th 2014
- P 24 Substitution of nevirapine or raltegravir for protease inhibitor versus rosuvastatin treatment for the management of dyslipidemia in HIV-infected patients on stable antiretroviral therapy (NEVRAST study)**
 L. Calza¹, E. Magistrelli¹, V. Colangeli¹, R. Manfredi¹, I. Bon², M.C. Re², P. Viale¹
¹Infectious Diseases Unit and ²Microbiology Unit, S.Orsola-Malpighi Hospital, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna
- P 25 PROJECT STOP Smoking in HIV patients, STOPS HIV. Preliminary results**
 G.V. De Socio¹, M. Dell'Omo², E. Schiaroli¹, V. Di Biase¹, A. Patacca¹, C. Sfara¹, L. Malincarne¹, C. Pallotto¹, D. Francisci¹, G. Muzi², F. Baldelli¹
¹Clinica delle Malattie infettive, ²Centro anti fumo di Medicina del Lavoro. Azienda Ospedaliero-Universitaria di Perugia
- P 26 Validation of a risk score for CKD in HIV-infected patients in an Italian cohort**
 M. Menozzi¹, A. Malagoli¹, S. Zona¹, A. Santoro¹, C. Stentarelli¹, F. Carli¹, R. Pulizzi², C. Mussini¹, R. Scherzer³, G. Guaraldi¹
¹Infectious Disease Clinic - AOU Policlinico di Modena, ²Nephrology Division - AOU Policlinico di Modena, ³Department of Medicine, University of California, San Francisco
- P 27 Impact of first line therapy on cardiovascular risk in a real-life clinical setting**
 S. Ferrara¹, A. Tartaglia², S. Sica¹, B. Grisorio¹
¹SSD Malattie Infettive Emergenti, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Foggia, ²ASL Foggia

- P 28 **Tenofovir disoproxil fumarate long term exposure in HIV infected kidney transplant recipients**
P.A. Grossi, S.D. Garavaglia, M.L. Balsamo, D. Dalla Gasperina
Infectious Diseases Section Department of Surgical and Morphological Sciences, University of Insubria - Ospedale di Circolo e Fondazione Macchi, Varese
- P 29 **Atherosclerosis, vascular events and dementia risk in HIV-infected patients. Preliminary data from the Italian multicentre cohort of the Cardiovascular and late-life dementia risk in HIV (CARDH) Study**
F. Vadini¹, E. Mazzotta¹, F. Sozio¹, M. Tontodonati¹, G. Madeddu², T. Ursini¹, E. Polilli³, B.M. Celesia⁴, G.V. De Socio⁵, P. Maggi⁶, G. Calella¹, G. Parruti¹, for CISA Study Group
¹Infectious Diseases Unit, Pescara General Hospital, Italy, ²Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy, ³Microbiology and Virology Unit, Pescara General Hospital, Italy, ⁴Department of Clinical and Molecular Biomedicine, Division of Infectious Diseases, University of Catania, Catania, Italy, ⁵Unit of Infectious Diseases, Santa Maria Hospital, Perugia, Italy, ⁶Infectious Diseases Clinic, University Hospital Policlinico, Bari, Italy
- P 30 **Endocrinological aspects of hypophosphatemia in HIV infection. Pilot study on Vitamin D supplementation: an observational study**
V. Guardigni¹, M. Celico², D. Segala¹, M.R. Ambrosio², L. Sighinolfi¹
¹Department of Infectious Diseases, S. Anna Hospital, Ferrara, Italy, ²Department of Endocrinology, University of Ferrara, Ferrara, Italy
- P 31 **Enthesal involvement in asymptomatic HIV patients: an ultrasonographic study**
L. Sighinolfi¹, G. Ciancio², F. Furini², D. Segala¹, V. Bagnari², I. Farina², E. Galuppi², M. Libanore¹, M. Govoni²
¹Infectious diseases Unit, ²Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda ospedaliero-Universitaria Sant'Anna - Ferrara, Italy
- P 32 **Determinants of bone diseases in tenofovir-treated HIV patients**
C. Gervasoni¹, P. Meraviglia¹, C. Resnati¹, D. Minisci¹, S. Baldelli², M.D. Pezzani¹, M. Galli¹, E. Clementi², G. Rizzardini¹, D. Cattaneo²
¹Department of Infectious Diseases, Luigi Sacco University Hospital, Milano, Italy, ²Unit of Clinical Pharmacology, Luigi Sacco University Hospital, Milan, Italy
- P 33 **Neurocognitive performance and cardiovascular risk in a cohort of HIV-infected patients**
C. Budroni¹, V. Lai¹, B. Zizi¹, F. Vadini², G.M. Calia¹, C. Lovigu¹, I. Maida¹, M. Mannazzu¹, V. Fiore¹, F. Peruzzu¹, G. Madeddu¹, M.S. Mura¹
¹Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy, ²Unit of Infectious Diseases, Pescara Hospital, Pescara, Italy
- P 34 **In vivo effect on platelet oxidative stress after 6 months of backbone switching to an antiretroviral regimen containing abacavir in HIV-1 patients**
D. Pastori¹, R. Carnevale^{1,2}, A. Esposito³, S. Bartimoccia¹, C. Nocella¹, A. Fantauzzi³, P. Pignatelli¹, V. Vullo⁴, F. Violi¹, I. Mezzaroma³
¹Department of Internal Medicine and Medical Specialties, "Sapienza" University of Rome, Rome, Italy, ²Department of Medical-Surgical Sciences and Biotechnologies, "Sapienza" University of Rome, Latina, Italy, ³Department of Clinical Medicine, "Sapienza" University of Rome, Rome, Italy, ⁴Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Rome, Italy
- P 35 **COPD risk in relation to smoking and social factors among people living with HIV**
A. Santoro¹, A. Gomes¹, T.D. Brothers², G. Besutti³, R. Scaglioni³, G. Ligabue³, B. Beghè⁴, P. Man⁶, D. Sin⁶, C. Mussini¹, G. Guaraldi¹
¹Department of Medical and Surgical Sciences for Children & Adults (Infectious Disease Clinic) University of Modena and Reggio Emilia, ²Faculty of Medicine, Dalhousie University, Halifax, Canada, ³Department of Radiology University of Modena and Reggio Emilia Modena, Italy, ⁴Department of Medical and Surgical Sciences for Children & Adults (Respiratory Disease Clinic) University of Modena and Reggio Emilia, ⁵Department of Medicine (Geriatric Medicine & Neurology), Dalhousie University, Halifax, Canada, ⁶Department of Medicine (respiratory division and), UBC James Hogg Research Centre, St. Paul's Hospital, Vancouver, British Columbia, Canada
- P 36 **Cardiovascular Risk in Advanced Naïve HIV-Infected Patients Starting Antiretroviral Therapy: Comparison of Three Different Regimens Based on ATV, DRV or EFV - PREVALEAT II (PREmature VAScular LESions and Antiretroviral Therapy II) Cohort**
C. Bellacosa¹, P. Maggi¹, A. Volpe¹, S. Altizio¹, A. Leone¹, N. Ladisa¹, S. Cicalini², E. Grilli², R. Viglietti³, A. Chirianni³, L.I. Bellazzi⁴, R. Maserati⁴, C. Martinelli⁵, P. Corsi⁵, B.M. Celesia⁶, F. Sozio⁷, G. Angarano¹
¹Clinical Infectious Diseases University of Bari, Policlinico Consorziale, Bari, Italy, ²INMI L. Spallanzani, IRCCS Roma2, Roma, Italy, ³Clinical Infectious Diseases, Ospedale Cotugno Napoli3, Napoli, Italy, ⁴Clinical Infectious Diseases, Policlinico San Matteo, Pavia, Italy, ⁵Clinical Infectious Diseases, Ospedale Careggi, Firenze, Italy, ⁶Clinical Infectious Diseases, Ospedale Garibaldi-Nesima, Catania, Italy, ⁷Clinical Infectious Diseases, Ospedale Civile Spirito Santo, Pescara, Italy



- P 37 **Assessment and management of BMD disorders among HIV infected patients in follow-up at Pescara General Hospital: preliminary results of a longitudinal evaluation**
E. Mazzotta¹, T. Ursini¹, A. Agostinone¹, F. Di Masi¹, M. Tontodonati¹, A. Pieri¹, A.D. Di Nicola², F. Sozio¹, E. Polilli³, A. Consorte¹, F. Vadini¹, V. De Francesco², L. Manzoli⁴, G. Parruti¹
¹Infectious Diseases Unit, Pescara General Hospital, Italy, ²Nuclear Medicine Unit, Pescara General Hospital, Italy, ³Microbiology and Virology Unit, Pescara General Hospital, Italy, ⁴Department of Medicine and Aging Sciences, University 'G. D'Annunzio' of Chieti, Italy
- P 38 **Calcaneal quantitative ultrasonography (QUS) as useful predictive tool of bone damage in a cohort of HIV-1 infected patients receiving effective cART**
A. Fantauzzi¹, F. Cacciatore², R. Pascone³, V. Vullo⁴, I. Mezzaroma¹
¹Department of Clinical Medicine, Sapienza University of Rome, Italy, ²Fondazione Salvatore Maugeri, IRCCS, Istituto di Telesse Terme, Benevento, Italy, ³Department of Experimental Medicine, Sapienza University of Rome, Italy, ⁴Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy
- P 39 **Cardiovascular risk factors in a cohort of HIV-infected children and young adults**
G. Gustinetti¹, L. Taramasso¹, B. Giannini², M. Giacomini², C. Viscoli¹, A. Di Biagio¹
¹IRCCS AOU San Martino-IST, Infectious Diseases Unit, University of Genoa, Genoa, Italy, ²Department of Informatics, Bioengineering, Robotics and System Engineering, Center of Excellence for Biomedical Research, University of Genoa, Genoa, Italy
- P 40 **Subclinical carotid atherosclerosis in HIV-infected patients treated with raltegravir or ritonavir-boosted protease inhibitors**
L. Calza, E. Magistrelli, V. Colangeli, R. Manfredi, A. Cascavilla, P. Viale
Infectious Diseases Unit, S.Orsola-Malpighi Hospital, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna
- P 41 **Use of hand-grip strength test and heel ultrasound mineralometry to estimate risk of fractures in HIV mono-infected patients and in patients coinfecting with hepatitis viruses**
C. Torti¹, M.C. Postorino¹, I. Carè², A. Strazzulla¹, V. Pisani¹, V. Vaccaro¹, C. Costa¹, F. Provenzano², A. Pujja², T. Montalcini²
¹Infectious Diseases Unit, "Magna Graecia" University, Catanzaro, ²Clinical Nutrition Unit, "Magna Graecia" University, Catanzaro
- P 42 **Ischemic heart disease in HIV+ patients. Descriptive analysis in a large regional cohort**
G. Vandi¹ and N. Girometti¹, L. Calza¹, C. Mussini², M. Arlotti³, A. Degli Antoni⁴, P. Bassi⁵, C. Cancellieri⁶, P. Viale¹
¹UO Malattie Infettive, Policlinico S.Orsola-Malpighi, Bologna, ²UO Malattie Infettive, Azienda ospedaliera e Universitaria di Modena, ³UO Malattie Infettive, Ospedale Infermi di Rimini, ⁴UO Malattie Infettive, Azienda Ospedaliero-Universitaria di Parma, ⁵UO Malattie Infettive, Ospedale di Ravenna, ⁶UO Malattie Infettive Ospedale G.B.Morgagni-L.Pierantoni, Forlì
- P 43 **Long-term efficacy and safety of unboosted atazanavir in combination with co-formulated abacavir/lamivudine: 5 year follow-up**
A. Tartaglia¹, S. Ferrara², S. Sica², B. Grisorio²
¹ASL Foggia, ²SSD Malattie Infettive Emergenti, Azienda Ospedaliero-Universitaria Ospedali Riuniti Foggia
- P 44 **Interference of 25 OH Vitamin D levels on neurocognitive disorders in young HIV patients**
E. Guerra¹, V. Penta¹, M. Onofrio¹, M. A. Carleo¹, F. Di Martino¹, R. Viglietti¹, A. Marocco¹, A. Colao², A. Chirianni¹
¹AORN Azienda dei Colli Monaldi-Cotugno-CTO, Ospedale D. Cotugno, Dipartimento per la cura dell'AIDS e malattie oncologiche, ²AOU Federico II di Napoli- Dipartimento di Medicina clinica e chirurgia
- P 45 **Common and uncommon skin manifestations of the immune reconstitution inflammatory syndrome (IRIS)**
A. Latini¹, C. Cota², M. Colafigli¹, M.G. Donà¹, M. Giuliani¹, A. Cristaudo¹
¹STI/HIV Unit, San Gallicano Dermatologic Institute (IFO-IRCCS), Rome, Italy, ²Pathology Department, San Gallicano Dermatologic Institute (IFO-IRCCS), Rome, Italy

HIV AND STI

- P 46 **Association between HPV infection and related disease with other sexually transmitted infections (STIs) in a cohort of Italian male and female HIVpositive patients**
A. Barco¹, A. Pandolfo¹, F. Bai¹, E. Suardi¹, M. Rovati², G. Marchetti¹, T. Bini¹, A. d'Arminio Monforte¹
¹Department of Health Sciences, University of Milan, Clinic of Infectious Diseases, S. Paolo Hospital, Milan, ²Department of Health Sciences University of Milan, General Surgery, S. Paolo Hospital, Milan
- P 47 **Association of syphilis with HIV infection in a cohort of newly HIV infected individuals**
R. Scaggiante¹, L. Sasse², A. Sattin¹, M.G. Cecchetto², A. Ferrari¹, A.M. Cattelan¹
¹General Hospital of Padova, Azienda Ospedaliera and University of Padova, Italy, ²S. Maria della Misericordia Hospital, Azienda ULSS 18, Rovigo

- P 48 **HPV 58: an emerging oncogenic HPV type in MSM HIV positive subjects**
M. Tamburro¹, C. Ucciferri¹, F. Vignale², K. Falasca², I. Fanelli¹, A. Prozzo³, P. Sabatini³, Z. Di Rosa¹, M. Sammarco¹, G. Ripabelli¹, J. Vecchiet²
¹Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy, ²Clinic of Infectious Diseases G d'Annunzio University, Chieti, Italy, ³Infectious Diseases Unit, A. Cardarelli Hospital, Campobasso, Italy
- P 49 **Detection of Alpha, Beta and Gamma Human Papillomaviruses in the anal canal of HIV-infected men who have sex with men**
M.G. Donà¹, T. Gheit², A. Latini¹, M. Benevolo³, M. Torres¹, V. Smelov², S. McKAy-Chopin², A. Giglio⁴, M. Colafigli¹, M. Zaccarelli⁵, A. Cristaudo¹, M. Tommasino², M. Giuliani¹
¹STI/HIV Unit, San Gallicano Dermatologic Institute (IFO-IRCCS), Rome, Italy, ²Infections and Cancer Biology Group, International Agency for Research on Cancer, Lyon, France, ³Pathology Department, Regina Elena National Cancer Institute (IFO-IRCCS), Rome, Italy, ⁴Clinical Pathology and Microbiology Department, San Gallicano Dermatologic Institute (IFO-IRCCS), Rome, Italy, ⁵National Institute for Infectious Diseases, Lazzaro Spallanzani, (IRCCS), Rome, Italy
- P 50 **Sexually Transmitted Infections trends among HIV positive patients in Novara**
M. Cantone¹, P. Farinelli¹, O. Bargiacchi², R. Brondolo², A. Rossati², P.L. Garavelli², E. Colombo¹
¹Dermatology Clinic, Department of Clinical and Experimental Medicine, University of Piemonte Orientale, Amedeo Avogadro, Novara, Italy, ²Infectious Diseases Unit, "Maggiore della Carità" Hospital, Novara, Italy
- P 51 **An unusual case of primary syphilis**
F. Vignale, Z. De Rosa, G. Ruggieri, K. Falasca, C. Ucciferri, J. Vecchiet
Clinic of Infectious Diseases "G. D'Annunzio" University, Chieti
- P 52 **HPV infection and disease in immunosuppressed males: prevalence and viro-immunological determinants of organ damage**
F. Bozzano^{1,2}, F. Marras³, A. d'Arminio Monforte⁵, G. Marchetti⁵, L. Comi⁵, D. Bedognetti⁶, L. Moretta³, A. De Maria^{2,4}
¹Department of Experimental Medicine, University of Genoa, Italy, ²Center of Excellence for Biomedical Research, University of Genoa, Italy, ³G Gaslini Institute, Genoa, Italy, ⁴IRCCS AOU San Martino-IST Genova, Italy, ⁵University of Milan, Ospedale San Paolo, ⁶SIDRA Medical & Research Center, Doha, Qatar
- P 53 **Prevalence of syphilis in HIV infected patients**
S. Staffolani, P. Castelli, L. Brescini, E. Marchionni, E. Orsetti, C. Valeriani, S. Castelletti, G. De Iaco, O. Cirioni, F. Barchiesi
Clinica Malattie Infettive - Università Politecnica delle Marche, Ancona
- P 54 **Neurosyphilis in HIV-infected patients**
S. Giuliano, S. Savinelli, G. Ceccarelli, G. d'Ettore, V. Vullo
Department of Public Health and Infectious Diseases. University "Sapienza" of Rome

MORBIDITY/MORTALITY IN THE ERA OF cART

- P 55 **Cardiovascular Risk Scores and N-terminal pro-brain Natriuretic Peptide in HIV-positive Patients in Primary Prevention**
C. Montrucchio¹, A. Calcagno¹, M. Cannillo², A. Livelli³, D. Vai⁴, W. Grosso Marra², D. Penoncelli³, M.E. Scarvaglieri¹, T. Ruggiero⁵, G. Di Perri¹, S. Bonora¹
¹Unit of Infectious Diseases and ²Unit of Cardiology, Department of Medical Sciences, University of Torino, ³Unit of Infectious Diseases, "Divisione A", Ospedale Amedeo di Savoia and ⁴Unit of Neurology, Ospedale Maria Vittoria, ASLTO2, Torino, ⁵Laboratory of Microbiology and Molecular Biology, Ospedale Amedeo di Savoia, ASLTO2
- P 56 **Virological efficacy of first-line HAART in AIDS presenters**
M. D'Abbraccio, A. Maddaloni, A. Busto, M. De Marco, M. Figoni, R. Pennone, N. Abrescia
U.O.C. Malattie Infettive ad alta complessità Sezione Femminile, P.O. D. Cotugno, A.O.R.N. "Dei Colli", Napoli
- P 57 **HIV clinical indicator diseases prior to HIV diagnosis are correlated to clinical progression in Late Presenters**
V. Guardigni¹, M.L. Morieri², D. Segala¹, L. Sighinolfi¹
¹Department of Infectious Diseases, S. Anna Hospital, Ferrara, Italy, ²Department of Medical Sciences, Section of Internal Medicine, Gerontology and Clinical Nutrition, University of Ferrara, Italy
- P 58 **Mortality in AIDS presenters in the HAART era**
M. D'Abbraccio, A. Maddaloni, A. Busto, M. De Marco, M. Figoni, R. Pennone, N. Abrescia
U.O.C. Malattie Infettive ad alta complessità Sezione Femminile, P.O. D. Cotugno, A.O.R.N. "Dei Colli", Napoli
- P 59 **Long-term mortality from any cause in HIV-infected individuals according to statin use**
LB N. Galizzi^{1,2}, L. Galli¹, A. Poli², S. Salpietro¹, V. Spagnuolo¹, S. Nozza¹, N. Gianotti¹, A. Carbone^{1,2}, S. Bossolasco¹, P. Cinque¹, A. Lazzarin^{1,2}, A. Castagna²
¹Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy, ²Università Vita-Salute San Raffaele, Milan, Italy

NEUROPATHOGENESIS AND NEUROLOGIC COMPLICATIONS

- P 60 **Diagnosis of HIV associated Neurocognitive Disorders in Italian cohort: comparison of Clinical Rating and Deficit Score**
A. Livelli^{1,2,3}, D. Penoncelli¹, T. Marcotte⁵, A. Calcagno⁴, D. Vai⁴, S. Bonora⁴, L. Pia³, G. Orofino¹
¹Division A of Infectious Diseases, Amedeo of Savoia Hospital, Torino, Italy, ²Giovanni Gorla Foundation and CRT Foundation, Italy, ³SAMBA (SpAtial, Motor & Bodily Awareness) research group, Department of Psychology, University of Torino, Torino Italy, ⁴Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, ⁵HNRP, Department of Psychiatry, University of California San Diego, San Diego, CA
- P 61 **Efficacy of zidovudine (AZT) in HIV encephalitis despite presence of AZT-resistance**
F. Ferretti¹, M. Nebuloni², C. Oltolini¹, S. Racca³, E. Boeri³, A. Lazzarin¹, P. Cinque¹
¹Department of Infectious Diseases and ²Department of Medicine Laboratory, San Raffaele Scientific Institute, Milano, ³Department of Patology, University of Milano
- P 62 **Undetectable Cerebrospinal Fluid HIV RNA is Predicted by Plasma HIV RNA and is Associated with Low Neopterin**
I. Motta¹, A. Calcagno¹, M.G. Milia², A. Romito³, M. Ferrara¹, D. Imperiale⁴, A. Prochet⁵, V. Ghisetti², G. Perri¹, S. Bonora¹
¹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, ²Laboratory of Microbiology and Molecular Biology, Ospedale Amedeo di Savoia, ASLTO2, ³Laboratory of Immunology, Ospedale Maria Vittoria, ASLTO2, ⁴Unit of neurology, Ospedale Maria Vittoria, ASLTO2, ⁵Unit of Radiology, Ospedale San Giovanni Bosco, ASLTO2, Torino, Italy
- P 63 **Evaluation of CSF viral escape in HIV-infected patients with long-lasting virological suppression on treatment with unboosted atazanavir with lamivudine or emtricitabine**
A. Bigoloni¹, L. Galli¹, S. Bossolasco¹, S. Nozza¹, M. Maillard¹, E. Carini¹, S. Salpietro¹, V. Spagnuolo^{1,2}, N. Gianotti¹, P. Panzini¹, E. Locati¹, T. Annicchiaro¹, A. Galli¹, P. Cinque¹, A. Lazzarin^{1,2}, A. Castagna¹, A. Carbone^{1,2}
¹Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy, ²Università Vita-Salute San Raffaele, Milan, Italy
- P 64 **Neuroinflammation setting in a naïve HIV cohort: preliminary analysis**
E. Teti¹, A. Pennica², L. Gianserra², A. Bianchi¹, G. Maffongelli¹, S. Gini¹, C. Cerva¹, V. Malagnino¹, P. Sordillo¹, L. Dori¹, M. Viscione¹, M. Montano¹, M. Andreoni¹, L. Sarmati¹
¹Tor Vergata University, Clinical Infectious Diseases, Rome, Italy, ²Sapienza University of Rome, Sant'Andrea Hospital, Clinical Infectious Diseases, Rome, Italy
- P 65 **Screening of HIV associated Neurocognitive Disorders in Italian Cohort: Use of Superiority Index to Identify Effective Cognitive Screening Tools**
A. Livelli^{1,2,3}, D. Penoncelli¹, T. Marcotte⁵, A. Calcagno⁴, D. Vai⁴, S. Bonora⁴, L. Pia³, G. Orofino¹
¹Division A of Infectious Diseases, Amedeo of Savoia Hospital, Torino, Italy, ²Giovanni Gorla Foundation and CRT Foundation, Italy, ³SAMBA (SpAtial, Motor & Bodily Awareness) research group, Department of Psychology, University of Torino, Torino Italy, ⁴Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, ⁵HIV Neurobehavioral Research Programme, Department of Psychiatry, University of California San Diego
- P 66 **HIV-associated neurocognitive disorders (HAND): longitudinal evaluation of HIV infected patients before and after antiretroviral therapy**
D. Motta, S. Compostella, D. Mangioni, A. Leoni, M.C. Pezzoli, A. Ferraresi, N. Brianese, A. Bonito, E. Quiros Roldan, S. Casari, F. Castelli, E. Focà
University Department of Infectious and Tropical diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy
- P 67 **HIV-1 gp120 induces type-1 programmed cell death through ER-stress employing IRE-1 , JNK and AP-1 pathway**
A. Shah, A. Kumar
UMKC School of Pharmacy
- P 68 **Effectiveness of Lumbar Puncture Performed as Screening in Patients with HIV-Associated Dementia (HAD) Receiving Suppressive Antiretroviral Treatment**
D. Motta¹, A. Bonito¹, S. Casari¹, N. Brianese¹, I. El Hamad², M.A. Forleo¹, A. Ferraresi¹, A. Scalzini¹, M.C. Pezzoli¹, E. Quiros Roldan¹, C. Torti^{1,3}, F. Castelli¹, E. Focà¹
¹University Department of Infectious and Tropical diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy, ²Division of Infectious Diseases, Spedali Civili General Hospital, Brescia, Italy, ³Division of Infectious Diseases, University Magna Graecia, Catanzaro, Italy
- P 69 **Montreal Cognitive Assessment test in patients with HIV infection: is a good tool in evaluation of cognitive deficits?**
G. Sparapani, M.C. Pasetto, L. Matta, L. Chessa
Department of Medical Sciences "Mario Aresu", University of Cagliari, Italy
- P 70 **Antiretrovirals inhibit arginase in human microglia expressing Inos**
L. Lisi¹, E. Laudati¹, T.F. Miscioscia², C. Dello Russo¹, A. Topai², P. Navarra¹
¹Institute of Pharmacology, Catholic University Medical School, Rome, Italy, ²Colosseum Combinatorial Chemistry Centre for Technology, Rome, Italy

TUBERCULOSIS, OPPORTUNISTIC INFECTIONS AND OTHER INFECTIONS

- P 71 **Treating Cytomegalovirus in HIV-positive Naïve Patients with CMV Viremia is Associated with Better Survival**
P. Bigliano¹, A. Calcagno¹, G. Gregori², M.L. Stella¹, S. Audagnotto¹, F. Lipani¹, V. Ghisetti², G. Di Perri¹, S. Bonora¹
¹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, ²Laboratory of Microbiology and Molecular Biology, Ospedale Amedeo di Savoia, ASLTO2
- P 72 **Is it really necessary to perform QuantiFERON-TB test every year in patients with HIV-infection living in low risk countries?**
M. Cordioli, G. Granà, E. Lattuada, P. Del Bravo, E. Concia, M. Lanzafame
Unit of Infectious Diseases, Azienda Ospedaliera Universitaria Integrata di Verona
- P 73 **Burden of AIDS defining diseases hospitalization in the last decade: a single center study in Central Italy**
E. Marchionni, E. Orsetti, L. Brescini, S. Staffolani, P. Castelli, C. Valeriani, G. De Iaco, A. Giacometti, F. Barchiesi
Clinica di Malattie Infettive, Azienda Ospedaliero-Universitaria "Ospedali Riuniti" di Ancona
- P 74 **Toxoplasma Encephalitis in a HIV-positive Patient With CD4+ T Lymphocyte Count above 200/uL**
C. Costa, F. Lipani, A. Lucchini, P. Bigliano, C. Montrucchio, A. Calcagno, G. Di Perri, S. Bonora
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino
- P 75 **Loiasis and HIV: a case report**
R. Niccolò¹, S. Grignolo², F. Magnè², C. Saffioti², F. Dodi², A. Ferrazin², C. Viscoli²
¹Division of Infectious Disease, IRCCS AOUS San Martino-IST, Genoa, University of Milan, Italy, ²Division of Infectious Disease, IRCCS AOUS San Martino-IST, Genoa, University of Genoa, Italy
- P 76 **A rare case of successful Extracorporeal membrane oxygenation (ECMO) treatment in an HIV+ late presenter patients with ARDS complicating a Pneumocystis Jirovecii pneumonia**
B.M. Celesia¹, S. Borracino³, A. Arcadipane⁴, G. Pantò², M. Gussio¹, S. Coniglio³, A. Pennisi⁵, B. Cacopardo¹, G. Panarello⁴
¹Unit of Infectious diseases University of Catania ARNAS Garibaldi Catania, ²Unit of Infectious diseases Cannizzaro Hospital Catania, ³Unit of Intensive Care ARNAS Garibaldi Catania, ⁴Unit of Intensive Care ISMETT Palermo, ⁵Unit of neurologic and respiratory rehabilitation Casa di Cura Riabilitativa Calaciura, Biancavilla (CT)

COINFECTIONS WITH HEPATITIS VIRUSES (HBV/HCV) AND HEPATITIS: RATIO CD4/CD8

- P 77 **CD4 and CD4/CD8 ratio progression in HIV-HCV infected patients after achievement of SVR**
A. Saracino¹, G. Bruno¹, L. Scudeller², N. Ladisa¹, N. de Gennaro¹, M. Allegrini¹, L. Monno¹, G. Angarano¹
¹Clinic of Infectious Diseases, University of Bari, Italy, ²Scientific Direction, Clinical Epidemiology Unit, IRCCS San Matteo Foundation, Pavia, Italy
- P 78 **Impact of PEG-IFN on CD4/CD8 ratio in Patients with HIV/HCV Coinfection**
F. Serra, L. Badia, V. Guardigni, P. Viale, G. Verucchi
Infectious Diseases Unit, S.Orsola-Malpighi Hospital, University of Bologna

COINFECTIONS WITH HEPATITIS VIRUSES (HBV/HCV) AND HEPATITIS: PATHOGENESIS

- P 79 **IP-10 and sCD163 level in patients with HCV mono-infection, HIV/HCV coinfection and HIV infection**
T. Tieghi¹, C. Mascia², R. Marocco¹, F. Schiavone², S. Vita², P. Zuccalà², S. Savinelli², M. Lichtner², V. Vullo², C.M. Mastroianni¹
¹Sapienza University of Rome, Polo Pontino, Latina, ²Sapienza University of Rome
- P 80 **Are atypical monocytes the reservoir of HCV that lead the acceleration of fibrosis in HIV-HCV co-infected patients?**
F. Schiavone², M. Lichtner¹, C. Mascia², S. Savinelli², T. Tieghi¹, R. Marocco¹, S. Vita², P. Zuccalà², R. Rossi², F. Mengoni², C.M. Mastroianni¹, V. Vullo²
¹Infectious Diseases Unit, Sapienza University, Latina, Italy, ²Public Health and Infectious Diseases, Sapienza University, Rome, Italy
- P 81 **Impact of Maraviroc-based antiretroviral therapy on liver fibrosis and chronic inflammation in a small group of HIV-1/HCV coinfecting patients**
G. Bruno, A. Saracino, P. Maggi, A. Volpe, G. Punzi, A. Lagioia, T. Tancon, N. Ladisa, L. Monno, G. Angarano
Clinic of Infectious Diseases, University of Bari, Italy

- P 82 **Immune Response to Hepatitis A and B Vaccine in HIV-Infected Subjects**
A. Carbone^{1,2}, A. Poli¹, D. Zandonà¹, R. Melzi¹, S. Zanetti, M. Merli^{1,2}, M. Ripa^{1,2}, S. Chiappetta^{1,2}, N. Galizzi^{1,2}, E. Messina^{1,2}, C. Oltolin^{1,2}, L. Galli¹, S. Nozza¹, H. Hasson¹, N. Gianotti¹, A. Lazzarin^{1,2}, A. Castagna¹
¹Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy, ²Università Vita-Salute San Raffaele, Milan, Italy
- P 83 **Correlation between intrahepatic and plasmatic HCV RNA levels in liver transplanted patients**
F.P Antonucci¹, M. Surdo¹, M. Manuelli², I. Lenci³, D. Sforza², M.C. Sorbo¹, A. Abedrabbo³, R. Salpini¹, V. Cento¹, M. Milana³, T. Manzia², M. Angelico³, G. Tisone², C.F. Perno¹, F. Ceccherini-Silberstein¹
¹Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy, ²Hepatology Unit, Policlinico Tor Vergata, Tor Vergata University, Rome, Italy, ³Virology Unit, Policlinico Tor Vergata, Tor Vergata University, Rome, Italy
- P 84 **Predominance of Q80K NS3 polymorphism among resistance-associated amino acid variants in Hepatitis C Virus Direct-Antiviral-Agent naïve patients**
T. Ruggiero¹, M.G. Milia¹, T. Alice¹, E. Burdino¹, G. Gregori¹, A. Proietti¹, L. Boglione², C.S. Cardellino², G. Cariti², G. Di Perri², V. Ghisetti¹
¹Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, Turin, Italy, ²Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Turin, Italy
- P 85 **A hyper-glycosylation in the major hydrophilic region of HBsAg characterizes immunosuppression-driven HBV reactivation and affects HBsAg recognition in vitro**
L. Colagrossi¹, R. Salpini¹, M. Surdo¹, A. Battisti¹, M. Pollicita¹, F. Di Santo¹, C. Becker², C. Mastroianni³, M. Marignani⁴, S. Maylin⁵, C. Delaguerre⁵, F. Morisco⁶, N. Coppola⁷, A. Marrone⁸, L. Sarmati⁹, M. Andreoni⁹, M. Angelico¹⁰, J. Verhejen³, C.F. Perno¹, V. Svicher¹
¹Tor Vergata University, Department of Experimental Medicine and Surgery, Rome, Italy, ²Institute of Virology, University of Cologne, Germany, ³"Sapienza" University, Rome, Italy, ⁴S. Andrea Hospital, Department of Gastroenterology, Rome, Italy, ⁵AP-HP Hopital Saint-Louis, Laboratoire de Virologie, Paris, France, ⁶University of Naples Federico II, Section of Infectious Diseases, Department of Clinical Medicine and Surgery, Naples, Italy, ⁷Second University of Naples, Department of Mental Health and Public Medicine, Section of Infectious Diseases, Naples, Italy, ⁸Second University of Naples, Internal Medicine and Hepatology Unit, Naples, Italy, ⁹Tor Vergata University Hospital, Infectious Diseases Unit, Rome, Italy, ¹⁰Tor Vergata University Hospital, Hepatology Unit, Rome, Italy

COINFECTIONS WITH HEPATITIS VIRUSES (HBV/HCV) AND HEPATITIS: TREATMENT

- P 86 **Feasibility of Pegylated Interferon (PegIFN) based therapies in HIV/HCV co-infected individuals seen for care in Italy: an estimate using data from ICONA and HepalCONA cohorts**
M. Puoti¹, M. Shanyinde², A. Cozzi-Lepri², C. Pinnetti³, A. Di Biagio⁴, E. Nicastrì³, G. Viale⁵, A. De Bona⁶, S. Bonora⁷, F. Castelli⁸, A. d'Arminio Monforte⁶ on the behalf of ICONA and HepalCONA study groups
¹Dept Infectious Diseases, Niguarda Ca Grande Hospital, Milan, Italy, ²Royal Free Hospital University College London, UK, ³Dept Infectious Diseases, INMI Spallanzani Roma, Italy, ⁴Clinic Infectious Diseases, Genova, Italy, ⁵Clinic Infectious Diseases, Bologna, Italy, ⁶Clinic Infectious Diseases, San Paolo Hospital Milan, Italy, ⁷Clinic Infectious Diseases University of Turin, Italy, ⁸Clinic Infectious Diseases, Brescia, Italy
- P 87 **Antiretroviral regimens containing atazanavir/ritonavir(ATZ/r), unboosted atazanavir (ATZ) or darunavir/ritonavir(DRV/r) in HIV/HCV co-infected patients: evaluation of safety, effectiveness and impact on liver fibrosis (MASTER cohort)**
P. Nasta¹, C. Mengoli², A. Spinetti¹, C. Pezzoli¹, N. Brianese¹, S. Casari¹, F. Maggiolo³, E. Di Filippo³, S. Di Giambenedetto⁴, S. Costarelli⁵, A. Sarracino⁶, B. Del Pin⁷, D. Segala⁸, F. Zacchi⁹, G. Carosi¹⁰ and the MaSTER study group
¹University Division of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy, ²Department of Molecular Medicine, University of Padua, ³Clinic of Infectious Diseases, Ospedali Riuniti Bergamo, ⁴Institute of Infectious Diseases, Catholic University of Sacred Heart Rome, ⁵Clinic of Infectious Diseases, Ospedale S. Gerardo Monza, ⁶Institute of Infectious Diseases Policlinico di Bari, ⁷Clinic of Infectious Diseases, S. M. Annunziata Hospital Florence, ⁸Clinic of Infectious Disease, S. Anna Hospital Ferrara, ⁹Clinic of Infectious Diseases, Istituti Ospitalieri Cremona, ¹⁰Infectious Diseases and International Health Foundation (M.I.S.I.)
- P 88 **IL28B and other predictive factors of virological response to antiviral therapy with PEG-interferon alfa and ribavirin: are they useful in the panorama of new direct-acting antivirals?**
L. Chessa¹, I. Maida², M.C. Pasetto¹, G. Serra¹, C. Balestrieri¹, F. Ortu¹, P. Piano¹, A. Civolan¹, O. Sorbello¹, M.G. Floris², R. Scioscia¹, L. Barca¹, M.S. Mura²
¹Department of Medical Sciences "Mario Aresu", University of Cagliari, Italy, ²Unit of Infectious Diseases, University of Sassari, Italy

- P 89 An oral high dose of cholecalciferol restores vitamin D status in deficient postmenopausal HIV-1 infected women independently of protease inhibitors therapy**
 J. Pepe¹, I. Mezzaroma², A. Fantauzzi², M. Falciano³, A. Salotti³, M. Di Traglia³, D. Diacinti⁴, S. Piemonte¹, C. Cipriani¹, M. Cilli¹, V. Vullo³, S. Minisola¹
¹Department of Internal Medicine and Medical Disciplines, ²Department of Clinical Medicine, ³Department of Public Health and Infectious Diseases, ⁴Department of Radiology "Sapienza" University
- P 90 Shortening overall treatment to 12 weeks of simeprevir plus pegylated-interferon/ribavirin according to early virologic response in treatment-naïve patients with chronic HCV genotype 4 infection and mild-to-moderate fibrosis**
 M. Levrero¹, T. Asselah², C. Moreno³, M. Gschwantler⁴, A. Craxi⁵, F. Sanai⁶, R. Ryan⁷, O. Lenz⁸, G. Van Dooren⁸, I. Lonjon-Domanec⁹, M. Schlag¹⁰, M. Buti¹¹
¹Sapienza University Rome, Italy, ²Beaujon Hospital, University of Paris, Paris, France, ³CUB Hôpital Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium, ⁴Wilhelminenspital, Vienna, Austria, ⁵University of Palermo, Palermo, Italy, ⁶Division of Gastroenterology, Department of Medicine, King Abdulaziz Medical City, Jeddah, Saudi Arabia, ⁷Janssen Research & Development, Titusville, NJ, USA, ⁸Janssen Infectious Diseases BVBA, Beerse, Belgium, ⁹Janssen Pharmaceuticals, Paris, France, ¹⁰Janssen-Cilag, Vienna, Austria, ¹¹Hospital Valle Hebron and Ciberehd del Institut Carlos III, Barcelona, Spain
- P 91 Shortening overall treatment to 12 weeks of simeprevir (SMV) plus Peg-IFN/RBV in treatment-naïve chronic hepatitis C (CHC) genotype 1 patients: assessment of baseline and week 2 on-treatment predictors of SVR**
 M. Levrero¹, T. Asselah², C. Moreno³, C. Sarrazin⁴, M. Gschwantler⁵, G.R. Foster⁶, A. Craxi⁷, P. Buggisch⁸, R. Ryan⁹, O. Lenz¹⁰, G. Van Dooren¹⁰, I. Lonjon-Domanec¹¹, M. Schlag¹², M. Buti¹³
¹Sapienza University Rome, Italy, ²Beaujon Hospital, University of Paris, Paris, France, ³CUB Hôpital Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium, ⁴Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany, ⁵Wilhelminenspital, Vienna, Austria, ⁶Queen Mary Hospital, University of London, Barts Health, London, UK, ⁷University of Palermo, Palermo, Italy, ⁸Institute for Interdisciplinary Medicine, Hamburg, Germany, ⁹Janssen Research & Development, Titusville, NJ, USA, ¹⁰Janssen Infectious Diseases BVBA, Beerse, Belgium, ¹¹Janssen Pharmaceuticals, Paris, France, ¹²Janssen-Cilag, Vienna, Austria, ¹³Hospital Valle Hebron and Ciberehd del Institut Carlos III, Barcelona, Spain
- P 92 Mixed HCV infection in different compartments during treatment with Peg-IFN plus ribavirin in HIV/HCV coinfecting patients: unmet questions in the era of direct antivirals**
 S. Bagaglio^{1,2}, C. Uberti-Foppa¹, C. Di Serio³, F. Trentini^{3,4}, A. Andolina¹, H. Hasson¹, E. Messina¹, M. Merli¹, A. Lazzarin^{1,2}, G. Morsica¹
¹Infectious Diseases Dept., Scientific Institute Ospedale San Raffaele, Milan, Italy, ²Vita-Salute University, Milan, Italy, ³University Centre for Statistics in the Biomedical Sciences (CUSBS), Vita-Salute San Raffaele University, ⁴L. Bocconi University
- P 93 Plasmatic ribavirin overexposure in patients taking new Direct Antiviral Agents to treat Hepatitis C**
LB L. Badia¹, V. Guardigni¹, M. Conti², F. Serra¹, G. Virgili¹, P. Viale¹, G. Verucchi¹
¹Department of Medical and Surgical Sciences, Section of Infectious Diseases, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy, ²Central Laboratory, Department of Haematology, Oncology, and Laboratory Medicine, Sant'Orsola-Malpighi Hospital, Bologna, Italy

COINFECTIONS WITH HEPATITIS VIRUSES (HBV/HCV) AND HEPATITIS: COMPLICATIONS

- P 94 Bone mineral density abnormality in HIV/HCV co-infected patients (MASTER cohort)**
 P. Nasta¹, S. Zaltron¹, S. Odolini¹, L. Praticò¹, F. Maggiolo², E. Di Filippo², A. Mondì³, S. Costarelli⁴, N. Ladisa⁵, M. Di Pietro⁶, L. Sighinolfi⁷, F. Zacchi⁸, M.C. Postorino⁹, G. Carosi¹⁰ for the MaSTER study group
¹University Division of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy, ²Clinic of Infectious Diseases, Ospedali Riuniti Bergamo, ³Institute of Infectious Diseases, Catholic University of Sacred Heart Rome, ⁴Clinic of Infectious Diseases, Ospedale S. Gerardo Monza, ⁵Institute of Infectious Diseases Policlinico di Bari, ⁶Clinic of Infectious Diseases, S. M. Annunziata Hospital Florence, ⁷Clinic of Infectious Disease, S. Anna Hospital Ferrara, ⁸Clinic of Infectious Diseases, Istituti Ospitalieri Cremona, ⁹Unit of Infectious Disease, Magna Grecia University, Catanzaro ¹⁰Infectious Diseases and International Health Foundation (MISI)
- P 95 Bacterial pneumonia in patients with liver cirrhosis, with or without HIV infection: clinical characteristics and associated risk factors**
 G. Cuomo¹, G. Brancaccio², D. Manno³, M. Puoti⁴, C. Mussini¹, G.B. Gaeta²
¹Azienda Ospedaliero Universitaria Policlinico di Modena, Clinica delle Malattie Infettive/Università degli Studi di Modena e Reggio Emilia, ²Seconda Università degli Studi di Napoli, Unità Epatiti Virali acute e croniche, ³London School of Hygiene and Tropical Medicine, ⁴AO Ospedale Niguarda Cà Granda, SC Malattie infettive, Milano

- P 96 **Combined liver-kidney transplant in HIV positive patients: Modena experience**
 E. Franceschini¹, G. Dolci¹, M. Codeluppi¹, R. Ballarin², R.M. Iemmolo², E. Rubbiani³, F. Facchini³, G. Cappelli³, F. Di Benedetto², G. Guaraldi¹, C. Mussini¹
¹Malattie Infettive, Azienda Ospedaliero-Universitaria Policlinico di Modena, ²Unità Trapianti Multiviscerale-Fegato, Azienda Ospedaliero-Universitaria Policlinico di Modena, ³Nefrologia e Dialisi, Azienda Ospedaliero-Universitaria Policlinico di Modena
- P 97 **Tubular damage, GFR decrease and liver stiffness in HCV cirrhosis**
 S. Grieco¹, A. Bachetoni², E. Biliotti¹, A. Cappoli³, M.D. D'Alessandro², R. Labriola², A.P. Mitterhofer³, D. Palazzo¹, P. Perinelli¹, F. Tinti³, I. Umbro³, G. Taliani¹
¹Clinic of Infectious and Tropical Diseases, Department of Clinical Medicine, ²Laboratory of Clinica Pathology, Department of General Surgery Paride Stefanini, ³Nefrology and Dialysis unit, Department of Clinical Medicine Sapienza University of Rome
- P 98 **Bone involvement in HIV/HCV infection using non invasive methodologies**
 R. Marocco¹, M. Lichtner¹, T. Tieghi¹, F. Schiavone², V. Mercurio³, P. Zuccalà², C.M. Mastroianni²
¹Sapienza University of Rome, Polo Pontino, Latina, Italy, ²Sapienza University of Rome, ³S.M. Goretti Hospital Latina

COINFECTIONS WITH HEPATITIS VIRUSES (HBV/HCV) AND HEPATITIS: EPIDEMIOLOGY

- P 99 **Estimating late HCV diagnosis in newly diagnosed HIV patients**
 P. Scognamiglio¹, C. Agrati², N. Orchi¹, A. Navarra¹, G. De Carli¹, F.M. Fusco¹, S. Pittalis¹, L. Scappaticci¹, A. Ammassari³, U. Visco Comandini³, M. Zaccarelli³, V. Puro¹, M.R. Capobianchi², Ippolito¹, E. Girardi¹
¹Department of Epidemiology and ²Virology Laboratory and ³Clinical Department, National Institute for Infectious Diseases "Lazzaro Spallanzani", Rome, Italy

ANY OTHER ISSUE

- P 100 **Starting with Tenofovir/Emtricitabine (TDF/FTC) based STR is less expensive, drive to longer treatment duration vs. PI-based regimens and improve the overall health status of HIV-treated patients**
 L. Oreni¹, S. Di Matteo², G.M. Bruno², G.L. Colombo^{2,3}, M. Galli¹
¹Infectious Diseases Unit Department of Biomedical & Clinical Sciences, University of Milano L.Sacco Hospital, ²S.A.V.E. Studi Analisi Valutazioni Economiche, Milan, ³University of Pavia, Department of Drug Sciences, Pavia
- P 101 **Is there any additive value of lymphocyte CD4+ percentage to the definition of late presentation - data from the Test and Keep in Care (TAK) project cohort**
 D. Bursa¹, J.D. Kowalska^{1,2}, P. Pulik², E. Firl g-Burkacka², A. Horban^{1,2}
¹Medical University of Warsaw, Department for Adult's Infectious Diseases, Warsaw, Poland, ²Hospital for Infectious Diseases, HIV Out-Patient Clinic, Warsaw, Poland
- P 102 **EBV and CMV DNA salivary shedding in HIV-infected men who have sex with men correlate with long-term plasma HIV-RNA suppression**
 R. Scaggiante¹, M. Basso², S. Andreis², E. Franchin², M. Franzetti¹, C. Del Vecchio², C. Torti³, C. Mengoli², M. Cruciani⁴, L. Sarmati⁵, G. Palù², S.G. Parisi²
¹Infectious Disease Unit, Padova Hospital, Padova, Italy, ²Department of Molecular Medicine, University of Padova, Padova, Italy, ³Unit of Infectious Diseases, University "Magna Graecia", Catanzaro, Italy, ⁴Center of Preventive Medicine & HIV Outpatient Clinic, Verona, Italy, ⁵Clinical Infectious Diseases, Tor Vergata University, Rome, Italy
- P 103 **Physical activity, a useful non pharmacological tool for fighting HIV-related immune-activation**
 G. Ceccarelli, G. d'Ettore, S. Savinelli, S. Giuliano, S. Gebremeskel, S. Serafino, I. Schetroma, N. Giustini, M. Andreotti, V. Vullo
 Department of Public Health and Infectious Diseases, University of Rome "Sapienza"
- P 104 **Quality of life in people living with HIV compared to HIV negative subjects: an observational study at Ferrara Hospital**
 G. Strizzolo, D. Segala, G. Fabbri, L. Sighinolfi, M. Libanore
 Infectious Disease Unit, S. Anna Hospital, Ferrara

HIV CLINICAL DIAGNOSTICS

- P 105 **Comparison of the new Aptima® HIV-1 Quant Dx assay with the Abbott RealTime HIV-1 assay for HIV-1 RNA viral load detection and quantification in plasma of infected individuals**
A. Amendola, M. Pisciotta, L. Aleo, V. Ferraioli, M.R. Capobianchi
Laboratory of Virology, National Institute for Infectious Diseases (INMI) "L. Spallanzani", Rome, Italy
- P 106 **A Real Time PCR Platform for the Simultaneous Quantification of Total and Extrachromosomal HIV DNA Forms in Blood of HIV-1 Infected Patients**
A. Casabianca^{1*}, C. Orlandi^{1*}, B. Canovari², M. Scotti¹, M. Acetoso², M. Valentini², E. Petrelli², M. Magnani¹
*These authors contributed equally to this work, ¹Department of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino (PU), Italy, ²Hospital Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore, Pesaro (PU), Italy
- P 107 **Elaboration of rapid confirmatory immuno-blot assay results to identify recent HIV infections at serodiagnosis**
C. Sias¹, N. Orchi², C. Angeletti³, A. Ammassari⁴, C. Pinnetti⁴, G. Rozera¹, G. De Carli², A. Navarra³, V.Puro², M.R. Capobianchi¹, I. Abbate¹, on behalf of the SENDIH group
¹Laboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani", ²AIDS Referral Centre and Epidemiology Department, National Institute for Infectious Diseases "L. Spallanzani", ³Epidemiology Department, National Institute for Infectious Diseases "L. Spallanzani", ⁴Clinical Department, National Institute for Infectious Diseases "L. Spallanzani"
- P 108 **CKD-EPI equations including cystatin in assessing e-GFR in HIV-infected individuals with suppressed viremia**
G. Contardi, E. Fronti, G. Chieffo, R. Maserati
Infectious Disease Dept, Foundation I.R.C.C.S. Policlinico "San Matteo", Pavia
- P 109 **A persistently false negative result of an oral fluid HIV rapid test in a man having sex with men with a recent HIV infection**
A. Callegaro¹, E. Di Filippo², P.A. Serna Ortega¹, R. Proia³, M. Rizzzi², C. Farina¹, D. Valenti², L. Trezzi⁴, V. Ghisetti³, F. Maggiolo²
¹Microbiology and Virology Laboratory and ²USC Infectious Diseases, AO Papa Giovanni XXIII, Bergamo, ³Microbiology and Virology Laboratory Infectious Diseases Dept., Amedeo di Savoia Hospital, Torino, ⁴Department of Medical Prevention, ASL Bergamo
- P 110 **Evaluation of the new commercial Duplica-RealTime HLA-B*5701 EZ Screen test for HLA-B*5701 typing**
T. Allice¹, M.G. Milia¹, E. Burdino¹, G. Gregori¹, T. Ruggiero¹, A. Bottoni¹, M. Cazzadore¹, M. Zazzi² and V. Ghisetti¹
¹Laboratory of Microbiology and Virology, Infectious Disease Department, Amedeo di Savoia Hospital, Turin, Italy, ²Department of Medical Biotechnologies, University of Siena, Italy
- P 111 **First external quality assurance program of the Italian HLA-B*5701 Network assessing the performance of clinical virology laboratories in HLAB* 5701 testing**
G. Meini¹, B. Bruzzone², R. D'Arrigo³, C. Dello Russo⁴, V. Ghisetti⁵, T. Allice⁵, M.R. Lipsi⁶, S. Paolucci⁷, F. Baldanti⁷, O. Turriziani⁸, F. Falasca⁹, S. Zanussi⁹, G. Basaglia⁹, A. Pirazzoli¹⁰, P. Navarra⁴, M. Zazzi¹
¹Università degli Studi di Siena, ²Azienda Ospedaliera Universitaria San Martino, Genova, ³I.N.M.I. Lazzaro Spallanzani, Roma, ⁴Università Cattolica Sacro Cuore, Roma, ⁵Ospedale Amedeo di Savoia, Torino, ⁶Azienda Ospedaliero-Universitaria di Foggia, ⁷IRCCS Policlinico S. Matteo, Pavia, ⁸Policlinico Umberto I, Roma, ⁹Centro di Riferimento Oncologico, CRO-Aviano, ¹⁰ViiV Healthcare, Verona
- P 112 **Comparative analysis of Real-Time methods to typing HLA B*57:01 in HIV-1 positive patients**
F. Falasca¹, B. Mora², C. Dello Russo³, P. Navarra³, A. Pirazzoli⁴, L. Borruso¹, O. Turriziani¹, G. Antonelli¹
¹Department of Molecular Medicine, Sapienza University of Rome, ²Department of Experimental Medicine Sapienza University of Rome, ³Institute of Pharmacology, Catholic University Medical School, Rome, ⁴ViiV Healthcare, Verona

HIV DRUG RESISTANCE AND TROPISM

- P 113 **Dolutegravir: successful experience in a challenging patient**
A.E. Maraolo, O. Tambaro, G. Palmiero, G. Di Filippo, G. Bonadies, R. Orlando
Unity of Viral Diseases Including AIDS Day Hospital, AOU "Federico II" di Napoli, Napoli
- P 114 **Estimating trends in the prevalence of transmitted and acquired HIV drug resistance in the Bergamo cohort**
A. Callegaro, P.S. Ortega, D. Valenti, E. Di Filippo, F. Maggiolo
AO Papa Giovanni XXIII, Bergamo, Italy

- P 115 **Evaluation HIV-1 subtypes and transmitted drug resistance prevalence using an HIV local Surveillance system in Emilia Romagna**
S. Tagliazucchi¹, W. Gennari¹, M. Pecorari¹, M.M. Santoro², D. Armenia², C.F. Perno², C. Lazzaretti³, C. Mussini³, V. Borghi³
¹Virology Laboratory, AOU Modena, ²Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, ³Clinic of Infectious Disease, AOU Modena
- P 116 **Non-R5 co-receptor tropism is associated with a larger size of the HIV-1 reservoir but not with a higher risk of virological rebound in patients under suppressive cART**
F. Lombardi¹, M. Fabbiani¹, S. Belmonti¹, G. Baldin¹, R. Gagliardini¹, S. Lamonica¹, B. Rossetti², R. Cauda¹, S. Di Giambenedetto¹, A. De Luca²
¹Istituto di Clinica delle Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, ²Unità Operativa Complessa di Malattie Infettive, Azienda Ospedaliera Universitaria Senese, Siena
- P 117 **Characterization of gp41 Mutations in Patients with Virological Failure on Protease Inhibitors**
A. Lai¹, M. Franzetti¹, N. Gianotti², F. Binda¹, F. Saladini³, G. Punzi⁴, V. Spagnuolo², C. Mussini⁵, A. Castagna², L. Monno⁴, M. Zazzi³, C. Balotta¹
¹Department of Biomedical and Clinical Sciences 'L. Sacco', University of Milan, Milan, Italy, ²Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy, ³Department of Medical Biotechnologies, University of Siena, Siena, Italy, ⁴Department of Biomedical Science and Human Oncology, University of Bari, Bari, Italy, ⁵Clinic of Infectious Diseases, University Hospital, Modena, Italy
- P 118 **A unique case of transmitted four-class drug resistant HIV-1: clinical and virological evolution**
F. Vignale, C. Ucciferri, P. Carboni, V. Barocci, K. Falasca, J. Vecchiet
Clinic of Infectious Diseases "G.D'Annunzio" University of Chieti
- P 119 **HIV-1 Integrase genotyping test in low and very low viral load**
B. Bruzzone¹, L. Sticchi^{1,2}, R. Barresi¹, P. Caligiuri², G. Cendarello³, A. Di Biagio⁴, E. Mantia⁵, M. Setti⁶, G. Icardi^{1,2} and Ligurian HIV/HCV Collaborative Study Group (A. Alessandrini, V. Bartolacci, S. Boni, G. Cassola, P. De Leo, C. Dentone, M. Guerra, G. Mazzarello, G. Penco, C. Viscoli)
¹Igiene Unit, IRCCS AOU San Martino-IST, Genoa, Italy, ²Department of Health Sciences, University of Genoa, Genoa, Italy, ³Infectious Diseases Unit, Galliera Hospital, Genoa, Italy, ⁴Infectious Diseases Unit, IRCCS AOU San Martino-IST, Genoa, Italy, ⁵Infectious Diseases Unit, AOS SS A. Biagio e C. Arrigo, Alessandria, Italy, ⁶Internal Medicine and Clinical Immunology Unit, IRCCS AOU San Martino-IST, Genoa, Italy
- P 120 **Evaluation of HIV-1 Coreceptor Tropism in naïve patients in central Italy over years 2009-2013 according to subtype**
G. Berno¹, L. Fabeni¹, D. Armenia², D. Di Carlo², C. Gori¹, A. Bertoli^{2,3}, V. Svicher², V. Fedele¹, E. Boumis¹, C. Pinnetti¹, R. Bellagamba¹, R. Libertone¹, V. Malagnino³, F.M. Fusco¹, D. Pizzi¹, F. Montella⁴, A. Pennica⁵, A. Cristaudo⁶, M. Lichtner⁷, E. Girardi¹, F. Ceccherini-Silberstein², M. Andreoni³, A. Antinori¹, C.F. Perno¹, M.M. Santoro²
¹National Institute for Infectious Diseases L Spallanzani - IRCCS, Rome, Italy, ²University of Rome Tor Vergata, Rome, Italy, ³University Hospital Tor Vergata, Rome, Italy, ⁴S. Giovanni Addolorata Hospital, Division of Clinical Immunology, Rome, Italy, ⁵S. Andrea Hospital, Sapienza University of Rome, Italy, ⁶IRCSS San Gallicano, Rome, Italy, ⁷Infectious Diseases Unit, Sapienza University, Polo Pontino, Latina, Italy
- P 121 **HIV-1 CRF02_AG is associated with a higher risk of virological rebound at first line ritonavir-boosted protease inhibitor based HAART**
D. Armenia¹, C. Gori², D. Di Carlo¹, A. Bertoli^{1,3}, V. Borghi⁴, L. Fabeni², S. Carta², P. Scognamiglio², R. Bellagamba², A. Ammassari², S. Cicalini², C. Cerva³, A. Latini⁵, A. Cristaudo⁵, C.F. Mussini⁴, E. Girardi², M. Andreoni^{1,3}, A. Antinori², F. Ceccherini-Silberstein¹, C.F. Perno², M.M. Santoro¹
¹University of Rome Tor Vergata, Rome, Italy, ²L Spallanzani Hospital, Rome, Italy, ³University Hospital Tor Vergata, Rome, Italy, ⁴Modena University Hospital, Modena, Italy, ⁵IRCSS San Gallicano, Rome, Italy
- P 122 **Identification of HIV mutations in a naive population in an Italian cohort**
A. Beltrame¹, B. Bruzzone², P. De Leo¹, R. Barresi², N. Nigro², M. Anselmo¹
¹Infectious Diseases Department, S. Paolo Hospital ASL 2 Savonese, Italy, ²Hygiene Unit; IRCCS AOU San Martino-IST, Genoa, Italy

PHARMACOLOGY, PHARMACOGENOMICS AND DRUG INTERACTIONS

- P 123 **Pharmacokinetics of once-daily 300 mg maraviroc in combination with tenofovir/emtricitabine/elvitegravir/cobicistat**
C. Alcantarini, M. Simiele, I. Motta, C. Montrucchio, L. Marinaro, M. Milesi, A. Calcagno, A. D'Avolio, G. Di Perri, S. Bonora
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino
- P 124 **Pharmacologic exposure to maraviroc and parameters of postural hypotension in patients stably receiving maraviroc 300 mg qd with darunavir/ritonavir as a dual therapy in the GUSTA trial**
C. Bianco^{1,2}, B. Rossetti^{1,2}, L. Lisi³, S. Lamonica², A. D'Avino², A. Mondì², P. Navarra³, S. Di Giambenedetto², A. De Luca¹
¹Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, ²Clinic of Infectious Diseases, Catholic University of Sacred Heart, Roma, ³Institute of Pharmacology, Catholic University of Sacred Heart, Roma

- P 125 **Comparison of the in vitro dissolution and in vivo pharmacokinetics of branded versus generic efavirenz formulation in HIV patients**
S. Baldelli¹, M. Cerea², D. Cattaneo¹, A. Gazzaniga², G. Cenderello³, T. Bin⁴, S. Vimercati¹, A. Riva¹, R. Iardino⁵, E. Clementi¹, C. Gervasoni¹
¹Luigi Sacco University Hospital, Milan, Italy, ²Università degli Studi di Milano, Department of Pharmaceutical Sciences, Milan, Italy, ³Galliera Hospital, Genova, Italy, ⁴San Paolo Hospital, Milan, Italy, ⁵NPS Italia Onlus, Milan, Italy.
- P 126 **The role of clinical pharmacist in the observation and evaluation of the suspected adverse reactions among patients with HIV disease**
L. Appolloni¹, C. D'Orlando¹, C. Sacripanti¹, M. Morotti¹, L. Calza², V. Colangeli², R. Manfredi², P. Viale², C. Puggioli¹
¹Farmacia Clinica, Policlinico S.Orsola-Malpighi, Università di Bologna, Bologna, ²U.O. Malattie Infettive, Policlinico S.Orsola-Malpighi, Università di Bologna, Bologna

VIROLOGY

- P 127 **Different residual viremia trends in patients successfully treated with first line antiretroviral therapy for one year**
A. Amendola¹, A. Ammassari², C. Pinnetti², G. Bibbolino¹, A. Navarra³, P. Pierro², L. Aleo¹, M. Pisciotto¹, V. Ferraioli¹, G. Rozera¹, I. Abbate¹, E. Girardi³, M.R. Capobianchi¹
¹Laboratorio di Virologia, INMI "L. Spallanzani", Roma, ²Dipartimento clinico, INMI "L. Spallanzani", ³Dipartimento di epidemiologia, INMI "L. Spallanzani"
- P 128 **The ADAR1 editing enzyme is encapsidated into HIV-1 virions**
E. Orecchini¹, M. Federico², M. Doria³, C. Arenaccio², E. Giuliani³, S.A. Ciafrè¹, A. Michienzi¹
¹Department of Biomedicine and Prevention, University of Rome "Tor Vergata", ²National AIDS Center, Istituto Superiore di Sanità, Rome, Italy, ³Laboratory of Immunoinfectivology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
- P 129 **Increased activity of APOBEC3G in a HIV-HCV co-infected patient harboring functionally competent Vif**
LB I. Bon¹, L. Badia², G. Musumeci¹, V. Guardigni², S. Morini¹, A. Miserochi¹, S. Longo¹, P.L. Viale², G. Verucchi², M.C. Re¹
¹Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Microbiology Section, University of Bologna, Bologna, Italy, ²Department of Medical and Surgical Sciences, Section of Infectious Diseases, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy

IMMUNOLOGY

- P 130 **Immunoactivation/senescence and lymphopoiesis capability in primary HIV infection: ALPHA study**
V. Bordoni¹, C. Pinnetti², D. Viola¹, I. Abbate³, G. Rozera³, P. Pierro², F. Besi¹, R. Casetti¹, A. Sacchi¹, E. Cimini¹, C. Agrati¹, M.R. Capobianchi³, A. Antinori², F. Martini¹, A. Ammassari²
¹Cellular Immunology Laboratory, National Institute for Infectious Diseases "L.Spallanzani", ²Clinical Department, National Institute for Infectious Diseases "L.Spallanzani", ³Laboratory of Virology, National Institute for Infectious Diseases "L.Spallanzani"
- P 131 **Altered expression of AIM2 and NLRC4 mRNAs in PBMCs from patients with primary HIV infection or CD4-guided treatment interruption**
M. Nasi¹, M. Pinti², L. Gibellini¹, S. De Biasi¹, E. Bianchini², R. Bartolomeo¹, S. Pecorini¹, S. Alboni², V. Borghi³, C. Mussini³, A. Cossarizza¹
¹Department of Surgery, Medicine, Dentistry and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, ²Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy, ³Infectious Diseases Clinics, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy
- P 132 **Different modulation of polyfunctional CD8 T cell response by cART in primary and chronic HIV infection**
R. Casetti¹, G. De Simone¹, C. Pinnetti², F. Besi¹, A. Sacchi¹, I. Abbate³, G. Rozera³, P. Pierro², C. Agrati¹, E. Cimini¹, V. Bordoni¹, N. Tumino¹, D. Viola¹, M.R. Capobianchi³, A. Antinori², F. Martini¹, A. Ammassari²
¹Cellular Immunology Laboratory, National Institute for Infectious Diseases "L. Spallanzani", ²Clinical Department, National Institute for Infectious Diseases "L. Spallanzani", ³Laboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani"
- P 133 **In HIV+ patients, granulocytic myeloid derived suppressor cells are expanded independently from cART, and induce T cell anergy by suppressing CD3zeta expression**
N. Tumino¹, F. Turchi¹, S. Meschi¹, E. Lalle¹, V. Bordoni¹, R. Casetti¹, C. Agrati¹, E. Cimini¹, C. Montesano², V. Colizzi², F. Martini¹, A. Sacchi¹
¹National Institute for Infectious Diseases "Lazzaro Spallanzani", ²Department of Biology, "Tor Vergata" University, Rome
- P 134 **CD62L down-regulation in HIV-1-infected individuals naïve for antiretroviral treatment**
L. Vassena¹, E. Giuliani¹, M.G. Desimio¹, A.R. Buonomini², V. Malagnino², M. Andreoni², M. Doria¹
¹Laboratory of Immunoinfectivology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy, ²Department of Medicine of Systems, Tor Vergata University, Rome, Italy

- P 135 **CD4+ T-cell Gene Expression of HIV-1 Elite Controllers: Immunological Chaos**
 M. Di Rosa¹, M.R. Pinzone¹, F. Condorelli², B. Cacopardo¹, G. Nunnari¹
¹Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Catania, Italy, ²DiSCAFF, University of Novara, Italy
- P 136 **Different frequency and activation of peripheral CD8+,FoxP3+ Treg cells in patients with different stages of HIV infection**
 S. De Biasi¹, M. Nasi¹, E. Bianchini², M. Digaetano³, L. Gibellini¹, S. Pecorini¹, R. Bartolomeo¹, V. Borghi³, M. Pinti², C. Mussini^{1,3}, A. Cossarizza¹
¹Department of Surgery, Medicine, Dentistry and Morphological Sciences, University of Modena and Reggio Emilia, ²Department of Life Sciences, University of Modena and Reggio Emilia, ³Infectious Diseases Clinics, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy
- P 137 **Evaluation of CD38 expression on CD8 T Lymphocytes as marker of viral replication control in HIV infected patients: one year longitudinal study**
 E. Schiaroli, S. Bastianelli, S. Pierucci, I. Bachiorri, F. Baldelli, D. Francisci
 Clinica delle Malattie Infettive, Università di Perugia

PATHOGENESIS AND IMMUNOPATHOGENESIS

- P 138 **Analyses of pre-erythroid cells in peripheral blood of HIV infected patients with different rates of disease progression**
 M.S. Tarkowski, L. Ghita, L. Milazzo, E. Calvi, A.M. Peri, C. Resnati, C. Gervasoni, M. Galli, A. Riva
 Università degli Studi di Milano, Dipartimento di Scienze Biomediche e Cliniche "L. Sacco", Milano

RESISTANCE TO HIV INFECTION AND TO DISEASE PROGRESSION

- P 139 **Virologically discordant non progressor HIV patients revealed: the role of NK cell activating receptors**
 F. Marras¹, F. Bozzano², A. Di Biagio³, L. Nicolini³, L. Taramasso³, C. Viscoli³, C. Dentone⁴, E. Pontali⁵, S. Boni⁶, M. Setti^{3,7}, G. Orofino⁸, E. Mantia⁹, L. Moretta¹, C. Orlandi¹⁰, A. Casabianca¹⁰, M. Magnani¹⁰, A. De Maria^{2,11}
¹Istituto Giannina Gaslini, Genoa, Italy, ²Department of Experimental Medicine, DIMES, University of Genova, Genoa, Italy, ³Department of International Medicine and infectious Disease IRCCS A.O.U. SanMartino-IST Genova, Italy, ⁴Unità di Malattie Infettive, Ospedale Sanremo, Sanremo, Italy, ⁵Unità di Malattie Infettive, Ospedale Galliera, Genoa, Italy, ⁶Unità di Malattie Infettive, Ospedale Sant'Andrea, La Spezia, Italy, ⁷Department of Internal Medicine, University of Genova, Genoa, Italy, ⁸Unità di Malattie Infettive, Ospedale Amedeo di Savoia, Turin, Italy ⁹Unità di Malattie Infettive, Az. Osp. Santi A.B.C.Arrigo, Alessandria, Italy, ¹⁰Department of Biomolecular Science University of Urbino "Carlo Bo", Urbino (PU), Italy, ¹¹Center of Excellence in Biomedical Research, University of Genoa, Genoa, Italy

EPIDEMIOLOGY OF HIV, HBV, HCV INFECTIONS

- P 140 **Characteristics of HIV-infected Patients Not Retained in Care of Three Cohorts of Italy**
 S. Zona¹, C. Lazzaretti¹, V. Borghi¹, E. Salsi¹, E. Franceschini¹, T. Bini², F.M. Fusco³, E. Giradi³ A. D'Arminio Monforte², C. Mussini¹
¹Azienda Ospedaliera Universitaria Policlinico di Modena, Modena, Italy, ²San Paolo Hospital, Milan, Italy, ³National Institute of Infectious diseases L. Spallanzani, Rome, Italy
- P 141 **HIV/HBV, HIV/HCV and HIV/HCV/HBV confessions' prevalence and characteristics in Tuscany**
 M. Puglia¹, C. Stasi^{1,2}, M. Da Frè¹, F. Voller¹
¹Health Agency of Tuscany, Florence, Italy, ²Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
- P 142 **Missed treatment in a Italian HBV infected patients cohort: HBV RER**
 G. Cuomo¹, V. Borghi¹, P. Andreone², M. Massari³, E. Villa⁴, A. Pietrangelo⁵, G. Verucchi⁶, C. Ferrari⁷, and HBV-RER Study Group
¹Infectious Disease, AOU Modena, ²Internal Medicine, AOU Bologna, ³Infectious Disease, IRCCS – ASMN Reggio Emilia, ⁴Gastroenterology, AOU Modena, ⁵Internal Medicine, AOU Modena, ⁶Infectious Disease, AOU Bologna, ⁷Infectious Disease and Hepatology, AOU Parma
- P 143 **Evaluation of HIV, HBV and HCV prevalence among transgender patients in an Italian Urological Clinic qualified for total sex-reassignment surgery**
 C. Maurel¹, C. Rosin¹, J. Monticelli¹, M. Zatta¹, M. Serafin², C. Trombetta³, R. Luzzati¹
¹Department of Infectious Diseases, University of Trieste, Trieste, Italy, ²Laboratory for Viral Serology, Trieste Hospital, Trieste, Italy, ³Department of Urology, University of Trieste, Trieste, Italy
- P 144 **I.C.E.B.E.R.G (Implementing Counselling and Education to Boost an Early- detection of HIV infection in high Risk Groups) Project**
 G. Palmiero, A.E. Maraolo, O. Tambaro, G. Di Filippo, G. Borgia, G. Bonadies
 Department of Clinical Medicine, Unity of Infectious Diseases, University of Naples "Federico II"

- P 145 **HIV infection and blood donation: risk behaviours, selection criteria and instruments to improve information. An experience of AVIS (Associazione Volontari Italiani Sangue) Association in Ferrara**
P. Ghinelli¹, F. Gavioli¹, S. Marchesi¹, F. Palma¹, F. Ghinelli¹, L. Sighinolfi²
¹AVIS Provinciale Ferrara, ²Infectious Diseases Unit – Azienda Ospedaliero Universitaria – Ferrara
- P 146 **Epidemiology of newly diagnosed HIV-positives subjects with avidity index: 13 months of observation**
N. Zanchetta¹, S. Rusconi², P. Meraviglia², A. Capetti², C. Galli³, G. Rizzardini², M. Galli², M.R. Gismondo¹
¹Clinical Microbiology, Virology and Bioemergency, University of Milan, Luigi Sacco Hospital, ²Department of Infectious Diseases, University of Milan, Luigi Sacco Hospital, ³Scientific Affairs, Abbott Diagnostici, Roma

GENDER ISSUES

- P 147 **HIV diagnoses during pregnancy in Tuscany**
M. Da Frè, M. Puglia, F. Voller
Epidemiology Unit, Regional Health Agency of Tuscany, Florence

HIV PREVENTION

- P 148 **Exploring the Impact of Social Marketing of Female Condoms in the City of Kumba, Cameroon. 2010-2011**
T.E. Enongene, B. Ehinak
Kumba Association of People Living with HIV
- P 149 **The Test Days in Modena: when Innovations in HIV Counselling and Testing Produce Effects beyond Diagnosis**
A. Toscano¹, A. Santoro², A. Bignardi³, C. Mussini²
¹Centro Studi Airone, ²Università di Modena e Reggio Emilia, Clinica Malattie Infettive, ³Arcigay Modena
- P 150 **Quantification of HbsAb levels in a population of young adults vaccinated to HBV who received post exposure prophylaxis to HIV (PEP)**
A. Franco¹, L. Aprea¹, C. Esposito², E. Manzillo¹, N. Maturo¹, T. Pizzella¹, L. Santangelo², F. Simioli¹, M. Gargiulo¹
¹Department of Infectious Diseases and Infectious Emergencies, ²Clinical Virology Laboratory

SOCIAL AND BEHAVIOURAL SCIENCE, COMMUNITY ASPECTS AND COMMUNITY SURVEYS

- P 151 **Increasing the awareness on HIV and STDs: a four-year program involving high school students in the Province of Pavia**
M. Zaramella¹, L. Pavesi¹, A. Uglietti¹, A. Malfitano¹, V. Martinelli², R. Maserati¹
¹Infectious Disease Dept, Foundation I.R.C.C.S. Policlinico "San Matteo", Pavia, ²Brain and Behavioral Dept, University of Pavia, Pavia, Italy
- P 152 **Transitioning HIV-infected children and adolescents into adult care: an Italian real-life experience**
A. Righetti¹, R. Prinapori¹, L. Nulvesu¹, L. Fornoni², A. Di Biagio¹
¹Unit of Infectious Diseases, IRCCS AOU San Martino-IST, Genoa, Italy, ²Institute Giannina Gaslini IRCCS- Children's nurses School Lorenza Gaslini, Genoa, Italy
- P 153 **Antiretroviral therapy in inmates: between guidelines and reality of Italian correctional facilities**
R. Ranieri¹, M. Casana², A. Foschi², D. Pavani², A. Radice², J. Sommella³, C. D'Angelo³, C. Lari⁴, D. Di Benedetto⁵, A. d'Arminio Monforte⁶
¹Consulente Infettivologo, Coordinatore Casa di Reclusione Opera e Casa Circondariale San Vittore Milano, A.O San Paolo Milano, ²Consulente Infettivologo, Casa di Reclusione Opera, A.O San Paolo Milano, ³Dirigente Farmacista, A.O San Paolo Milano, ⁴Responsabile, Coordinamento della Assistenza Sanitaria negli Istituti Penitenziari di Milano, ⁵Direttore U.O Farmacia, A.O. San Paolo Milano, ⁶Direttore U.O. Malattie Infettive A.O. San Paolo, Cattedra Malattie Infettive, Università degli Studi di Milano
- P 154 **Adjustment to New HIV Diagnoses Health Adviser Counselling and Support Service An evaluation and feedback from users**
R. Tobin, J. Woods, D. Lakhani
CNWL Sexual health Services
- P 155 **A local evaluation of an HIV partner notification system**
D. Lakhani, R. Tobin, M. Longman
CNWL Sexual Health services

- P 156 **Improving Quality in HIV Prevention?**
A. Palummi¹, M.L. Cosmaro², C. Di Cicco², M. Oldrini², A. Cerioli², G. De Carli¹, V. Puro¹, G. Ippolito¹
¹National Institute for Infectious Diseases "L. Spallanzani" IRCCS – Rome, ²Lega Italiana per la lotta contro l'AIDS (LILA)
- P 157 **Criminal Liability for sexual transmission of HIV: What role does the criminal law play when an individual discovers he is HIV positive?**
F. Manfredi¹, E. Garlassi², E. Barchi², M. Cocchi², N. Solomita², G. Magnani², A. Cadoppi¹
¹University of Parma, Law, ²Infectious Diseases Department, Azienda Ospedaliera S. Maria Nuova, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Reggio Emilia, Italy
- P 158 **What do you know about it? - Knowledge of HIV / AIDS in the general population, with focus in the age group 14-18 years and in the sexually active population**
C. Carraro, F. Perocco, A. Battistella, M. Errico, G. Rizzardini, C. Zucchet, C. Nicoara, M. Errico, A. Cavassi, G. Simonini, C. Morbelli, A. Piccirillo, A. Sannino, D. Parisi, S. Lodico
University Ca' Foscari Venice – General Director, University Ca' Foscari Venice - Member of the Academic Board of the degree program in Social Work; responsible for the teaching of the Master on Immigration; professor of Methods of analysis and social research, sociology of migration, University Ca' Foscari Venice - Professor of "Analysis and innovation of social and health services", 8NPS Italia Onlus- Network of people living with Hiv – NPS Italia sez. Campania, Luigi Sacco Hospital, Milan, Italy, Equality, Milan, Italy, NPS sezione Sicilia, Palermo, Italy, NPS Emilia Romagna, Faenza, Italy, Movimento qualità per la vita, Massa Carrara, Italy, Laici Terzo Mondo, Naples, Italy, Istituto Opera Don Calabria, Naples, Italy, Comitato provinciale Arcigay "Antinoo" Naples, Italy, Soc. Coop. No Colors – Palermo – Italy, Ass. Interculturale Narramondi – Palermo – Italy
- P 159 **"Can I use new anti-HCV DAA drugs and where can I find them?" Results from a spontaneous Survey**
S. Marcotullio¹, D. Osorio¹, S. Reniè², F. von Schloesser¹
¹Nadir Onlus, Rome, Italy, ²EsseRe, Rome, Italy
- P 160 **Data analysis on Generics between healthcare staff**
A. Battistella, M. Errico, D. Cattaneo, A. Cavassi
Centro Studi "Gianni Grosso" di NPS Italia Onlus, NPS Italia Onlus – Network of People Living with Hiv, Luigi Sacco Hospital Authority, Milan, Italy, NPS Emilia Romagna – Network of People Living with Hiv- sezione Emilia Romagna
- P 161 **The impact of coping strategies on Burnout and mental quality of life: a study in healthcare professionals involved in caring HIV/AIDS patients**
M.M. Ratti^{1,2}, G.B. Delli Zotti², B. Vai^{3,4}, S. Sofisti¹, N. Gianotti⁵, L. Sarno^{1,2}
¹Vita-Salute San Raffaele University, Milan, Italy, ²Health and Clinical Psychology Service, IRCCS San Raffaele Hospital, Milan, Italy, ³Department of Clinical Neurosciences, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy, ⁴Department of Human Studies, Libera Università Maria Ss. Assunta, Roma, Italy, ⁵Infectious Diseases Unit -San Luigi Center-IRCCS San Raffaele Turro Hospital, Milan, Italy
- P 162 **Tablet Technologies to drive triage for diagnostic screening in HIV patients and collect patient related outcomes to built a frailty index**
A. Malagoli, S. Garlassi, C. Stentarelli, F. Carli, S. Zona, G. Guaraldi
University of Modena and Reggio Emilia
- P 163 **Oral rapid HIV testing in a friendly environment: the experience of "Esedomani" association in Terni, Umbria**
G. Margiotta¹, L.M. Saraca², R. Desi³, C. Di Giulì⁴
¹University of Siena, Section of Legal Medicine, Siena, ²University of Perugia, Unit of Infectious Diseases, Perugia, ³"Esedomani" Volunteering Association, Terni, ⁴"Santa Maria" Hospital of Terni, Unit of Infectious Diseases, Terni



La nostra lotta contro le malattie infettive

Noi di Janssen abbiamo degli obiettivi molto ambiziosi.

Ci impegniamo a fondo per prevenire, diagnosticare, trattare e curare le malattie infettive.

Dall'epatite C all'HIV, dalla tubercolosi all'influenza, la nostra missione è migliorare la vita delle persone e assicurarci che le generazioni future possano vivere senza paura.

Con questi obiettivi non c'è tempo da perdere. Ecco perché collaboriamo con le organizzazioni di tutto il mondo mettendo a disposizione le nostre competenze.

Questi ostacoli non sono insormontabili, possono essere superati nello stesso modo in cui sono stati risolti i più grandi problemi dell'umanità: impegno costante e innovazioni che hanno fatto la differenza.



è uno sforzo comune. **Unisciti a noi.**

Fortunatamente possiamo contare su entrambi.

Noi siamo Janssen.
Collaboriamo con il mondo per la salute di tutti.

Scopri di più su www.janssen.com

janssen 
PHARMACEUTICAL COMPANIES
OF *Johnson & Johnson*

abbvie

L'INNOVAZIONE
GUIDA LA NOSTRA
SCIENZA.
LA VITA DELLE
PERSONE GUIDA
IL NOSTRO IMPEGNO.

Per rispondere alla domanda di salute nel mondo, AbbVie unisce lo spirito di un'impresa biotecnologica alla solidità di un'azienda farmaceutica di successo.

Il risultato è un'azienda biofarmaceutica che coniuga scienza, passione e competenza per migliorare la salute e la cura delle persone, con modalità innovative.

Incidere significativamente sulla vita delle persone è, per noi, più di una promessa. È il nostro obiettivo.

abbvie.it



INFO

General Information

Conference Venue

Palazzo dei Congressi - Viale Virgilio, 17 - 47838 Riccione - www.palariccione.com

How to reach the Conference Venue



RAILWAY STATION

Riccione: 600 m from station

Rimini: 11 km from station



BOLOGNA AIRPORT

131 Km from the airport - 1 hour and 15 minutes by car



CAR

Wide pay parking available in the Conference Venue

Official languages

Italian and English. Simultaneous translation provided only in Auditorium.

Pre-conference advanced courses and Congress dates

PRE-CONFERENCE ADVANCED COURSES: Sunday, May 17 from 14.30 to 17.00

CONFERENCE: from Sunday May, 17 h. 15:00 to Tuesday May, 19 h. 17:15

Conference Secretariat opening times

SUNDAY, MAY 17 from 10.30 to 20.00

MONDAY, MAY 18 from 08.00 to 18.30

TUESDAY, MAY 19 from 08.00 to 17.30

Exhibition Area opening times

SUNDAY, MAY 17 from 14.30 to 20.00

MONDAY, MAY 18 from 08.30 to 18.30

TUESDAY, MAY 19 from 08.30 to 17.30

ICAR official events

SUNDAY, MAY 17

- **Quick test for HIV and HCV:** Riccione, Piazzale Ceccarini from 11.00 to 14.00
- **Opening Session:** Conference venue, from 17.00 in Auditorium
- **ICAR-CROI Awards:** Conference venue, from 19.20 in Auditorium
- **ICAR 2015 Welcome Reception:** Conference venue, from 20.00 to 22.30

MONDAY, MAY 18

- **ICAR Run:** Riccione, Piazzale Ceccarini, from 19.30 to 20.30

TUESDAY, MAY 19

- **ICAR 2015 Awards:** Conference venue, from 16.50 in Auditorium

Quick links

ORGANIZING SECRETARIAT icar2015@effetti.it

ABSTRACT SECRETARIAT abstract.icar2015@effetti.it

ICAR WEBSITE www.icar2015.com

SETTIMO CONGRESSO NAZIONALE



ICAR
Italian
Conference on
AIDS and
Retroviruses

Instructions for Speakers

It is not possible to bring presentations directly to the lecture hall. All presentations have to be handed over at the Slide Center Room at least 2 hours before the session. At the Slide Center Room, Speakers will have the possibility of:

- Reviewing power-point presentations
- Last minute changes of power-point presentations
- Being supported by technical staff
- Uploading power-point presentation in the dedicated session conference room

All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide.
For more information: www.icmje.org/conflicts-of-interest/

Oral Communication Sessions

Selected abstract will be presented in Oral Communication Sessions. The Authors are requested to attend those sessions and **provide max 10 (power-point) slides** resuming their abstract. Time allowed for each **presentation: 7 minutes followed by 3 minutes for discussion.**

All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide. For more information: www.icmje.org/conflicts-of-interest/

Oral Poster Sessions

Selected abstract will be presented in Oral Poster Sessions. The Authors are requested to attend those sessions and **provide max 5 (power-point) slides** resuming their poster. Time allowed for **presentation: 5 minutes followed by 2 minutes for discussion.**

All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide. For more information: www.icmje.org/conflicts-of-interest/.

Authors can set up their posters on **May 17, 2015 from h. 10.30 to 17.00, at the third floor of the Congress Center**, according to the number received from the Organizing Secretariat, **and remove them on May 19, 2015 at the end of the Congress.**

Poster Exhibition

ICAR Poster exhibition will take place within dedicated areas of the Congress Center:

- **posters from P 1 to P 70 at the third floor**
- **posters from P 71 to P 163 at the fourth floor**

Dimensions should not exceed 70x100 cm. Authors can set up their posters on **May 17, 2015 from h. 10.30 to 17.00**, according to the number received from the Organizing Secretariat, **and remove them on May 19, 2015 at the end of the Congress.**

Thanks for ICAR 2015 Awards

The 7th ICAR Chairs, Scientific Secretariat and Organizing Secretariat would like to thank the Scientific Societies SIMIT, SIVIM and AVIRALIA Foundation for the Special Awards addressed to Young Investigators:



SIMIT Awards

3 Awards of € 3.000,00 each one, for the best abstracts of **Clinical, Basic Science and Social-Epidemiological**



SIVIM Award

1 Award of € 1.000,00 for the best abstract of **Basic and Clinical Virology**



Foundation AVIRALIA Award

2 Scholarships for the best abstracts of **Virology**

Abstracts will be selected by dedicated Commissions and winners will be announced during the ICAR 2015 Awards session which will be held on **Tuesday, May 19th, 2015 from 16.50 to 17.05 in Auditorium.**

ICAR services for participants



The Congress has provided for posters' Authors the "Poster-for-you" service which allowed to ask to the Organizing Secretariat to create and print their own posters and pick them up at Poster exhibition area inside Congress venue. **Poster-for-you** available on the ICAR Poster CD-ROM at the Bristol-Myers Squibb booth.

Abstract USB Pendrive

All registered participants can ask for the **ICAR Abstract USB Pendrive** at ViiV Healthcare booth: it contains abstracts of all oral communications, oral posters and posters.

Wi-Fi zone

Free Wi-Fi zone available within the exhibition area: password can be requested at Hologic booth.

Web Repository

After the Congress, the ICAR official website (www.icar2015.com) will publish the ICAR 2015 web repository with abstracts, presentations, oral communications and accepted posters.



ICAR Highlights on webcast available after the Congress on ICAR and ViroVip websites.

Unrestricted educational grant of MSD

ICAR Special Events

In collaboration with



The **7th ICAR Conference 2015** proposes for the first time a series of special Events organized in collaboration with Patients' Community and the Municipality of Riccione, with the aim of involving and raise public awareness on the issue of prevention.

SUNDAY, MAY 17



Quick test for HIV and HCV Piazzale Ceccarini from 11.00 to 14.00

Healthcare personnel from Infectious Disease Department, University Hospital Ferrara, will perform free rapid testing for HIV and HCV at the request of citizens as confidential and anonymous. The test is noninvasive, requires short time and is highly reliable.

In collaboration with Cepheid and Meridian Bioscience Europe



School Project: RaccontART HIV Auditorium, Palazzo dei Congressi from 15.00 to 17.00

RaccontART HIV is an art competition launched by ICAR to students who are invited to present their views on HIV/AIDS through various forms of expression. During the Conference Opening Session the finalists will present their artistic works and the winners will be awarded by the Jury composed of leading representatives of the cultural national world, ICAR Scientific Coordinators and Patients' Community.

Unrestricted educational grant of Gilead

MONDAY, MAY 18



ICAR RuN Piazzale Ceccarini, from 19.30 to 20.30

A non-competitive foot race, promoted by ICAR and the Community. ICAR Run will unfold for 3.5 km beachfront hotel in Riccione with start and finish in Piazzale Ceccarini. The event will conclude with the top three awards and a drink in Piazza for all participants.

Upon registration participants will receive the ICAR hat, T-shirt and the numbered bib.

Unrestricted educational grant of Janssen



SETTIMO CONGRESSO NAZIONALE



ICAR
Italian
Conference on
AIDS and
Retroviruses

CME Accreditation



Conference

The 7th ICAR Conference has been accredited to the Italian Ministry of Health for **10 CME Credits**.

Every single day has been accredited for the following professionals:

ID ECM Number	Credits	Professionals
Sunday May, 17		Medical Doctor Infectious and Tropical Diseases Hygiene, Epidemiology and Public Health Microbiology and Virology Allergology and Clinical Immunology Internal Medicine Gastroenterology Biologist Pharmacist Nurse Medical laboratory technician Psychologist
150-117292	1	
Monday May, 18		
150-117294	5	
Tuesday May, 19		
150-117297	4	

Pre-conference advanced Courses

The 7th ICAR advanced Courses have been accredited to the Italian Ministry of Health for each single course.

ID ECM Number	Credits	Professionals
La virologia e l'immunologia incontrano la clinica: i parametri virologici e immunologici di frontiera oggi		Medical Doctor Infectious and Tropical Diseases Hygiene, Epidemiology and Public Health Microbiology and Virology Allergology and Clinical Immunology Internal Medicine Gastroenterology Biologist Medical laboratory technician
150-122304	2	
Il rischio di infezione da HIV e altri patogeni a trasmissione ematica per il personale sanitario		All CME health professionals
150-122328	2	
Dalla ricerca traslazionale: Brain Wave in HIV. Diagnosi mirata e precoce al paziente con disturbi neurocognitivi		Medical Doctor Infectious and Tropical Diseases Hygiene, Epidemiology and Public Health Microbiology and Virology Allergology and Clinical Immunology Internal Medicine Gastroenterology Biologist Pharmacist Nurse Medical laboratory technician Psychologist
150-122136	2	

Obtaining credits**PARTICIPANTS**

To obtain credits, registered participants are required to:

- Wear the identification badge during working sessions
- Provide their signature and write entrance/exit times before and after attending working sessions
- Complete assessment and satisfaction questionnaires for each day

SPEAKERS

Speakers will be given 1 credit for each half-hour of consecutive teaching.

Speakers, moderators and discussants can decide to obtain credits as participants (see Participants).

ATTENDANCE TRACKING

Attendance will be tracked through participants' signature at the start/end of each day, and through assessment and satisfaction questionnaires.

CME CERTIFICATES

Credits will be given only if a participant attends 100% of the working sessions and provides correct answers to at least 75% of the questions included in the final assessment questionnaire. The Provider will send CME certificates to the participants after the Conference.



Registrations fees

Pre-conference advanced Courses

Free of charge (registrations available on a "first come, first served" basis)

Registration includes: congress kit (delegate bag, badge, certificate of attendance), CME registration and materials, working brunch and coffee breaks during the day of the course.

Conference

CONFERENCE REGISTRATION FEES (22% VAT non included)

Physicians	€ 600,00
Physicians < 35 years of age, Biologist, Biotechnologist, Pharmacist, Nurse, Psychologist	€ 250,00
Post-graduate medical trainees	€ 50,00
Students/PhD	free
Members of HIV/AIDS Community	free

The registration fee includes: congress kit (delegate bag, badge, certificate of attendance), Opening Session and Welcome Cocktail on May 17, coffee breaks and lunches on May 18 and 19, CME registration, Conference USB/abstract and poster CD-Rom

DAILY CONFERENCE REGISTRATION FEES (22% VAT non included)

Physicians	€ 600,00
Physicians < 35 years of age, Biologist, Biotechnologist, Pharmacist, Nurse, Psychologist	€ 250,00
Post-graduate medical trainees	€ 50,00
Students/PhD	free
Members of HIV/AIDS Community	free

The registration fee includes: attendance to the sessions of the day, congress kit (delegate bag, badge, certificate of attendance), Conference USB/abstract, poster CD-Rom coffee break and lunch for the day, certificate of attendance for the sessions of the day.

abbvie

L'INNOVAZIONE
GUIDA LA NOSTRA
SCIENZA.
LA VITA DELLE
PERSONE GUIDA
IL NOSTRO IMPEGNO.

Per rispondere alla domanda di salute nel mondo, AbbVie unisce lo spirito di un'impresa biotecnologica alla solidità di un'azienda farmaceutica di successo.

Il risultato è un'azienda biofarmaceutica che coniuga scienza, passione e competenza per migliorare la salute e la cura delle persone, con modalità innovative.

Incidere significativamente sulla vita delle persone è, per noi, più di una promessa. È il nostro obiettivo.

abbvie.it




CONGRESS MAP

Floor 1

1 Congress Secretariat

2 Community Suite

3 Test HIV/HCV




Legenda

Keys

Scala mobile
EscalatorUscite di sicurezza
Security exit

Entrance



Floor 3

Exhibition Area

1  Bristol-Myers Squibb


2  Janssen

3  GILEAD

4  ReAdfiles  Fondazione Icona
ITALIAN COHORT NAIVE ANTIRETROVIRALS

5  ViiV
Healthcare

6  HOLOGIC®
The Science of Sure



Floor 3

Domenica 17 maggio

SETTIMO CONGRESSO NAZIONALE




ICAR
Italian
Conference on
AIDS and
Retroviruses



Legenda

Keys

- Poster Area
- Conference hall
- Entrance hall

 Scala mobile
Escalator

 Uscite di sicurezza
Security exit



Floor 4

Community Village


1		5	
2		6	
3		7	
4		8	

Hospitality suites

9	
10	

Exhibition Area

A	
B	
C	NEW MICROBIOLOGICA
D	




Floor 5

City Eye Lunch Area

SETTIMO CONGRESSO NAZIONALE





ICAR
Italian
Conference on
AIDS and
Retroviruses



Legenda

Keys

- Poster Area
- Meeting rooms
- Conference hall
- Slide Center
- Hospitality suite
- Entrance hall
- Scala mobile
Escalator
- Uscite di sicurezza
Security exit



SETTIMO CONGRESSO NAZIONALE



ICAR
Italian
Conference on
AIDS and
Retroviruses

Thanks to the Sponsors

The Chairs, the Scientific Secretariat and the CME Provider wish to thank for support given in the form of unrestricted educational grants the following Companies:

PLATINUM SPONSOR



GOLD SPONSOR



OTHER SPONSOR





ICAR
Italian
Conference on
AIDS and
Retroviruses

CME Provider and Organizing Secretariat

Effetti srl Via Gallarate, 106 - 20151 Milan, I

Phone +39 02 3343281 - Fax +39 02 33496370 - Mail: icar2015@effetti.it

Congress venue

Palazzo dei Congressi - Viale Virgilio, 17 - 47838 Riccione, I

www.icar2015.com

RAD